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Summary
The emergence of antibiotic resistant microorganisms is one of the most 
concerning problems in health welfare, and particularly, that of multi drug resistance. 
The active efflux of compounds from the cell is one of the key strategies used by 
microorganisms to avoid the noxious effects of toxic compounds and has become one 
of the most important mechanisms of multiple resistance, such transport processes 
being catalysed by an array of membrane associated proteins.
ATP-Binding Cassette Transporters, that carry out an energy dependent active 
transport process by which substances cross the cell membrane on the hydrolysis of 
ATP, also display the ability to translocate a number of unrelated molecules, 
including antibiotics. These transporters have been identified as one of the largest and 
most widely distributed families of such transmembrane transport systems. Virtually 
ubiquitous in nature, ABC transporters have been found in the genomes of every 
organism from the simplest archea through to man. The fact that they contribute the 
main pathway for resistance to anticancer drugs in humans highlights their importance 
and urgent need to study them.
In addition to the well known groups of antibiotics produced by members of 
the Streptomyces genus, that include aminoglycosides, tetracyclines, chloramphenicol, 
and some (3-lactams, which inhibit the protein synthesis or the proper formation of 
bacterial cell walls, the species Streptomyces peucetius produces the antibiotics 
doxorubicin and daunorubicin. These latter compounds are classified into the 
anthracyelines group and possess antitumoral activity, expanding the arsenal of 
compounds with different activity produced by Streptomyces.
The manner, in which S. peucetius avoids the effect of the antitumorals it 
produces, is by pumping them out of the cells, and the system that it utilises is that of 
an ABC transporter. In this system two subunits are present, one of them, DrrA, a 
peripheral membrane protein that acts as the energy-transducing component, and the 
other, DrrB, the membrane carrier. This type of permease carries out export of 
antibiotics in an ATP-dependent manner.
The expression of DrrA in E. coli proved to be a challenging enterprise as only 
low yields were obtained for DrrA at 16 °C, that were only improved when DrrA was 
fused to Thioredoxin. The over-expression and purification of DrrA allowed a partial 
characterisation of the catalytic activity of DrrA fused to Thioredoxin, with traditional 
biochemical methods, complemented by additional characterisation assays in wild 
type DrrA. The characterisation was based on assays of the ATPase activity of Thio- 
DrrA and DrrA, which displayed a measurable catalytic activity compatible with a 
role in energising transmembrane transport. These proteins were shown to be cation 
dependent ATPases able of binding and hydrolysing ATP in a similar manner to the 
NBD proteins of well-characterised prokaryotic ABC transporters, also showing 
common features to other NBD’s.
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Chapter 1
GENERAL INTRODUCTION 
1.1 The Resistance Problem
When antibiotics appeared, they were seen as a true miracle (although 
penicillin was discovered by Duchesne in 1896 (Duchesne, 1897; Ramon and Richou, 
1946), and rediscovered by Fleming in 1929, its clinical use was introduced in 1942 
and only widespread by 1946, after which a number of important antibiotics were 
being discovered; Levy, 1992). They were made by one microorganism and could 
stop growth and kill another one. Expectations were surpassed until it was realised 
that bacteria developed resistance against antibiotics (In 1946, 14% of all strains of 
Staphylococcus isolated in one hospital were found to be resistant to penicillin. By 
the end of that decade, the number had risen to 59%; Levy, 1992). Consequently, as 
more and more drugs were discovered and extensively used, bacteria were selected 
that were no longer killed by the antibiotic. These strains settled down in the 
environment and caused the re-emergence of infections such as tuberculosis, 
pneumonia, and some other nosocomial infections, that could not be treated by these 
compounds (Levy, 1998), Soon, it was observed that genes, which were responsible 
for conferring resistance to antibiotics, were copied and transferred by conjugation 
from resistant to sensitive organisms, spreading this resistance through bacterial 
populations (Franklin, 1992). In 1959, bacterial dysentery, linked to Shigella  
dysenteriae, was reported in Japan to be resistant to four different antibiotics. In 
1965, a strain o f Salmonella typhimurium, was shown to be simultaneously resistant 
to the antibiotics streptomycin, sulphonamides, tetracycline, ampicillin, neomycin, 
kanamycin and chloramphenicol (Smith, 1966), which has been an evident sign of 
concern since then.
The ability to transfer genes responsible for conferring resistance to different 
drugs by conjugation is due to the existence in the bacterial cell of transferable DNA 
elements of autonomous replication known as plasmids of resistance. This is one of 
the most important sources of resistance in diverse microorganisms. Other ways by 
which microorganisms acquire resistance are via transposons, and the events of 
transduction and transformation. Transposons are a very interesting resistance tool, as
they are mobile genetic elements, which can insert at random into plasmids or the 
bacterial chromosome independently of the host cell recombination system. In 
combination, these processes can enable a single bacterium to accumulate multiple 
antibiotic resistance genes harboured in a single plasmid that can in turn be passed 
between members of the same species or even across genera. In some transduction 
events, the host cell bears a special site for the attachment of bacterial viruses, also 
known as bacteriophages. If they integrate into the host chromosome, when the phage 
enters into a lytic phase it can carry pieces of that chromosome with its genetic 
information to a new target cell (Canchaya et al., 2003). Apart from plasmids, during 
transformation some naked DNA is taken up by the receptor cell and can be 
incorporated in its genome (Lorencz and Wackernagel, 1994; Dubnau, 1999).
Nowadays, there is a perceived fear of not having useful drugs to combat 
multiresistant-pathogenical microorganisms. An example of this, was the emergence 
of vancomycin resistance in enterococcus as this could spread to staphylococcus and 
pneumococcus, making common infections such as otitis and pneumonia untreatable 
(Travis, 1994). That fear seemed to become a reality when the first clinical isolate of 
Staphylococcus aureus with decreased susceptibility to vancomycin (MIC = 8 pg/ml) 
was isolated in Japan in 1997 (Hiramatsu et ah, 1997). These forms designated as 
glycopeptide-intermediate (GISA) or vancomycin-intermediate S. aureus (VISA), are 
characterised by a thickening of their cell wall (Cui et ah, 2000) due to an increased 
number of D-ala-D-ala targets in their outer layers that may trap the vancomycin 
molecules, increasing their MIC for vancomycin (Hiramatsu, 2002). Although these 
isolates proved not to be the feared threat and the vancomycin MIC remained low 
enough (<16 pg/ml), in June 2002, a high-level vancomycin-resistant S. aureus 
(VRSA, MIC= 1024 pg/ml) was finally reported (Chang et a l, 2003).
1.1.1 Resistance mechanisms
Microorganisms defend themselves from the effects of different drugs by 
several resistance mechanisms:
1) Modification of the antibiotic or drug
2) Alteration of the drug target
3) Decreased permeability of the cell towards drug molecules
4) Active-efflux of the drug
1.1.1.1 Inactivation or enzymatic degradation of the drug
In 1940, eleven years after the crucial discovery of penicillin by Fleming, 
Abraham and Chain reported the existence of a bacterial enzyme that degraded the 
antibiotic by hydrolysis of its -lactam ring, and discussed the possibility of its 
interference with future penicillin therapy (Abraham and Chain, 1940).
The P-lactamases, which inactivate the P-lactam antibiotics penicillin and 
cephalosporins, are the best-known example of this type of resistance mechanism. 
These antibiotics, containing a p-lactam ring, can act as pseudo substrates for the 
transpeptidases, enzymes that are responsible for the last stages of biosynthesis of the 
bacterial cell wall. Acylation of the active sites of the transpeptidases takes place. 
With a slow déacylation rate, these transpeptidases are slow to release the p-lactam 
ring from their active sites, preventing normal cross linking of peptide chains in the 
peptidoglycan layer, which remains mechanically weak and susceptible to lysis on 
changes in osmotic pressure (Walsh, 2000). The |3-lactamases cleave the ^-lactam 
ring, rendering these antibiotics inactive. Nowadays, more than two dozen of these 
enzymes, specified by different bacterial resistance genes, are known and are found in 
both Gram-positive and Gram-negative bacteria (Jacoby, 1994).
The therapeutic approach to counteract the action of these enzymes has 
consisted of producing many different semi-synthetic forms of the (3-lactam antibiotic. 
However, bacteria have evolved with point mutations in the (3-lactamases genes, 
resulting in enzymes with different amino-acid sequences and alteration of their 
substrate specifities (Jacoby and Medeiros, 1991). Additionally, the use of 
Augmentin (U.S. Trademark), a combination of amoxicillin and clavulanate, an 
inhibitor of p-lactamases, has also been an effective approach.
Another class of antibiotics that can be enzymatically inactivated are the 
amino-glycosides (e.g. streptomycin, kanamycin, and gentamicin). These molecules 
are covalently  m odified by enzym es such as phosphotransferases, 
nucleotidyltransferases and acetyltransferases, using the phosphoryl group of ATP, a
nucleotide triphosphate, and the acetyl group of acetyl-CoA, respectively (Shaw et a l, 
1993; Azucena and Mobashery, 2001). As a result of modification, the antibiotics 
have reduced affinity for the 168 rRNA in the ribosomal 308 subunit (Fourmy et a l, 
1996), and they can not exert their effect as inhibitors of protein synthesis. Whereas 
only one type of chemical modification in the |3-lactam antibiotic (hydrolysis of its 
ring) produces bacterial resistance, a dozen different types of modification are found 
that leads to resistance to a broad range of aminoglycosides. Aminoglycoside- 
modifying enzymes that work by acétylation are distributed in several groups and are 
characterised by the AAC prefix, the best studied being AAC(6’)-IV (also known as 
AAC(6’)-Ib) (Okamoto and 8uzuki, 1965) and AAC(3)-I (Williams and Northrop, 
1978), Enzymes that modify aminoglycosides by adénylation also comprise several 
groups, best characterised being ANT(4’) and ANT(2” )-I (Joshua et al., 1993; 
Pedersen et a l, 1995). Fourteen groups of enzymes phosphorylate aminoglycosides, 
the best studied being APH(3’)-IIIa (McKay et a l,  1994), APH(3’)-IIa and APH(3’)- 
la (Azucena and Mobashery, 2001). The enzymes involved in the chemical 
modification of amino-glycosides do not share more than 56% amino acid identity, 
and it is thought unlikely that these enzymes share a common ancestor.
In Gram-positive pathogens a bi-functional enzyme that modifies 
aminoglycosides has been found, being the only example of fused resistance genes. 
This enzyme encodes acetyl and phosphotransferase activities in separate protein 
domains, which have been acquired from different resistance genes (Davies, 1994; 
Ferretti et a l, 1986; Azucena et a l, 1997).
In the same way as the aminoglycosides, chloramphenicol is modified by 
acétylation, and this is carried-out by a dozen different chloramphenicol acetyl- 
transferases (CATs) (Bannam and Rood, 1991; Parent and Roy, 1992). The modified 
antibiotic is unable to bind to the ribosome and it cannot exert its effect. One CAT of 
note is the type I enzyme which acetylates chloramphenicol and also binds the 
antibiotic fusidic acid, thereby avoiding their action on protein synthesis. As with 
enzymes that inactivate aminoglycosides, the CATs seemed to have emerged through 
convergent evolution and do not seem to be related by point mutations to an ancestral 
gene (Bennett and Shaw, 1983).
The formation of glutathione adducts is a widely used mechanism to detoxify 
cell poisons in eukaryotes (e.g. herbicides in plants) and is another example of how 
antibiotics can be inactivated through modification. Although the formation of large 
quantities of glutathione is common in bacteria, the only example of this kind of 
modification is the inactivation of fosfomycin, another antibiotic that interferes with 
cell wall biosynthesis. A plasmid-encoded glutathione-5'-transferase, which catalyses 
the formation of an inactive fosfomycin-glutathione adduct, is responsible for the 
resistance phenotype (Area et al., 1990). Serratia marcensens and S. aureus 
fosfomycin resistance genes were cloned and sequenced but were found not to be 
related at the sequence level (Suarez and Mendoza, 1991; Zilhao and Courvalin, 
1990).
Other examples o f resistance by modification of antibiotics are the (9- 
phosphorylation of erythromycin and hydrolysis of its lactone ring (O’Hara et al., 
1989), and the (9-nucleotidylation of lincosamides in Gram positive bacteria (Arthur 
et aL, 1987; Brisson-Noël et al., 1988).
1.1.1.2 Alteration of the drug target
The main examples of this resistance mechanism relate to key macromolecules 
in some part of microbial metabolism, such as cell wall synthesis or DNA replication. 
An example of this mechanism is mutation of the transpeptidases involved in cell wall 
synthesis to create penicillin-binding proteins (PBPs) with lower affinities for the 
drug (Song et al., 1987; Chu et al., 1996). The ribosomes are other targets, and at 
least two different types of modification that render resistance to antibiotics are 
loiown.
To confer resistance, these mutations have to involve that part of the bacterial 
protein that interacts with the antibiotic (e.g. PBPs and ribosomes). When these 
regions are mutated they show less affinity for the drug and which cannot then 
interfere successfully with bacterial metabolic processes. m u r M N  genes in 
Streptococcus pneumoniae, which are separate from PBPs genes, and which control 
the addition of the short dipeptide units seryl- or alanyl-alanine to the stem peptide 
lysine, appeared to build a chemically unusual cell wall enriched with branched
muropeptides (Filipe and Tomasz, 2000). These processes might also make a good 
target for the design of new antibacterial drugs that work synergistically to treat 
resistant pneumococcal infections. In ribosomes, méthylation of the adenine residue 
A2058 in the 23 S rRNA component of the 50S ribosomal subunit by the Erm methyl 
transferase (Bussiere et ah, 1998) does not impair protein biosynthesis but lowers the 
ability of erytliromycin and pristamycin antibiotics to bind the rRNA.
One of the most concerning examples involving this type of resistance is 
found in Mycobacterium tuberculosis. To counteract the inhibiting effect of 
streptomycin on protein synthesis, mutations have appeared in the ribosome that 
prevents the antibiotic from binding. Mutations in the ribosomal gene rspL, which 
encodes the ribosomal protein S I2, produce a high resistance to streptomycin when an 
original lysine residue is changed into arginine. Another mutation affects the rrs 
gene, which encodes 16S rRNA, and also produces resistant phenotypes (Finken et al, 
1993).
Alteration of the drug target is an effective mechanism for conferring 
resistance to fluoroquinolones and rifampicins. Fluoroquinolones inhibit the 
metabolism of bacterial nucleic acids in Gram-positive and Gram-negative bacteria. 
They interact with the enzyme DNA gyrase, an A2B2 tetramer encoded by the gyrA 
and gyrB  genes, which mediates DNA negative supercoiling. The drug forms a 
complex with the enzyme and doubly cleaved DNA covalently bound to GyrA 
subunits. In this way the enzyme cannot re-ligate the cleaved DNA, which is 
accumulated and cell death is induced (Hooper, 1995). Mutations in these genes are 
linked to resistance to the fluoroquinolones. Rifampicin acts on the bacterial RNA- 
polymerase (3-subunit, encoded by the rpoB gene, preventing transcription. Point 
mutations, deletions and insertions in the 27 base pairs that encode the RNA- 
polymerase active site, confer resistance against rifampicin in Escherichia coli 
(Lisitsyn et al., 1984), M. tuberculosis (Mani et ah, 2001; Pozzi et ah, 1999) and S. 
aureus (Wichelhaus et ah, 1999).
We can also find this type of mechanism of resistance in eukaryotes. The 
resistance of pathogenic fungi to the synthetic nucleotide analogue 5-fluorocytosine 
(5FC) is the most studied. The nucleotide analogue is transported into the cell by a
cytosine permease and deaminated by a cytosine deaminase to 5-fluorouracil (5FU), 
then converted into 5-fluorouridylic acid, which is phosphorylated and incorporated 
into the fungus mRNA. This inhibits fungal growth as the transcript cannot be 
effectively translated. At the same time, 5FU is converted into 5-fluorodeoxyuridine 
mono-phosphate, which inhibits the enzyme thymidylate synthase, and by this 
mechanism prevents DNA synthesis and nuclear division. Resistance against this 
compound appears when some of the biosynthetic enzymes mutate so as not to utilise 
this compound, avoiding its incorporation into the RNA of the cell (Vanden Bossche 
et aL, 1994).
In the inhibition of ergo sterol biosynthesis we find another example of 
resistance in eukaiyotes. In this case, azole compounds act on the enzyme sterol 14 - 
demethylase (cytochrome P450 14DM or P45051). Mutations in this enzyme reduce its 
affinity for azoles, thus conferring resistance (Vanden Bossche et al, 1994).
Finally, a less generally utilised mechanism is used to arrest the effect of 
tetracyclines, when some microorganisms {Streptococcus spp; Staphylococcus spp; 
Listeria spp; Bacteroides spp) produce a protein that binds to the ribosome (TC 
resistance classes M, O, S and Q, respectively), preventing the access of the antibiotic 
to the ribosomal target (Burdett, 1996).
1.1.1.3 Decreased permeability of the cell towards drug molecules
It is well known that the plasma membrane is a very selective barrier to the 
permeation of solutes between the cell and the extracellular environment. This 
property ensures the rapid entry to the cell of essential molecules like amino acids, 
glucose and lipids, the maintenance of metabolic intermediates and the ejection of 
waste compounds from the cell.
The decrease of cellular permeability seems to be an important mechanism of 
bacterial resistance, especially in Gram-negative bacteria, which possess an outer 
membrane. While porins in the outer membrane allow some small hydrophilic 
molecules to enter, antibiotics are excluded because they are bigger and charged 
(Nikaido, 1994). This was the first resistance mechanism reported for Penicillin (in
Levy, 1992). Nowadays, some synthetic P-lactam antibiotics can cross through porins 
and are effective in the absence of any other resistance mechanism. A mutation in the 
gene that encodes the porin can cause resistance against drugs that enter the cell 
through this pathway. The decrease of cellular permeability to the drug is effective 
when it is coupled synergistically with another mechanism of resistance (Nikaido, 
2001; 2003).
Other bacteria like Mycobacterium possess an outer layer in their cell wall, 
characterised by the presence of mycolic acids. Resistance to isoniazid has been found 
in M  tuberculosis. This drug inhibits the synthesis of mycolic acids, which are 
incorporated into their cell wall and are essential for the permeability barrier function 
(Brennan and Nikaido, 1995).
1.1.1.4 Active-efflux of antibiotics and other drugs
The phospholipid bilayer, the basic structural entity of biological membranes, 
is substantially impermeable to most water-soluble molecules, including essential 
molecules. There is a need to transport these molecules across cellular membranes 
and this is mediated by transport proteins inserted into the lipid bilayer.
The active efflux of compounds from the cell has become one of the most 
important mechanisms of multiple resistance. In 1980, McMurry reported that the 
plasmid-encoded resistance to tetracycline in E. coli was due to energy-dependent 
efflux (McMuriy et al, 1980). This stimulated research into the mechanisms.
Transporters have usually been classified on the basis of tliree criteria, namely 
the energy source, the phylogenetic relationship, and the substrate specificity. The so- 
called primary active transporters mainly use chemical energy and constitute the bulk 
of drug efflux pumps in eukaryotic cells (Paulsen et al., 1998). They are usually 
energised by ATP. Secondary active transporters predominate in bacteria (Paulsen et 
al., 1998) (Table 1.1) and act as symports and antiports, coupling the movement of the 
solute to the transport of an ion along a concentration gradient (Poolman and Konings,
1993).
Within each of these two main classes of transporters, phylogenetic studies 
have led to the recognition of superfamilies, families and clusters, in correlation with 
their substrate specificity. According to their molecular assembly and the homology 
of their sequences, four families were known that presented this type of resistance 
mechanism in bacteria (Nikaido, 1994): the major facilitator (MF) superfamily, which 
shows homology to sequences of the glucose facilitators of mammalian cells (Saier et 
aL, 1999; Pao et aL, 1998; Ward et aL, 2001); the small multidrug resistance (SMR) 
family that consists of small transporters containing only four transmembrane helices 
(Paulsen et aL, 1996; Chung and Saier, 2001); and the resistance-nodulation-cell 
division (RND) that includes transporters for expelling cadmium, cobalt and nickel 
ions (Tseng et aL, 2003; Paulsen et aL, 1996; Saier et aL, 1994). These tliree families 
are classified as secondary active transporters (Fig. 1.1). The ATP-binding cassette 
(ABC) transporters comprise the fomlh family. In prokaryotes, transport or extrusion 
of drugs is predominantly carried out by antiporters that belong to the first three 
families. The ABC transporters are less represented in prokaryotes, but they are much 
more prevalent in eukaryotic organisms. This family of transporters use ATP to drive 
the expulsion of antibiotics and other compounds from the cell. Two new families of 
transporters, named DME (drug metabolite efflux) and MATE (multidrug and toxic 
compound extrusion) (Putman et al., 2000) have been added. A re-classification of 
SMR family as member of the DME has been suggested (Poole, 2004) and, a new 
superfamily named drug/metabolite transporter (DMT) has been proposed (Jack et aL,
2001), which includes the DME family.
Structurally, the MF family is characterised by having 12 membrane-spanning 
helices with a central loop between helices 6 and 7 that joins the two halves of the 
transporter, and as they are sequence-related, family members are thought to have 
arisen by gene duplication. There is another subfamily having 14 -helices, which 
could have evolved from the insertion of an increasingly hydrophobic central loop 
into the 12 _-helices precursor (Saier ei aL, 1999). The average size for the 
transporters of this family is 400 amino acid residues. Sugars and drugs are the main 
compounds transported by members of this family. TetA(B) and TetB(K) tetracycline 
transporters in E. coli and S. aureus respectively, are some of their best studied 
representatives. A particular case is shown where some MF (e.g. EmrB) and RND 
transporters can act in concert with an outer membrane protein such as TolC, which
acts as a protein channel that spans the outer membrane and the periplasm, for the 
translocation of drugs (Fig. 1.1).
The SMR transporters are the smallest of these four groups, composed 
approximately of 100 amino acids arranged into four helices (Paulsen et aL, 1996). 
Different studies of the E. coli multidrug transporter EmrE, that confers resistance to 
ethidium bromide and methyl viologen (Yerushalmi et aL, 1995, 1996), indicated that 
it could function as an oligomer (trimer) o f similar tertiary structure to the MF 
transporters (Rotem et a l,  2001) or, as suggested by 2-D crystallisation trials, perhaps 
as a dimer (Borges-Walmsley et aL, 2003). Studies had indicated that EmrE was a 
tetramer, comprised by two "conformational heterodimers", whose polypeptides were 
chemically but not structurally identical (Ma and Chang, 2004). However, a 
homodimer conformation was confirmed for this protein in complex with its substrate 
tetraphenyIphosphonium (TPP) (Pornillos et aL, 2005). In this conformation both 
subunits present opposite orientations in the membrane (they are antiparallel) and 
adopt slight different folds.
RND transporters also have a 12 -helix topology but with a large periplasmic 
domain between helices 1 and 2, and 7 and 8, and are much bigger than those of the 
MF family, consisting of some 1000 amino acid residues. Again, the resemblance in 
the sequences of the two halves suggests an internal duplication of a 6 -helix 
segment (Tseng et aL, 2003). All the members of this superfamily work as efflux 
transporters. AcrB, whose structure has been already determined (Murakami et aL,
2002), is one of the best-studied examples in this family of transporters, considered in 
Gram-negative bacteria, the most relevant multidrug efflux system in terms of 
resistance against clinically important agents (Poole, 2004). The DME family, 
recently described but poorly defined, seems to show similarities to the SMR family 
of proteins (Jack et a l, 2001).
MATE transporters are comparable in size to the MF transporters, with an 
average composition of 450 amino acids putatively arranged into 12 helices, but do 
not share similar sequences with members of the MF family. MATE transporters are 
a relatively new family among bacterial drug transporters, being less 
characterised than the former transporters. NorM and YdhE from Vibrio
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parahaemolyticus and E. coli respectively, are examples of these transporters that 
have been characterised, with NorM revealed as being a multidrug Na^-antiporter that 
confers resistance against dyes, fluoroquinolones and aminoglycosides (Morita et aL, 
1998); and YdhE conferring resistance to cationic antimicrobials (Yang et aL, 2003) 
(Table 1.1; Borges-Walmsley et aL, 2003).
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Pump Organism Substrate/modulatory ligands MFP/OMP References
MF
TetA E.coli TC Yin et a l,  2000
EmrB E.coli CCCP, NA, TL, CHH EmrA/TolC Lomovskaya, 1992
EmrD E.coli CCCP Nishino ct a/., 2001
MdfA/Cmr/ E.coli EtBr, PM, TC, Ery, Neo, Nor, CP, Yang et aL, 2003
CmlA IPTG, TPPf R6G, DAR, DXR, QA,
RP
FarB Neisseria gono- Fatty acids FarA/MtrE Lee and Shafer, 1999
rrhoeae
NorA Bacteroides fragilis Ery, Nor, PM Miyamae et aL, 1998
VceB Vibrio cholera CCCP, NA, Cip, Ery, PhMA, DOC VceA/TolC Colmer et aL, 1998
TetK S. aureus TC Guay et aL, 1993
NorA S. aureus EtBr, AC, QA, FQ, R6G, T P P \ PM Markham et aL,
1999
QacA S. aureus EtBr, QA, CH, PI Mitchell âr/., 1999
Bmr Bacillus subtilis EtBr, AC, QA, FQ, R6G, TPP+, PM Neyfakh A., 1992
LmrP Lactococcus lactis EtBr, DM, TPP^, QUN, TXlOO Van Veen et aL,
1999
MdrL Listeria EtBr, Ery, CTX Mata et aL, 2000
monocytogenes
Tap M. tuberculosis TC Wu et a l,  1999
Mmr M. tuberculosis EtBr, AC, Ery, TPP, SO, PY Wu et a l,  1999
Tap Mycobacterium TC, GM, 2-A'- and 2-N ’- Ainsa et al., 1998
fortuitum ethylnetilmicin, SM
LfrA Mycobacterium EtBr, AC, QA, FQ Sander et a l,  2000
smegmatis
CaMDRl Candida albicans FZ, NQO, benomyi, MTX Vanden Bossche et
al., 1998
SMR
Smr/QacC S. aureus EtBr, CV, QA, MV, TPP^ Littlejohn et a l.
1992
EmrE E.coli EtBr, AC, MY, TPP+ Yerushalmi et a l.
1995
EbrAB B. subtilis EtBr, AC, TPP^ Masaoka et a l ,  2000
YkkCD B. subtilis EtBr, PF, CV, PY, MV, CPC, CP, SM, Jack et a l,  2000
TC, TPP
Tbsmr M. tuberculosis AC, EtBr, MV Wu et a l,  1999
Pasmr Pseudomonas AC, EtBr, MV Li et aL, 2003
aeruginosa
QacE Gram-negative EtBr, QA, SU Kucken et a l ,  2000
organisms
QacEAl Gram-negative and Cip, EtBr, GM, QA, SU, TC Kucken et al., 2000
positive organisms
RND
AcrB E. coli
AcrB Haemophilus
influenza 
MexB P. aeruginosa
SmeB Stenotrophomonas
maltophila 
AcrB S. typhimurium
ArpB Pseudomonas puti-
da
MtrD N. gonorrhoeae
MATE
Bex A Bacillus thetaiota-
micron
NorM V ibrio  p a ra h a e ­
molyticus
YdhE E, coli
VcmA V. cholera
YdhE B. fragilis
NorM  N. gonorrhoeae
NorM Neisseria
meningitidis
EtBr, AC, CV, SDS, TX-lOO, bile AcrA/TolC 
salts, -lactam s, Nov, Ery, Fus, TC,
CP, MMC, FQ, NA, organic solvents,
NBD-FC
EtBr, CV, Ery, RP, Nov
AZ, Cip, CV, RP,TX -100 
EtBr, Ery, TC
AC, DOC, Cip, Ery, Fus, NA 
Nor, Nov, RP, SDS, TC
Cip, E ry, N ov, TC, TX-lOO, _- 
lac tam s, A Z, v e rte b ra te  pep tide  
antimicrobials, spermicides
AC, EtBr, MV
CP, EtBr, Nor
AC, Cip, KM, Nor, SM, TPP^
Nor, Cip, DAR, DXR, SM, KM, EtBr,
H33342
Nor, Cip, EtBr
AC, EtBr, Ber, Cip, Nor
AC, EtBr, Ber, Cip, Nor
AcrA/
MexA/OprM
MtrC/E
M urakam i e t a l . , 
2002
Sanchez et al., 1997
Li et al., 2003 
A l o n s o  a n d  
Martinez, 2000 
Lacroix e ra /., 1996 
K ieboom  and de 
Bont, 2001 
Hagman et ah, 1995
Miyamae et al., 2001
M orita era /., 1998
Morita era /., 1998 
Hu da et al., 2001
Miyamae et al., 1998 
Rouquette-Loughlin 
et al., 2003 
Rouquette-Loughlin 
et al., 2003
Table 1.1 Secondary transporters that act as drug pumps
MFP and OMP stand for membrane fusion protein and outer membrane protein, respectively.
Substrate and ligand abbreviations: AC, acriflaviii; AZ, azithromycin; Ber, berberine; CCCP, carbonyl 
cy an id e  m -ch lo ro p h e n y lh y d ra zo n e ; C TX , C efo tax im e; CH , ch lo rh e x id in e ; CH H , 2- 
chlorophenylhydrazine hydrochloride; Cip, ciproflaxacin; CL, clarithromycin; CP, chloramphenicol; 
CPC, cetylpyridinium  chloride; CV, Crystal Violet; DAR, daunorubicin; DM, daunom ycin; DOC, 
deoxycholate; DXR, doxorubicin; Ery, erythromycin; FQ, fluoroquinolones; Fus, fusidic acid; FZ, 
fluconazole; GM, gentam icin; H33342, H oechst 33342; IPTG, isopropyl _-D-thiogalactoside; IS, 
indolizine sulphones (e.g. SR33557); KM, kanamycin; KZ, ketoconazole; LTC4, cysteinyl leukotriene; 
MMC, mitomycin; MTX, methotrexate; MV, methyl viologen; MZ, miconazole; NA, nalidixic acid; 
N B D -P C , 7 -n itro b e n z -2 -o x a - l,3 -d ia z o lp h o sp h a tid y lc h o lin e ; N B D -P E , l-m y ris to y l-2 - [6 -  
(NBD)aminocaproyl]phosphatidyIethanol-amine; Neo, neomycin; Nor, norfloxacin; Nov, novobiocin; 
N QO, 4-nitroquinoline N -oxide; OL, oleandom ycin; CM , oligom ycin; PF, proflavine; PhMA, 
phenylmercuric acetate; PI, pentamidine isothionate; PM, puromycin; PY, pyronine Y; QA, quaternary 
am ine compounds (including benzalkonium  chloride and cetyltrimethylammonium bromide); QUN, 
quinine; R 6G, rhodam ine 6G; R123G, rhodam ine 123G; RB, rhodam ine B, RP, rifampicin; SO, 
safran  in O; SM, streptom ycin; SP, spiram ycin; SU, sulphonam ides; TC, tetracycline; TL, 
thiolactomycin; TPP^, tetraphenylphosphonium; TXlOO, Triton X-100; VB, vinblastin; VC, vincristine; 
VP, verapamil, (modified from Borges-W almsley et al., 2003).
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Figure 1.1 Schematic representation of the membrane topology of proton-driven 
drug pumps representing main Secondary transporters families found in Gram- 
negative bacteria.
The helices o f the pumps appear spanning the lipid bilayer, and lipophilic antibiotics (in red circles) 
freely permeate the lipid bilayer. The three classes o f  antiporters are shown; SMR, four-helix small 
multidrug transporters; RND, 12-helix resistance-nodulation-cell division transporters; MF, 12- and 14- 
helix m ajor facilitator transporters. These transporters are shown using the proton motive force 
generated by respiration to eject antibiotics and other drugs into the periplasmic space between the 
inner and outer membranes. MF and RND transporters can act in concert with a membrane fusion 
protein (MFP) and an outer membrane protein (OMP), such as TolC, to translocate drugs across both 
the inner and outer membranes, expelling them from the cell. TolC acts as a protein channel that spans 
the outer m em brane as a -barrel, and also possibly spans the periplasm, as an -helical barrel 
(Koronakis et a l ,  2000). Although the exact role o f the MFP remains unknown, it may act as a protein 
channel translocating drugs between the inner-membrane transporter and the helical barrel o f TolC. 
Alternatively, it is believed that MFP pulls the two membranes together, so that the inner-membrane 
transporter can pass drugs directly (based on diagram by Borges-W almsley et aL, 2003, and McKeegan 
et aL, 2004).
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ATP-Binding Cassette Transporters carry out an energy dependent active 
transport process by which substances cross the cell membrane driven by the 
hydrolysis of ATP (Higgins, 1992). They have also been proposed to have a 12 
helix topology. The ability of these transporters to translocate a number of unrelated 
molecules, including antibiotics, and the fact that they contribute the main pathway 
for resistance to anticancer drugs in humans, highlights their importance and urgent 
need to study them.
The SMR transporter EmrE can exemplify a putative mechanism for multidrug 
transport involving the proton motive force in secondary transporters. Based upon 
site-directed mutagenesis experiments, the following steps have been proposed 
(Paulsen et aL, 1996; Murdoch et aL, 1999; Yerushalmi and Schuldiner, 2000; 
Schuldiner et aL, 2001) (Fig. 1.2):
a) Exchange between the drug and a pair of protons associated with a charged 
residue in the protein.
b) Translocation of the drug by a series of conformational changes driving it thi ough 
a hydrophobic pathway (in the EmrE case), and
c) Replacement of the drug by a pair of protons in the external medium and return to 
the initial conformational state.
The overall result of this process is the exchange of the drug and the proton 
(antiport). Similar to proton antiporters, a conformational change of the ABC proteins 
involved in drug extrusion is possible and is probably triggered by drug binding and 
ATP hydrolysis (Sonveaux et al, 1996; Sharom, 1997).
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Figure 1.2. Possible multidrug resistance mechanism for E, coli SMR EmrE
(based on the Yerushalmy and Schuldiner model; Yerushalmy and Schuldiner, 2000). 
As the substrate approaches the hydrophobic binding pocket (left), two protons are released from the 
negatively charged glutam ate cluster (top). W hen occupied by the substrate, the binding pocket 
becomes accessible to the other face o f  the membrane (right). The subsequent protonation o f  the 
carboxyl groups allows the release o f  the bound substrate (bottom). The protonated binding pocket 
relaxes back to the original membrane face so a new cycle can start.
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1.2 The ATP-Binding Cassette Transporters
ABC proteins are the largest superfamily of proteins with more than 3500 
members (Stieger and Biber, 2002). This family of transporters (also called traffic 
ATPases) includes many different transport proteins, found in organisms ranging 
from bacteria to humans (Lodish et al, 2000). In E. coli, about 5% of the entire 
genome encodes components of ABC transporters (Linton and Higgins, 1998).
While there are ABC groups involved only in the import or export of 
molecules, other members of this superfamily are not involved in transport (Dassa and 
Bouige, 2001). In prokaryotes, these transporters are localised exclusively in the 
cytoplasmic membrane of bacteria, while in eukaryotic organisms, they are found in 
the plasma membrane, endoplasmic reticulum membrane, mitochondrial inner 
membrane and intracellular vacuoles.
The histidine periplasmic permease system, HisJQMP, of S. typhimurium (Ames, 
1972), and the maltose transport system, MalEFGK, of E. coli (Davidson and 
Nikaido, 1991) were pioneer systems in the gradual discovery of the family. The 
human multidrug resistance P-glycoprotein, which renders cells resistant to anti­
cancer treatments, has become the paradigm for ABC transporters involved in the 
problem of resistance and has renewed interest in the study of these transporters 
(Sharom, 1997). The term ABC was coined in 1990 (Hyde et al., 1990) enhancing 
the recognition of the importance of this diverse family of proteins. Nowadays, many 
more ABC transporters have been recognised in resistance to diverse classes of drugs 
and other chemical compounds (Table 1.2).
16
Pump Organism Substrate/modulatory ligands References
M DRl/P-gp
(A BC Bl)
Homo sapiens DNR, DOX, R6G, R123G, H3342, NBD-PE, 
NBD-PC, PM, VC, VB, CC, TAXOL, 
dexamethasone, steroids, VP, Nic, IS, 
antimalarials
Sauna et a l,  2001
MRPl
(ABCCl)
H. sapiens Similar specificity to P-glycoprotein + LTC4 
and other glutathione s-conjugates.
Leslie et al., 2001
Pdrs (ABCG 
subfamily)
Saccharomyces
cerevisiae
R6G, R123G, RB, FZ, DNR, DOX, CM, 
CHX, CP, TAM, TFPZ, steroids, NBD- 
PE/VB, VC, TAXOL, VP, ionophoric 
peptides, QUN, CC.
Golin et al., 2003
Cdfi
(ABCG
subfamily)
C. albicans FZ, KZ, MZ, steroids Vanden Bossche et 
al., 1998
Pfmdrt Plasmodium
falciparum
MFQ, Art, Co, a-factor (yeast pheromone). Peel, 2001
PGPA Leishmania spp. Pentostam, metal-thiol conjugates Callahan et al., 1994
LmrA L  lactis EB, R6G, R123G, DNR, DOX, VB, VC, DM, 
CC, TPPL H33342, NBD-PE/VP, Nic, QUN, 
QUND, CA, IS.
van Veen et al., 2000
DrrAB Streptomyces
peucetius
DOX, DNR Kaur, 1997
MacB E. coli AZ, CL, Ery, OL Kobayashi et al., 
2001
Msr Streptomyces
rochei
DXR, Ery, OL, SP, TC Fernandez-Moreno et 
al., 1998
YvcC B. subtilis P-gp homologue Steinfels et al., 2002
MsbA E. coli Major transporters o f lipids from cytoplasm to 
outer membrane
Chang and Roth, 
2001
Pst M. smegmatis FQ Banerjee et al., 2000
Table 1.2 ABC drug pumps
A bbreviations in Table 1.2: ABC, ATP-binding cassette; Art, artemisinin; AZ, azithromycin; Cc, 
chloroquine; CC, colchicine; CHX, cycloheximide; CL, clarithromycin; CP, chloramphenicol; DM, 
daunomycin; DNR, daunorubicin; DOX, doxorubicin; EB, ethidium bromide; Ery, erythromycin; FQ, 
fluoroquinolones; FZ, fluconazole; H33342, Hoescht 33342; IS, indolizine; KZ, ketoconazole; LTC4, 
cysteinil leukotriene; MFQ, M efloquine; MZ, m iconazole; NBD-PC, 7-nitrobenz-2-oxa-l ,3-diazol- 
phosphatidylcholine; N BD -PE, l-m yrysto il-2-[6-(N B D ) am inocaproy 1] -phosphatidyl-ethano lamine ; 
N ic, nicardipine; OL, oleandom ycin; OM, oligom ycin; PM, puromycin; QUN, quinine; QUND, 
quinidine; R 6G, rhodamine 6G; R123G, rhodamine 123G; RB, rhodamine B, SP, spiramycin; TAM, 
tamoxifen; TC, tetracycline; TFPZ, trifluoroperazine; TPP^, tetraphenylphosphonium; VB, vinblastin; 
VC, vincristine; VP, verapamil, (modified from original by Borges-W almsley et al., 2003).
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1.2.1 Identification of ABC transporters
Nutrient uptake studies in E. coli gave the first indications of the existence of 
this remarkable group of proteins (Berger, 1973), Three systems were found 
responsible for nutrient transport: the phosphotransferase group, an osmotic shock- 
insensitive transporter group energised by the electrochemical gradient (secondary 
transporters), and a third group formed by primary, osmotic shock-sensitive systems 
energised by the hydrolysis of ATP and associated with periplasmic binding proteins. 
By using membrane vesicles was noticed that cells subjected to osmotic shock 
exhibited reduced transport rates for certain amino acids, whereas the uptake of others 
remained unaffected by the treatment. Subsequent studies showed that the transport in 
the shock-sensitive systems was abolished due to the loss of a vital substrate-binding 
protein (SB?) from the periplasm (Heppel, 1969).
Additional evidence for the presence of more of one type of transport was 
collected by studies of energy coupling mechanisms in E. coli (Berger, 1973; Berger 
and Heppel, 1974). SBP-dependant transporters were found to be insensitive to the 
effect of chemicals that uncoupled oxidative phosphorylation, whilst shock- 
insensitive transporters lost the capacity to uptake nutrients. Investigators concluded 
that the energy donors for the two classes of transporters were essentially different. 
The shock-sensitive transporters (SBP-dependant) required phosphate-bond energy to 
drive the transport process, whereas in the shock-resistant systems transport was 
driven by an energised membrane state, provided by the proton motive force 
generated via oxidative phosphoiylation.
In 1982, the first complete sequence of one of these periplasmic transporters, 
the histidine transporter of S. typhimurium, was published (Higgins et a l, 1982). 
Apart from the periplasmic “substrate”-binding protein (HisJ), this transporter has 
three membrane-associated components (HisQMP). Shortly after this sequence was 
published, the sequence of a component of the E. coli maltose transporter (MalK) was 
also determined. A 32% identity between proteins MalK and HisP was reported 
(Gilson et ah, 1982). The similarity in both sequences suggested they evolved from a 
common ancestor. When the oligopeptide transporter of S. typhimurium OppD was 
also shown to share similarities with the aforementioned proteins (Higgins et al..
1985), it was noticed that they included a consensus nucleotide-binding motif similar 
to those previously identified in ATP synthase, myosin and adenylate kinase (Walker 
et al., 1982). From that moment, the involvement of these domains in coupling ATP 
hydrolysis with the transport process became a central feature.
Although the first eukaryotic example of this family of transporter, the human 
multidrug resistance P-glycoprotein, was identified in 1974 (Ling and Thompson, 
1974; Juliano and Ling, 1976), the recognition that the ATP binding subunits from 
bacterial transporters described a large superfamily of proteins dates from 1986. 
Around this time, it was also proposed they were organised in a core of four domains. 
These domains were composed by two integral membrane subunits and by two 
nucleotide-binding subunits, which bind and hydrolyse ATP (Higgins et al, 1986). 
Actually, the general approach to the identification and analysis of ABC transporters 
consists in searching sequence conservation in the nucleotide-binding sites (NBDs) 
first. Thereafter, the search is directed to find genes that code for proteins with 
membrane spamiing domains (MSDs) and proteins with solute-binding motifs.
As ATP-binding domains display a high degree of sequence similarity, 
conserved m otifs can be deduced using the PRO SITE web site 
(http://br.expasy.org/prosite/). The ABC signature sequence (LSGGQ) was used 
initially to characterise these domains and it is commonly present in members of the 
ABC family. Nowadays two additional internal domains are used for this purpose: 
the first domain is that of the Walker A motif, also known as the ATP/GTP-binding 
motif (PROSITE:PDOC00017). The second domain overlaps the ABC signature 
motif (also known as C motif) (PROSITE:PDOCOOI85) and the Walker B motif. 
Walker A and Walker B motifs can be present in ATPases that are not part of the 
ABC family.
Having identified NBDs, genes that can code for membrane-spanning domains 
(MSDs) are sought. Four or more transmembrane spanning sequences in proteins 
with NBDs or in gene products from NBD-adjacent genes become candidates for 
MSDs components. Some MSD-containing proteins (prokaryote permeases) also 
contain a conserved EAA— G.........— I-LP m otif located in a cytoplasmic loop
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(PROSITE:PDOC00364), that can be used in the analysis of these transporters. This 
sequence is believed to interact with the NBD (Mourez et aL, 1997).
The current methodology underpinning these studies takes advantage of the 
STD GEN and ORAL GEN databases as primary sources of protein and DNA 
sequences. Searches for similarity are based on the use of some BLAST tools from 
NCBL The XDOM tool (Gouzy et a\., 1997) was also used to analyse the modular 
arrangement of protein domains. The PHDhtm program was used to predict the 
number and location of transmembrane regions and the pattern-matching program 
SIGNALP, to predict the signal peptide. The ChistalW (Thompson et aL, 1994) and 
MultAlign program (Corpet et aL, 1988) were used for multiple alignments.
1.2.2 The structural organisation of ABC transport proteins
Generally, ABC transporters have four domains arranged into two 
homologous halves. Each has a transmembrane domain arranged into six _-helices, 
and a nucleotide-binding domain (NBD) of about 200 amino acids (Ouellette et al,
1994) (Fig. 1.3). The transmembrane domains seem to be composed of very 
hydrophobic integral proteins, and their two six helix motifs are arranged so as to 
form a transmembrane pathway to transport the selected compounds. Additional 
membrane domains have been reported in some cases, but they do not seem to change 
the general behaviour of the system; for example, an extra five-helix membrane 
domain has been located at the N-terminus of the multidrug resistance protein (MRP) 
(Flou et al., 2000). The other two domains that bind nucleotides are relatively 
hydrophilic and peripheral to the membrane. It is thought that they appear in the 
cytoplasm associated with the membrane. Their hydrolysis of ATP releases energy to 
drive the efflux of different compounds out of the cell (Van Bambeke, 2000; Lodish 
et a l,  2000).
In several cases, a single gene encodes the four domains (e.g. P-glycoprotein; 
Higgins, 1992). In other cases, each domain is encoded as a separate polypeptide 
(e.g. the OppBCDF transporter; Hiles et al., 1987). Intermediate genetic organisation 
of ABC transporters can also exist, where separate genes encodes both membrane 
domains and both NBDs. A diagram of the topology of drug transporters belonging
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to the ABC superfamily is presented (Fig. 1.4). Exceptions to the classical 
arrangement of four domains is exemplified by the multidrug transporter LmrA 
from Lactococcus lactis, where the ImrA gene encodes a protein with a fused single 
membrane and nucleotide binding domain (van Veen et al., 1996), and drrA and drrB 
from S. peucetius (Kaur, 1997), which encode individually the NBD and the 
membrane domain respectively. Recent experiments have shown that DrrB forms at 
least eight helices instead of the six-helix model proposed for ABC transporters 
(Gandlur et al., 2004). In cases in which one of the ABC domains appears to be 
absent, one of the remaining domains functions as a homo dimer to maintain the 
proposed ABC complex (Higgins, 2001). As LmrA is thought to be assembled as a 
homodimer and DrrAB as a tetramer, it is believed that these transporters are 
topologically analogous to full size ABC transporters. In full size ABC transporters, 
the two halves of the protein resemble one another, suggesting that they have 
originated by gene duplication (Saier and Paulsen, 2001). Additional proteins are 
involved in some of these ABC systems. That is the case of importers (periplasmic 
binding-protein dependant (BPD)-ABC transporters), which employ an extra protein 
to bind the substrate to be transported (e.g. histidine and maltose transporters), but 
these proteins are associated in a reversible manner and do not form part of the four 
domain complex. Another example is the additional “R domain” present in the cystic 
fibrosis transm em brane conductance regulator (CFTR). The reversible 
phosphorylation of the R domain seems to regulate the function of the CF channel 
(Gadsby and Nairn, 1999).
P-glycoprotein (ABCBl), which is a large plasma-membrane glycoprotein, 
has two similar halves, characteristic of many of the transporters of this superfamily, 
containing six putative transmembrane helices and one NBD (Loo and Clarke, 1995; 
Kast et al., 1995). The two NBDs share 30-40 % amino acid sequence identity with 
each other and the equivalent domains of many other transporters included in the 
ABC family (Higgins et al., 1997). Besides P-glycoprotein, which is considered the 
most important example of an ABC transporter because it is responsible for resistance 
in humans against antitumoral drugs, MRP (ABCCl) (multiple resistance protein), 
which acts in the lungs, is also an important resistance-related transporter (Cole et al.,
1992). Other ABC proteins of medical importance are the chloride-chamiel protein 
involved in cystic fibrosis (CFTR; ABCC7; Gadsby and Nairn, 1999), the human
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adrenoleukodystrophy protein (ALDP; ABCDl), an ABC transporter associated with 
transport o f very long chain fatty acids (VLCFAs) into the peroxisome (Mosser et al,
1993), and the endoplasmic reticulum (ER) peptide transporter involved in antigen 
presentation (TAP; ABCB2 and ABCB3) (Abele and Tampe, 1999).
TMD 2
Figure 1.3 Putative structural organisation of an ABC transporter
TMD: Transmembrane domain 
NBD: Nucleotide binding domain
ABC transporters have four domains arranged into two homologous halves. Each one possesses a 
transmembrane domain arranged into six a-helices, and a nucleotide-binding domain. Some 
transporters function as importers whilst other export molecules out o f the cell.
This model depicts a structure with each half (TMD-NBD) o f the transporter encoded by a single gene.
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P-glycoprotein
H. sapiens
OppBCDF
S. typhimurium
RbsAC
E. coli
LmrA
L. lactis
DrrAB
S. peucetius
IQQQQQQn QQQQQOn n * XIQQOQO. .hDQQOOOQQO QQQQCOOCD
L Î DOOODDOOCD
ATP ADP 
+ Pi
Single polypeptide 
2 X 6-helix domains 
2 X ABC domain
ATP ADP 
+ Pi
Four polypeptides 
2 X 6-helices 
2 X ABC domains
ATP ADP 
+ Pi
Three polypeptides 
2 X 6-helix domains 
1 X ABC 
polypeptide with 2 
NBDs
ATP ADP 
+ Pi
Single poly­
peptide 
1 X 6-helix 
domain 
1 X ABC 
domain
ATP ADP 
+ Pi
Two polypeptides 
1 X 8-helix 
domain
1 X ABC domain
Figure 1.4 Schematic representation of the membrane topology of diverse 
transporters belonging to the ABC superfamily
The prototype o f  ABC transporter presents two NBDs and 12 membrane-spanning a-helices arranged 
in two groups o f  six. In P-gp, a single gene encodes all four domains (Higgins, 1992); in OppBCDF 
each o f  the four domains are encoded by different genes (Hiles et al., 1987); in LmrA, a single gene 
encodes only one membrane and one NBD (van Veen et al., 1996); for DrrAB, separate genes encode 
one membrane and one NB domain (Kaur, 1997)*. Intermediate genetic organisations are also found: a 
single gene encodes both NBDs o f  RbsAC whilst membrane domains are encoded separately (Lida et 
al., 1984); or a single gene encodes both TMDs and NBDs but as heterodimers, as for TAP (Daumke 
and Knittler, 2001). MRP, C-class eukaryotic member (not shown) is also encoded by a single gene as 
P-gp, but it carries an additional five-helix TMD at the N-terminus (Hou et al, 2000).
*A new model has been proposed for the 5. peucetius DrrB TMD arranged in a group o f eight a-helices 
(Gandlur et al., 2004).
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1.2.3 The Nucleotide-Binding Domain (NBD)
The nucleotide-binding domains bind and hydrolyse ATP and couple this 
hydrolysis to solute translocation across the membrane. These domains consist of a 
core o f about 200-230 amino acids, and contain the ABC signature sequence 
(LSGGQ), also known as the C-loop or linker-peptide that has been the key to 
identification of new members of this transporter family. Also included are the two 
highly conserved sequences. Walker A (Wa) and Walker B (Wg) motifs (Walker et 
a l,  1982), which are responsible for ATP hydrolysis (Fig. 1.5). It is the conservation 
of this entire domain which is important in defining the family (Higgins et a l, 1986). 
The Walker A motif is generally present with the sequence “G-X-X-G-X-G-K-S/T”, 
X being any amino acid and a serine or threonine occupying the final position. The 
lysine in this motif interacts with the _- and _- phosphate groups of ATP, being 
essential for its hydrolysis. This region is also known as the phosphate (P-) loop. The 
Walker B motif is less conserved and is represented by the sequence “R/K-X-X-X-G- 
X-X-X-L-_-_-_-_-D”, _ being any hydrophobic residue. An aspartate in the Wg motif 
is responsible for eo-ordinating the Mg "^^  ion of Mg-ATP, which is required for 
nucleotide binding. Mutations of the Walker sequences generally impair the ATP 
binding or hydrolysis, particularly when lysine in the Walker A motif or aspartate in 
the Walker B motif are involved, leading to a complete loss of the ATPase activity in 
the protein. The Walker A motif is located near the N-terminus of the NBD, followed 
by the ABC signature motif, that appears immediately upstream of the Walker B 
motif (Fig. 1.5).
Based on sequence similarities with the RecA protein in E. coli, the so-called 
“Switch region” has also been reported. This is located downstream of the Walker B 
motif and is characterised by the presence of a histidine in the last position that seems 
necessary to maintain the transport integrity (Fig. 1.5). Additionally, the Q loop, also 
called the _-phosphate switch, between the Walker A motif and signature sequence, 
and the D loop (Hopfner et al., 2000), that contains an aspartic acid residue 
downstream of the Walker B motif, also forms part of the conserved sequences (Fig. 
1.5). All of these sequences are involved in the interaction with ATP and its 
hydrolysis.
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Figure 1.5 Sequence alignment of S. peucetius DrrA and some well-known ABC 
ATPases
Sequences are ordered to enable comparison with DrrA. Orange ovals or arrows indicate the main
conserved amino acid motifs
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1.2.3.1 Biochemical properties of ABC transporter Nucleotide-binding domains
The ability to bind and hydrolyse ATP and use the energy released to drive an 
active transport process, is the elemental feature that characterises these domains. 
Understanding how ABC transporters interact with the molecules or compounds that 
are transported is vital in elucidating their physiological role, and also in the design of 
strategies to circumvent the increasing problem of resistance to antimicrobials and 
cancer treatments.
The knowledge o f the conformations that these NBDs acquire when they 
interact with the substrate (ATP) and when other components of the transporter 
system are present is necessary to clarify the whole nature of the process. This 
section presents information generated by studies of the biochemical factors involved 
in ATP hydrolysis and conformational changes gathered from work with isolated 
NBD’s and intact ABC transporters alike.
The characterisation of ABC transporters has not proved an easy task. Whilst 
present in high numbers in eukaryotic cells, overexpression in the native host has not 
always been successful and has often resulted in low yields. Despite the predicted 
cytoplasmic localisation of the NBDs, many attempts to express them as soluble 
proteins or as fusion proteins have also met with limited success in the past. E. coli is 
the most common expression host for experiments of this sort and can overproduce 
recombinant protein from diverse organisms, retaining the proper folding of the native 
target protein. Some of the best-characterised ABC transporters that have been 
overexpressed in E. coli are proteins that occur naturally in that host (e.g. the 
maltose/maltodextrine transporter) or its close relatives {S. typhimurium maltose and 
histidine transporters). The characterisation of these transporter proteins requires the 
recovery and purification of sufficient amounts of soluble, stable and active protein 
for analysis by biophysical techniques such as X-ray crystallisation and nuclear 
magnetic resonance (NMR). Newer approaches such as the definition of domain 
boundaries within the protein to be overexpressed (Kerr ei al., 2003) may aid the 
effective expression of isolated NBDs.
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Working from the four domain structure for an ABC active transporter, it has 
been suggested that both NBDs are involved in powering the translocation of the 
transported solute. In systems such as the maltose transporter of S. typhimurium and 
E. coli, the transporter is composed of the periplasmic maltose-binding protein MalE 
(MBP), the two integral cytoplasmic membrane protein subunits MalF and MalG, and 
two copies of the ATPase subunit MalK (Ehrmann et aL, 1998). Purified MalK was 
shown to have constitutive ATPase activity and to be insensitive to vanadate, a 
compound that causes strong inhibition to the assembled transport complex 
(Sclmeider, 2001). These results indicate that functional coupling of the NBD to those 
parts of the ABC transporter embedded in the membrane must exist in order to 
explain the action of vanadate. The favoured model proposes that the protein 
undergoes a conformational change upon binding of Mg-ATP, and then interacts with 
the membrane components (Mourez et a l ,  1998), The proposed physical interaction 
between the NBDs and the transmembrane domains of the maltose transporter has 
been supported by site-directed chemical cross-linking experiments (Elunke et aL, 
2000). Results obtained with a proteoliposome-reconstituted transport system 
suggested that MBP transmitted, tlirough MalF and MalG, a signal to MalK inducing 
it to hydrolyse ATP (Davidson et ah, 1992). Co-operativity between the NBDs to 
drive the transport process has been reported for several systems, as in the case of P- 
glycoprotein (Buxbaum, 1999), MalK (Davidson and Sharma, 1997) and HisP 
(Nikaido and Ferro-Luzzi Ames, 1999). In isolated NBDs, Methanococcus 
jannasckii MJ0796 (Moody et a l,  2002) also showed co-operativity to hydrolyse 
ATP.
For the P-glycoprotein (MDRl; ABCBl), where both NBD subunits appear to 
be functionally equivalent (Loo and Clarke, 1994; Urbatsch et aL, 1995), Senior 
proposed a model for the NBD activity in which ATP hydrolysis occurs alternatively 
at each NBD (Senior et a l, 1995). In other transporters such as the multidrug 
resistance protein (M RPl), the NBDs are non-equivalent (Nagata et al, 2000). 
Photoaffinity labelling experiments revealed ATP binding exclusively at NBDl, 
whilst ADP trapping appeared predominantly at NBD2 of MRPl (Hou et aL, 2000). 
The NBDs of TAP (TAPi/TAPi; ABCB2/ABCB3), the transporter associated with 
antigen processing; also show different nucleotide binding affinities. In 
photolabelling experiments with free 8-azido ATP[_-^^P], the labelling efficiency for
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TAPi was markedly higher than for TAP2 (Alberts et aL, 2001), and identical 
mutations in the domains had different effects on peptide transport (Daumke and 
Knittler, 2001). On the other hand, it was reported that one intact ATP-binding 
subunit was sufficient to support ATP hydrolysis and translocation in the ABC 
transporter of histidine permease although at a rate half of that of the wild type 
transporter (Nikaido and Ames, 1999). These studies also indicated that only one 
NBD would be involved in the hydrolysis of ATP by isolated HisP.
The formation of a dimer as the active form of the NBD was proposed for 
HisP (Nikaido et aL, 1997). This conformation was also suggested for other NBDs of 
ABC transporters like the OpuAA of Bacillus suhtilis, where equilibrium between 
monomeric and dimeric forms has been reported (Horn et aL, 2003) and GlcV from 
Sulfolohus solfataricus (Verdon et aL, 2003).
In addition to the site for nucleotide binding, these domains in P-glycoprotein 
also bear a site for ligands such as flavonoids, which modulate drug transport (Conseil 
et aL, 1998). When exposed to several drugs that P-glycoprotein ejects from the cell, 
the rate of ATP hydrolysis was increased several fold (Ambudkar et aL, 1992). This 
effect of stimulation by drugs however, is only noticed when all the subunits are part 
of the complex (Loo and Clarke, 1994). Although it is not part of the ABC family, the 
E. coli arsenical efflux pump ArsAB shares similar structural and functional features 
to ABC transporters like the human multidrug-resistance P-glycoprotein (Gottesman 
et ah, 1996; Ambudkar et aL, 1999), and its ATPase subunit ArsA, has an allosteric 
site that exemplifies this behaviour. Although ArsA possess two nucleotide-binding 
sites (NBSs), its allosteric site is basically composed of three arsenite/antinionite 
binding sites formed by: His 148 (A l) and Ser420 (A2); Cysl 13 (A l) and Cys422 
(A2); and C ysl72 (A l) and His453 (A2) (Zhou et al., 2000). A l and A2 refer to the 
two NBDs of the ArsA ATPase catalytic subunit of the ArsAB transporter. Each one 
of these sites can accommodate a molecule of arsenate or antimonite. It has been 
proposed that the binding of antimonite or arsenite makes the two halves of ArsA 
come together, and that this conformational change induces an increase in ATP 
activity (Rosen et al, 1999), In other transport NBDs like OleB (fused to maltose 
binding protein) and KpsT, involved in the export of oleandomycin and polysialic 
acid by Streptomyces antibioticus and Æ coli (Buche et al., 1997; Bliss and Silver,
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1997) respectively, there are indications of an interaction with the substrate. Those 
results, however, do not rule out the possible participation of other components.
Although it is known the ABC transporter NBDs preference for ATP, other 
nucleotides can be accepted, usually with less affinity and reduced hydrolysis rate 
(e.g. in Buche et al., 1997). A similar situation prevails for divalent cations different 
from Mg^ "^  that are utilised to stimulate ATP hydrolysis, but in this case, the range and 
concentration of the cation can influence the catalysis. For example in the 
characterisation of HisP, the ATP-binding subunit of the histidine transporter, Nikaido 
and co-workers found that Mn^ "^  was the best stimulator of HisP ATPase activity at 
high concentrations (above 1.5 mM) whilst Co^ "^  was the best at low concentrations 
(<1 mM) (Nikaido et a l, 1997).
A number of inliibitors of ATP hydrolysis have been found to interact directly 
with NBDs. Vanadate is a specific inhibitor for P-type ATPases and its action is used 
to distinguish different types of pumps. Vanadate inliibits the enzymatic activity of P- 
glycoprotein by trapping ADP at the catalytic site, preventing the release of the 
nucleotide from the protein (Urbatsch et a l, 1995). Vanadate also catalyses the UV- 
dependent cleavage of the polypeptide backbone at both the ABC signature and the 
Walker A motifs when it is trapped in the nucleotide-binding site o f the E. coli 
maltose transporter (Fetsch and Davidson, 2002). While reported for transport 
complexes, isolated NBDs remain insensitive to its effect (Table 1.3). Another 
inliibitor, N-ethylmaleimide (NEM), also affects intact transport proteins (Urbatsch et 
a l ,  1994). A covalent modification of a cysteine present in the Walker A motif is 
pointed out as the target of this compound (Feng and Forgae, 1992). ADP and other 
non-hydrolysable analogues have also been shown to affect the ATPase activity of 
many ABC proteins (Schneider and Hunke, 1998).
Mutations in key amino acids in any of the conserved sequences in the NBD 
can be used to abolish ATPase activity but not the binding of ATP. The affinity of 
ABC transporters for ATP shows a very broad range of variability (Table 1.3). It is 
probable that in some cases, the purification conditions and the status of its 
association with the full complex have affected the reported K,n and Vmax.
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Table 1.3 Enzymatic properties of some purified ABC transport systems and 
their isolated components
Protein Km (ATP) V  max Inhibitor Reference
(pM ) (nm ol/m in/m g prot.)
MalFGKa {E. coli) 74 860 Vanadate Davidson era /., 1992, 1996
MalK (S', typhimurium) 23.9 322 Insensitive to 
vanadate
Morbach et al., 1993
MalK {E. coli) 120 275 Insensitive to 
vanadate
Mourez et a/., 1998
HisQMPa (S. typhimurium) 8000 350 Liu and Ames, 1997
HisP (S. typhimurium) 205 500 Insensitive to 
vanadate
Nikaido et a i ,  1997
MglECA (S. typhimurium) nd 20 Vanadate Richarme et al., 1992
MglA {S. typhimurium) 60 140 Vanadate Richarme et al., 1993
HlyB-ABC {E. coli) 200 1000 Vanadate Koronakis et al., 1993
OleB (N-term.) 1 19400 Azide Aparicio et al., 1996
P -g ly c o p ro te in  (chinese 940 300 Vanadate, Shapiro and Ling, 1994
hamster) NEM
P-glycoprotein (human) 400 1650 Vanadate, Sharom eta l., 1995
(A B C B l) bafilomycin
P -g ly -N B D 2  ( c h in e s e 24 20000 Nd Sharma and Rose, 1995
hamster)
P-gly-NBDl (human) nd 180 Vanadate Shimabuku er a/., 1992
PstB (M. tuberculosis) 71.5 122 Sarin et al., 2001
Trx-DrrA 
(M  tuberculosis)
84.8 52 Nash, 2003
C FT R N B D l (human) 110 30 Azide Ko and Pedersen, 1995
CFTR NBD2 (human) 86 6 Ap5A R andake/a /., 1997
Ap5A, p \  p^ -d i  (adenosine-5’) pentaphosphate; NEM , N-ethylmaleimide; NBD, nucleotide binding 
domain. (This table is an adaptation from Schneider and Hunke, 1998).
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1.3 Structure of ABC transporters
I.3.1 Nucleotide-binding domains
The periplasmic histidine permease transporter (HisQMPi), present in E. coli 
and S. typhimurium is one of the best characterised ABC transporters and may be 
regarded as a good example of this superfamily. It consists of a membrane-hound 
complex comprising the integral membrane subunits HisQ and HisM, and two copies 
of the ATP-binding subunit HisP, which has properties intermediate between those of 
integral and peripheral membrane proteins (Kerppola et al., 1991), being accessible 
from both sides of the membrane (Baichwal et al., 1993). These two HisP subunits 
form a dimer as suggested by their cooperativity in ATP hydrolysis (Liu et al., 1997). 
The X-ray crystal structure of HisP from S. typhimurium was elucidated in 1998 
(Hung et a l, 1998) (Fig. 1.6).
The overall fold shape derived from the ciystal structui e of the HisP monomer 
(Fig. 1.6) is considered to be different from any other known protein, resembling an 
“L” with two thick arms (described as arm I and arm II). The ATP-binding 
pocket, containing the “phosphate-binding loop”, is localised near the end of arm I, 
which also includes the Walker B motif. The ABC signature motif forms part of arm
II, characterised by a higher _-helices composition. Limited similarities can be found 
between the structures of HisP and RecA (Story and Steitz, 1992) and the and _- 
subunits of bovine Fi-ATPase (Abrahams et al., 1994).
Thereafter, when structures were resolved for other bacterial ABC transporters 
(e.g. MalK, MJ1276, TAPI), a consensus fold for the NBD was revealed (Diederichs 
et al., 2000; Karpowich et al., 2001; Yuan et al., 2001; Gaudet and Wiley, 2001; 
Chang and Roth, 2001; Locher et al., 2002; and Smith et al., 2002). This fold shows 
the two armed L shape and localisation of the P- and C- loops that was first reported 
for HisP by Hung and collaborators (1998).
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Figure 1.6 X-ray ciystal structure of 5. typhimurium HisP monomer (Hung et al,,
1998)
A dimer conformation has been suggested as the active form o f several NBDs, 
and although the monomer conformation was similar, the manner o f how monomers 
were associated to form the dimer was significantly different (Janas et at., 2003). 
Dimer conformations have been indicated in some crystal structures like those of 
MalK from the archeon Thermococcus litoralis (Diederichs et al., 2000), and the 
structures o f wild type MJ0796 (Yuan et al., 2001) and mutant MJ0796-E171Q of 
Methanococcus janaschii (Smith et al., 2002). However, the best dimer model for 
NBD:NBD interaction is based upon ABC domains not from a transporter, but from 
the DNA repairing enzyme Rad50. In this dimer structure (Fig. 1.7), two nucleotides 
are clamped at the interface between two monomers, inducing them to dimerise 
(Hopfiier et al., 2000). In this model, the ATP molecules are sandwiched between the 
Walker A and B motifs of one monomer and the C-loop of the other monomer. The 
NBDs form a dimer with ATPase activity, they share homology with ABC-type 
ATPases and they are structurally similar to the monomeric MalK and HisP proteins. 
This NBD dimer from Rad50 is stable in solution in the presence o f Mg^  ^ and the 
non-hydrolisable ATP analogue adenyl imido diphosphate (AMP-PNP) (Hopfher et 
a l,  2000).
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Figure 1.7 Pyrococcus furiosus ATP-bound RadSO dimer crystal structure
(Hopfiier et al., 2000)
To support this dimer model, a MalK structure, which resembles Rad50, was 
obtained from E. coli (Chen et al., 2003) (Fig. 1.8). In the structure, it can clearly be 
seen that the ATP molecules interact with the Walker A motif (in red) o f one 
monomer and the signature (in purple) o f the other monomer in a sandwich type 
manner. MalK was crystallised in the absence and presence of ATP and showed a 
stable dimer conformation in the three different crystal conformations obtained. The 
stability o f these dimer structures in comparison to those of other NBDs can be 
attributed to an additional C-terminal sequence called the regulatory domain (not 
shown in Fig. 1.8), that contributes substantially to the dimer interface.
The architecture o f this ATP-bound MalK dimer is consistent with 
biochemical data obtained with the intact maltose transporter. Maltose-binding 
protein (MBP) stimulates ATP hydrolysis by MalFGKi, and vanadate traps a complex 
of Mg ADP, MBP, and MalFGK2 in the catalytic transition state (Chen et al., 2001). 
The highly specific photocleavage o f the MalK subunits in the presence o f UV light at 
the Walker A and LSGGQ motifs mediated by vanadate, demonstrates that both 
motifs lie very close to the position o f the ATP y phosphate in the catalytic transition
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State, and since the ABC signature motif is well separated from the Walker A motif in 
one subunit, specific cleavage at both sides provides strong evidence that the LSGGQ 
motifs complete the nucleotide binding sites of the opposing subunits (Chen et al.,
2003).
Figure 1.8 E. coli MalK dimer crystal structure (Chen et al., 2003)
Dimer structures similar to the configuration shown for RadSO were also 
discovered for NBDs of the vitamin B12 transporter BtuCD (Locher et al., 2002) and 
the E. coli maltose transporter (Chen et al., 2003).
1.3.2 Transmembrane Domains
Detailed structural studies o f membrane proteins have been particularly 
difficult in the past. A prerequisite for these studies is to overexpress such proteins in 
large quantities. E. coli is widely adopted as the system of choice for this purpose due 
to its high growth rate, well-characterised genetics and the wide range o f available 
vectors. However, the production o f properly folded transmembrane proteins and their
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purification has not been easily achieved. One obstacle in working with proteins that 
carry hydrophobic domains is the requirement for detergents. Whilst detergents 
generally aid solubility, they can also result in dénaturation of proteins and can be 
detrimental to their enzymatic activity (Swiderek et ah, 1997). Although advances in 
the crystallisation of single NBDs have occmred, the transmembrane domains show 
less conservation of sequence than NBDs and the involvement o f the membrane 
components in the global interaction with the NBDs still needs to be clarified.
The existence of mutations allowing maltose transport in the absence of the 
MBP led to the identification of sites in MalF and MalG thought to be important for 
the interaction with the MBP (Covitz et ah, 1994). A highly conserved motif of 20 
amino acids, EAA-X(3)-G-X(9)-I-X-L-P (Saurin and Dassa, 1994), called the EAA 
loop, has been suggested to interact with the NBD in the ABC importer-type proteins 
(Hunke et a l, 2000; Mourez et ah, 1997). This region is hydrophilic and lies in a 
loop facing the eytoplasm in all of these proteins of recognised topology (Saurin et 
ah, 1994). This EAA m otif seems to be of functional importance since several 
mutations have been characterised that have reduced or abolished transport in 
different uptake systems (e.g. maltose, Dassa 1990; iron (III) hydroxamate, Koster 
and Bohm, 1992; and phosphate, Webb et ah, 1992).
Site-directed mutagenesis experiments by Mourez and eollaborators (1997) 
showed that single substitutions in the EAA region of MalG abolished transport 
completely, but the same mutation in MalF had no effect, suggesting that these EAA 
motifs and perhaps the MalG and MalF proteins do not function symmetrically. In 
some cases, double mutants possessed properties that were not equivalent to the 
combined characteristics of their corresponding single mutants. This result suggested 
some kind of cooperativity between the EAA regions of MalG and MalF in the 
formation of a functionally important site. Two classes of mutants were also found 
that indicated two probable roles for the EAA motifs. Firstly, they may play a 
fundamental role in the association of MalK with the membrane and the formation of 
a functional transporter. This has been inferred from the observation that some EAA 
mutations result in localisation of MalK to the cytoplasm (in the normal transporter, 
80 % of MalK appears in a particulate fraction extracted by Triton X-100, which also 
contains MalF and MalG). Suppressor mutations in malK  that reconstitute the
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transporter function indicate that mutations in the EAA loop can be eorrected by 
mutations in the ATPase (“helical domain”). The second role inferred for the EAA 
regions from mutagenesis is that they might form part of a substrate binding site or a 
site that transduces a signal to MalK (Mourez et al., 1997).
Mourez and co-workers presented the following conclusions from their 
analysis: mutations in EAA loops might affect their direct participation in the 
membrane-NBD association, or indirectly, inducing a conformational change in other 
region of the proteins more directly involved in the interaction with MalK. EAA 
mutations might also disrupt the formation of the MalF-MalG heterodimer, resulting 
in the release of MalK in the cytoplasm. Another possibility is that EAA mutations 
alter a functional site that involves the three proteins MalF, MalG and MalK (Mourez 
et al., 1997). An EAA-like motif has been identified in some eukaryotic ABC 
transporters that may indicate a more generalised role for this sequence (Schneider 
and Hunke, 1998).
Although the EAA—  sequence might be distinctive in membranes involved 
in influx processes, an equivalent sequence has not been reported for transporters 
involved in efflux. Interactions between substrates and TM domains are not 
completely understood but they seem to be dependent on the nature and architecture 
of the drug-binding sites in the membrane, rather than the presence of particular 
conserved sequence motifs. This indeed might explain the broad substrate specificity 
found in multidrug transporters such as P-glycoprotein. The existence of many 
separate binding sites as well as the presence of a single flexible site that can 
accommodate different chemical structures within different sub-regions, have been 
proposed (Neyfakh, 2002). Several separate binding sites have been reported for P- 
glycoprotein: a lipid-exposed substrate binding site (Qu and Sharom, 2002), two non­
identical drug interaction sites in the human protein (Dey et al., 1997), and a 
minimum of four distinct drug binding sites for substrates and modulators of P- 
glycoprotein transport (Martin et al., 2000). Nevertheless, the idea o f a common 
drug-binding pocket prevails for other investigators (Loo et al., 2003; Shapiro et al., 
1999). The existence of many separate binding sites to accommodate all the known 
different chemical classes of drugs known to be expelled by P-glycoprotein seems 
improbable. A single large flexible drug binding pocket might explain better the
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translocation of multiple different substrates. Structural analysis of a number of 
soluble multidrug-recognising proteins have shown the presence of large hydrophobic 
binding sites and that the binding of substrates is due to a combination of hydrophobic 
effects and electrostatic attraction rather than specific interactions (Neyfakli, 2002).
The concept of a single flexible binding site was based on research into the 
Bacillus subtilis transcriptional regulator BmrR (Neyfakh et al., 1991; Vazques- 
Laslop et al., 2000; Zhelesnova et al., 2000; Zhelesnova and Brennan, 2001). The X- 
ray crystal structure of this soluble multidrug-binding protein in complex with one of 
its substrates has been determined (Zhelesnova and Brennan, 2001). The drug is held 
in place within the protein eore by extensive van der Waals and stacked hydrophobic 
interactions, and with positively charged drugs, electrostatic interactions with a buried 
glutamate residue are important. In this system, each compound forms a different set 
of atomic contacts within the protein, in a flexible binding site. There is no special 
mechanism for multiple drug recognition by the BmrR protein, an idea that has been 
suggested for other proteins involved in multidrug transport (Sharom et al., 2001).
The staphylococcal protein QacR activates expression of the multidrug pump 
QacA in S. aureus (Schumacher et al., 2001), Although QacR is not an ABC 
transporter, it is the best example of how multidrug resistance proteins interact with 
their substrates. Six QacR structures bound to different substrates have been 
obtained, establishing that one large drug-binding pocket accommodates the different 
ligands. Aromatic and polar residues are present within the large pocket that also 
comprises several multiple drugs-binding mini pockets. Four glutamate residues, 
E57, E58, E90 and E l20 are involved in the charge neutralisation for different 
cationic drugs (Schumacher and Brennan, 2002). Conformational changes were 
observed when drugs were bound, allowing the hydrophobic core of the pocket, 
buried in the absence of drugs, to be exposed. On binding a drug, two aromatic 
residues Tyr92 and Tyr93, present in the drug-free state pocket, are expelled resulting 
in the displacement of glutamate 90 into the pocket and creation of the drug-binding 
pocket (Kaur, 2002). Two independent binding-sites have been identified for R6G 
and for ethidium, and a third site that overlaps part of the other sites (Schumacher and 
Brennan, 2003).
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Many of the features of the QacR structure are also found in BmrR (Kaur, 
2002). Although QacR and BmrR are not transporters, the architecture of the pocket 
of these structures appears to be well suited as a general characteristic of the MDR 
transporters.
1.3.3 Structure of complete ABC transporters
The recent determination of the crystal structure of various bacterial ABC 
transporters, such as the transporters for Lipid A and Vitamin B12 (e.g. E. coli MsbA; 
Chang and Roth, 2001 and BtuCD; Locher et al., 2002), is helping to elucidate the 
structure and mode of operation of ABC pumps. Although impeded for many years 
by the difficulty of expression and purification of the target proteins, the first high- 
resolution X-ray crystal structures of these membrane proteins are now available. 
Until recently, the only thi'ee-dimensional structure of a complete ABC transporter 
was a 25 Â resolution structure determined by electron diffraction (Rosenberg et al.,
1997). In 2001, Geoffrey Chang and Christopher Roth determined the first crystal 
structure of a complete ABC transporter at a resolution of 4.5 A, that of the E. coli 
MsbA transporter (Chang and Roth, 2001). This particular ABC transporter is a lipid 
flippase that translocates lipids from the inner layer of the cell membrane to the outer 
layer, and is more closely related to the mammalian P-glycoproteins than any other 
bacterial ABC transporter (Chang and Roth, 2001).
The overall organisation is consistent with most bacterial MDR-ABC 
transporters. The msbA  gene encodes a half transporter that contains a single 
membrane-spamiing region fused to a NBD, which is assembled into a homodimer. 
Hydropathy analyses confirm a six membrane spanning region and the localisation of 
the NBD on the cytoplasmic side of the membrane. Chang and Roth’s approach was 
to explore the cloning, overexpression and purification of more of than 20 full-length 
bacterial transporters and their homologues derived from several MDR-ABC 
transporter families and 12 bacterial species. From these, they sought the best subject 
for ciystallisation trials, attempting not less than 96,000 crystallisation conditions with 
about 20 detergents to finally obtain crystals of 35 different membrane proteins.
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The crystal structure obtained is compatible with that expected for this 
transporter; a homodimer, with each subunit composed of two domains. The structure 
also shows an additional intracellular domain (ICD) connecting the NB and TM 
domains. All the transmembrane -helices are tilted between 30° and 40° with respect 
to the plane of the membrane and give a cone shape to the structure (Fig. 1.9). The 
outer leaflet is the region where both TM halves contact at the top of the chamber 
cone holding the two monomers of the transporter together. The base of the structure 
facing the cytoplasm is -  45 Â in its widest dimension, being sufficient volume to 
accommodate the Lipid A molecule. There is no contact between NBDs, which are 
separated by ~ 50 Â at the closest point. Although in the structure of the NBDs the 
Walker A motif section was not well resolved, the ATP-binding sites are predicted to 
face away from the centre of the dimer. The inner leaflet is characterised by a eluster 
of positively charged amino acids contrasting with the hydrophobic environment in 
the outer membrane side. TM2 and TM5 (shown circled in Fig. 1.9) lead the contact 
between TM halves in the formation of the cone, and with TM6, have been proposed 
to play a role in the substrate recognition. The ICD region occupies an important part 
in the structure and shows considerably contact with both the TM and NB domains, 
including a direct contact with the NBD and TM 2, 5 and 6.
Chang and Roth (2001) suggested a possible mechanism to flip hydrophobic 
substrates in the E. coli MsbA transporter; the substrate (Lipid A as model) moves 
towards the base of the chamber presumably via the inner leaflet of the membrane. 
ATP binding and hydrolysis is triggered in the NBDs. Recruitment of the substrate 
and closure of the chamber is caused by the rearrangement of the TMs 2, 5 and 6 and 
the two NBDs. The polar environment in that part of the membrane presents an 
unfavourable environment for hydrophobic substrates and the substrate is flipped to a 
more favourable position in the outer leaflet bilayer of the chamber where it can 
establish hydrophobic interactions. The flipping of the substrate induces the chamber 
to undergo additional re-arrangements that include the separation of the NBDs and the 
repositioning of the main TM helices, enabling the complete expulsion of the 
substrate to the exterior and re-setting of the system. This particular mechanism 
explains the ability of multidrug transporters to drive the efflux of a number of 
different hydrophobic substrates. Additionally, the size and shape of the chamber 
allows the accommodation of a wide diversity of amphipathic molecules. This
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structure provides a foundation for the understanding o f the bioenergetics o f  
lipid/drug “flip flop” for the entire MDR-ABC transporter family.
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Figure 1.9 Structure of the E. coli MsbA homodimer (Chang and Roth, 2001)
TMD: transmembrane domain; ICD: intracellular domain; NBD: nucleotide binding domain
A second complete ABC transporter structure has been obtained, that o f the E. 
coli vitamin B12 importer BtuCD, at 3.2 Â resolution. All critical parts have been 
ordered and resolved (Locher et al., 2002). With a similar approach to the MsbA 
crystallisation, a number o f  different transporters were obtained from cloning and 
overexpression in E. coli and assayed in crystallisation trials. Crystals o f high quality 
were obtained for the BtuCD transporter and its structure is shown in Figure 1.10. 
This transporter consists o f two copies o f the TMD BtuC, and two copies o f the NBD 
BtuD, with subunits showing that the two ABC cassettes are in close contact with 
each other. The assembled complex is -  90 À tall, 60 Â wide and ~ 30 Â thick, and 
viewed from the front face, shows an overall shape resembling an inverted gate 
(Locher et al., 2002). Its structure contrasts with that of MsbA; in this case the TMD 
shows an asymmetric ordering and in a number higher than the 12 predicted 
transmembrane helices, there are not indications of the presence o f the ICD, and both 
NBDs are in close contact with each other.
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Each of the two BtuC subunits crosses the membrane 10 times creating a total 
of 20 helices in the transporter. Although very different from canonical transporters 
like MsbA that possess 12 helices, it is similar to the predicted transmembrane helices 
for other transporters such as the human antigen transporter TAP (19 helices; Lankat- 
Buttgereit and Tampe, 2002), and the ferrichrome-transporting FhuB protein (20 
helices; Groeger and Koster, 1998). The 10 transmembrane helices found per subimit 
are packed together in a rather entangled way with no similarities to the MsbA 
monomer. The interface between two membrane-embedded subunits allows a cavity 
to be formed (top section in the Figure) that is believed to correspond to the 
translocation pathway, being of sufficient size to accommodate the Vitamin B 12 
molecule.
The BtuCD structure shows the NBDs to be associated in a manner very 
similar to that reported for Rad50, where the P-loop of one monomer closely contacts 
the ABC signature region in the other monomer. This dimer interface consists mainly 
of amino acid residues from the highly conserved Walker A (P-loop) and D-loop, and 
from the moderately conserved Switch region, indicating that this dimer arrangement 
may be common to all members of the ABC family. Nevertheless, this dimer 
interface between both cassettes is rather small for a specific dimer contact surface 
and smaller than the interfaces between each pair of BtuC-BtuD subunits or between 
the two BtuC subunits. The structure suggests that the TM domains are required to 
stabilise the dimeric conformation of NBDs (Locher et al., 2002); in their absence the 
weak forces holding the dimers together may be insufficient to maintain their 
association. This would explain the divergence in dimer conformations for HisP and 
MalK.
Although there is not an ICD that links the TM and NB domains as occurs in 
the MsbA dimer, a long cytoplasmic loop between TM 6 and 7 from BtuC that folds 
into two short helices (LI and L2; shown in yellow in the Figure), provides the largest 
contribution to the TM-NB interface. This L loop has resemblance to the EAA motif 
of bacterial importers (Mourez et al., 1997), to the fourth intracellular loop of CFTR 
(ICL4) and to the first cytoplasmic loop in drug exporters, and it is believed that it 
may represent a general interface between ABC cassettes and membrane-spanning 
domains (Locher et al., 2002). The mechanism proposed for BtuCD is again based on
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a series o f binding and rearrangement events coupled to ATP hydrolysis by the NBD. 
In this case, it involves a permanent contact between the TM and NB domains. It is 
proposed that the binding o f the periplasmic binding protein-vitamin B 12 complex to 
the periplasmic domain o f BtuC induces ATP hydrolysis by BtuD. Consequently, this 
energy powers further re-arrangement o f the NB and TM domains to allow substrate 
translocation to a large water-filled space in the cytoplasmic side o f the membrane. 
Release o f ADP re-sets the transporter to its original state.
Translocation pathway
TMD
Cytoplasm
NBD
N te r N-ter
Figure 1.10 Structure of E. coli BtuCD (Locher et al,, 2002)
The differences noted between crystal structures may be also influenced by the 
crystallographic techniques, leading to non-physiological interactions. Although a 
useful tool to determine the architecture of ABC transporters, it is still necessary to 
verify as far as possible proposed modes o f action. The crystal structure of Vibrio
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cholera MsbA (Chang, 2003) has been informative in this regard since it shows the 
same features of its predecessor E. coli MsbA, but with a notable difference. In this 
structure (Fig. 1.11) the NBDs do not present an interface separation as in E. coli 
MsbA but they are in very close contact. This finding, again, supported the suggested 
close interaction between both nucleotide-binding subdomains and indicated that the 
E. coli and V. cholera transporters crystal structures might differ because they 
represent different stages in the transport process.
Figure 1.11 Structure of V, cholera MsbA (Chang, 2003)
More recently, the structure o f S. typhimurium MsbA has been added to the 
understanding o f this transporter, providing further knowledge on its architecture and 
that o f ABC transporters in general (Reyes and Chang, 2005). This new structure, 
obtained in complex with Mg* ADP «Vanadate and Ra Lipopolysaccharide to a 
resolution o f 4.2 Â, seems to show a post-hydrolysis intermediate (Fig. 1.12). In this 
structure, the NBDs appear folded as expected, and face each other in close proximity 
to perform ATP hydrolysis and possibly drive substrate translocation. The resolution 
of this new X-ray structure by Chang’s group further supports the "flip flop" 
mechanism described earlier for the translocation o f lipids from the inner layer o f the 
cell membrane to the outer layer (see p. 39, and Chang and Roth 2001).
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RaLPS
Figure 1.12 Structure of S. typhimurium MsbA in complex with 
Mg«ADP«Vanadate and Ra Lipopolysaccharide (Reyes and Chang, 2005)
P: periplasm; M; lipid bilayer matrix; C: cytoplasm; Ra LPS: Ra lipopolysaccharide; TMD: 
transmembrane domain; ICD: intracellular domain; NBD: nucleotide binding domain
1.4 Distribution and classification of the ABC transporter superfamily
ABC systems are involved in transport as importers or exporters, and this 
feature is the primary approach to their classification, although they are also 
implicated in many cellular processes and in their regulation. Importers comprise 
mostly the prokaryotic “transport substrate” binding protein-dependent (BPD) 
transporters and are involved in the acquisition of essential nutrients by bacteria. 
Exporters are extensive in both prokaryotes and eukaryotes and are implicated in the 
expulsion o f harmful substances, the secretion o f extracellular toxins and the targeting 
of membrane components (Path and Ko Iter, 1993). A third class o f ABC systems is
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not apparently involved in transport but in cellular processes such as DNA repair 
(Thiagalingam and Grossman, 1993), translation and regulation of gene expression 
(Belfield e ta l ,  1995).
A global phylogenetic tree of ATP-binding modules of ABC systems based on 
the MalK protein sequence was prepared in order to classify ABC transporters (Saurin 
et al, 1999). Two main branches were constructed, with one branch corresponding to 
proteins involved in export, while the other branch grouped proteins involved in 
import processes. Prokaryotes and eukaryotes were present in the first branch but the 
second one included only prokaryote proteins and mainly components of BPD 
transporters. ABC transporters were then divided in the families ABC-A and ABC-B. 
ABC genes in eukaryotes had already been classified in different families from 
ABC A to ABCG, based on gene organisation and primary sequence homology 
(Anjard et al, 2002; Klein et a l,  1999). Due to the broad distribution of ABC 
systems, more detailed use was made of the functions associated with these systems 
and three classes were primarily defined on the basis of cluster sequences analysis 
(Fig. 1.13) (Dassa and Bouige, 2001). Class 1 contains the majority of known 
exporters with fused nucleotide-binding domains (NBDs) and transmembrane 
domains (TMDs). Class 2 includes all systems with no known TMDs associated with 
ABC modules and consists of systems involved in antibiotic resistance and cellular 
processes other than transport. Class 3 contains all BPD importers and other poorly 
characterised systems which seem not to be involved in import. The general 
properties of the systems to which they belong appear summarised in Table 1.4.
45
f t
NO 
CCM
  FAF
DPL (e.g. P-gp, LmrA)
NO
OAD
MCMLc>NO
(e.g. CFTR,MRP1)
EPD-C
CLASS 1
(Majority o f known 
exporters)
EPD-N
RLI
ART
CBU
MET
ISVH
OSP (e.g. Mai) 
MOI 
OTCN
OPN-D
L MKL
OPN-F
"PAO
HAA-G
ABCY
YHBG
HAA-F
ABCX
MOS-N
MOS-C
L  CLS ORA (e.gOrrAB) 
L  DRI
CLASS 2
(No known
transmembrane
domains)
CLASS 3
(mainly BPD 
importers)
Figure 1.13 Unrooted phylogenetic tree of ABC proteins and domains presented 
by Dassa and Bouige
Only the branches pointing to families were drawn. The three classes and their main branches are 
indicated by different colours; black for class 1, violet for class 2 and teal blue for class 3. In class 3 
systems that are not conclusively related to import are highlighted by blue light squares. NO represent 
a few sequences with unknown function and apparently unrelated to neighbouring families. OPN-D 
and OPN-F, and HAA-F and HAA-G, correspond to the two different ABC subunits o f  OPN and HAA 
systems respectively. -C  and -N  added to a family name correspond to the C- and N- terminal ABC 
dom ains o f  system s w ith (TM -A BC)2, (A B C -TM ji and ABC] organisations; ABC refers to the 
nucleotide-binding domain, and TM, to the transm em brane domain. The ABC fam ilies are mainly 
named according to their functions. CCM: Cytochrome C maturation or Heme biogenesis; FAE: Long 
chain fatty acids or enzymes; DPL: Drugs, peptides, lipids; OAD: Organic anions, ions, drugs; MCM: 
M ethanogenesis; EPD: Eye pigm ent precursors, drugs; RLI: RNAse L inhibition, RNAse stability; 
ART: Antibiotic resistance, translation, regulation; CBU: Cobalt uptake; MET: Metals; ISVH: Iron- 
siderophores, vitam in B12, hem in; OSP: Oligosaccharides and polyols; MOI: M ineral and organic 
ions; OTCN: Osmoprotectants, taurine, cyanate, nitrate; PST: N ot mentioned; MKL: Unknown; OPN: 
O ligopeptides and nickel; PAO: Polar amino acids, opines; ABCY: Unknown; CDI: Cell division; 
LPR; Release o f lipoproteins from membrane; HAA: Hydrophobic amino acids and amines; YHBG: 
Unknown; ABCX: Unknown; MOS: Monosaccharides ; CLS: Capsular, Lipopolysaccharides, teichoic 
acids; DRA: Drug and antibiotic resistance; DRI: Drug resistance, bacteriocin immunity (based on 
diagram by Dassa and Bouige, 2001).
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Family
FAE
DPL
OAD
EPD
CCM
MCM
Saier
(a)
FAT
(5)
(9)
(8)
HemeE
HGNC Function 
(b)
Substrate type or process
ABCD EXPORT Long chain fatty acids or
enzymes
ABCB EXPORT Drugs, peptides, lipids
ABCC EXPORT Organic anions, ions, drugs
ABCG EXPORT Eye pigment precursors,
drugs
EXPORT Heme biogenesis 
Unknown Methanogenesis
ABC protein 
prototype (c)
ALD_HUMAN
HLYD_ECOLI
MDRl_MOUSE
CFTR_HUMAN
MRPI_Hl)MAN
WHlT_DROME 
PDR5_YEAST 
CCMA ECOLI
Organisation (d)
TM ABC
TM ABC (TM -AB02
(TM-ABC)2
ABC TM (ABC TM)2 
2TM ABC
Methyl coenzymc ABC2 
M reductase A
ART (7) ABCF Cellular
processes
Antibiotic resistance, 
translation, regulation
MSRA STAEP 
EF3_YEAST
ABC2
RLI
IIVR
ABCE RNase L inhibition, RNA 
stability
DNA repair, antibiotic 
resistance
RNA SELI 
irVTlA_ECOLI
ABC2
ABC7
MET MZT IMPORT Metals (Fe, Zn, Mn) ZNUC ECX>LI BP, 2TM, ABC
ISVH (3) IMPORT Iron-siderophores, vitamin B12, hemin
FHIJC_ECOLI OMR, BP, 2TM, ABC
OSP CUTI IMPORT Di or oligosaccharides and 
polyols
MALK_ECOLI BP, 2TM, ABC
MOI (1) IMPORT Minerals and organic ions CYSAECOLI POTD ECOIJ BP, 2TM, ABCOTCN (2) IMPORT Osmoprotectants, taurine, 
cy anate, nitrate TAlîB_ECOLI BP, TM, ABC
OPN PepT IMPORT Oligopeptides and nickel OPPD SAI.TY NIKE_ECX)LI BP, 2TMJABC
PAO PAAT IMPORT Polar amino acids, opines HISP SALTY BP, 2TM, ABCHAA HAAT IMPORT Hydrophobic amino acids 
and amides
L iv e  ECOLI BP, 2TM, 2 ABC
MOS CUT2 IMPORT Monosaccharides RBSAECOLI BP, TM, ABC2
CBU
MKL
ABCY
YHBG
CDI
CoT Unknown
Unknown
Unknown
Cobalt uptake? 
Unknown
Cell division
CBIG SALTY 
MKL MYC’LE 
ABC ECOLI 
YHBOECOLI
FISE ECOLI
TM, ABC 
SS,TM,ABC 
LPP, TM,ABC 
SS, TM, ABC
TM, ABCLPR DevE Release of lipoproteins from 
membranes
LOLD_ECOLI MFP or SS, (2)TM, ABC
ABCX ABCA EXPORT Unknown ABCX C \ APA ABC, 2 CY T
DRA (10) Drug and antibiotic 
resistance DRRASTRPE 2TM, ABC (TM ABC7)2
DRI
CLS
(6)
(4)
Drug resistance, bacteriocin 
immunity
Capsular, lipopolysacchari­
des, teichoic acids
BCILV_BACLI
KSTIECOLI
2TM, ABC
OMA, MPA2, TM, ABC
Table 1.4. Families of ABC systems identified in living organisms (Dassa and 
Bouige, 2001)
The three classes o f ABC systems appear with colour codes similar to presented in Fig. 1.13. Family 
names are abbreviations o f the substrate or the biological process handled by the systems. For families 
comprised o f systems with unknown function, an arbitrary name was assigned, (a) Names adopted by 
M. Saier for the classification o f transporters www.biolouy.ucsd.edu/-msaier/tTansport/tit iepage2.html. 
Some phylogenetic families described In this table are separated by his author in subfamilies according 
to substrate type. (I)  = SulT, + PhoT + MolT + FeT + POPT + ThiT; (2) = QAT + N itT + TauT; (3) -  
VB12T + FeCT; (4) = CPSE + LPSE + TAE; (5) = LipidE + GlucanE + P ro tlE  + Prot2E + Pep IE  + 
Pep2E +Pep3E + DrugE2 + DrugE3 + MDR + CFTR + Ste + TAP + HM T + MPE; (6) = NatE; (7) = 
D rugRA l + DrugRA2; (8) = EPP + PDR; (9) = C T l + CT2; (10) = D rugEl + CPR. (b) HGNC: these 
a re  th e  n am es  a d o p te d  by th e  H u m an  G en e  N o m e n c la tu re  C o m m itte e  
w w w .E en e .u c l .a c .u k / i i s e rs /h e s te r /a b c .h tm l . (c) When available, the Swissprot ID o f  the prototype 
protein is given, (d) Schematic representation o f  the organisation o f ABC systems. BP = extracellular 
substrate binding protein; LPP = extracytoplasmic protein with a lipoprotein type signal sequence; SS -  
uncharacterised secreted protein with a signal sequence; TM  = integral cytoplasmic membrane domain 
or protein; ABC = ATP binding cassette module; CYT = cytosolic protein; OM R ^  high affinity outer 
membrane receptor; OMP = outer membrane protein; OMA = outer membrane auxiliary protein; MFP 
= membrane fusion protein; MPA2 = type 2 cytoplasmic membrane periplasmic auxiliary protein
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1.5 Physiological role of ABC transporters
Different physiological roles have been listed for this superfamily of 
transporters, which is not too surprising if we take into account the many 
representatives from diverse lineages that form part of this group of transporters. 
Transport substrates comprise from veiy simple (e.g. ions) to complex molecules (e.g. 
proteins, complex polysaccharides and lipids). In some cases, these transporters are 
very specific, but in others, they show broad compound specificity. This is the case 
for transporters involved in multidrug resistance, which not only transport molecules 
with different physico-chemical properties but also compounds that vary significantly 
in size.
Apart from humans, fungi and bacteria, ABC transporters are also found in 
several parasitic protozoa, responsible for important illness around the world. For 
instance, the P-glycoprotein homologous gene, p fm d rl has been reported for the 
chloroquine resistant Plasmodium, the causative agent of malaria (Foote et al., 1989; 
Wilson et a l, 1989). Arsenate and antimony resistant Leishmania, where the gene 
ItpgpA has been isolated and its product shown to be more similar to the multidrug- 
resistance-associated protein (MRP) and to the cystic fibrosis transmembrane 
regulator (CFTR) than to P-glycoproteins (Cole et a l, 1992); emetine-resistant 
Entamoeba histolytica, which causes the universal amoebiasis (Descoteaux et a l ,  
1992), and metronidazole resistant Trichomonas vaginalis (Johnson, 1993) are other 
important examples of parasitic protozoa producing severe diseases in developing 
countries. In yeast, the STE6  gene of Saccharomyces cerevisiae encoded the first 
non-mammalian P-glycoprotein described so far (McGrath and Varshavsky, 1989). 
This protein is not involved in the transport of drugs but of a pheromone, which is 
necessary for mating. Other ABC transporters are involved in drug resistance, 
examples of those transporting drugs are the products of the SNQ2 gene, that confers 
resistance to 4-nitroquinolone-N-oxide and others chemicals (Servos et a l, 1993); and 
STSl and PD R5  that confer a multidrug resistance phenotype when they are 
overproduced (Bissinger and Kuchler, 1994). A more extended view of some of 
the different roles displayed by ABC transporters, with their respective examples, is 
presented in Table 1.5 to illustrate the importance of this family.
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Table 1.5. Physiological role of ABC transporters
Physiological
role
ABC
transporter
representative
Substrate Organism Reference
Nutrient HisJQMP Histidine S. typhimuriiim Ames, 1972
uptake MalEFGK Maltose E. coll D avidson and N ikaido, 1991
BtuCD Vitamin B 12 E. coll Reynolds et a i ,  1980
ModBC Molybdenum E. coll M aupin-Furlow  et a i , 
1995
Polysaccharide KpsTM K5 c a p su lla r
f ^ v ' tA a
E. coll K5 R e izere /a /., 1992
export
Pep tide and HlyBD Haemolysin E. coli Fath and Kolter, 1993
protein export BcrABCD Bacitracin Bacilluslicheniformis Podlesek et a i ,  1995
PrtED Proteases Erwinia
chrysantemii
Létoffé et a i ,  1990
NisT Nisin precursor L. lactis Engelke et a i ,  1992
LcnC Lactococcins L. lactis Franke et a i ,  1999
CvaB Colicin V E. coli Wu and Tai, 2004
Cellular NodlJ Nod factors Rhizobium
leguminosarum
Spaink et a i ,  1995
signalling and YbdAB" Unknown" B. subtilis Isezaki et a i ,  2001
differentiation
Multidrug P-gp (A B CB l) Multidrugs H. sapiens Gottesman et a i ,  1996
MRP (A B CC l) Multidrugs H.. sapiens Cole and Deeley, 1998resistance LmrA Multidrugs L. lactis Van Veen et a i ,  1998
Pdr5 Multidrugs S. cerevisiae B issinger and Kuchler, 
1994
MacB Macrolides E. coli Kobayashi et a i ,  2001
PghT Multidrugs*^ P. falciparum KneXzet a i ,  1996
Intracellular TAP" Peptides'^ H. sapiens Beck et a i ,  1992
export Atm Ip Iron/sulphurclusters S. cerevisiae L eigh ton  and Schatz, 1995
ADLP (A B CD l) Long-chain 
fatty acids H. sapiens
Mosser et a i ,  1993
Ion channels CFTR (ABCC7) Chloride anions H  sapiens Luckie et a i ,  2003
SURd
(ABCC8/ABCC9)
Potassium
cations'*
K  sapiens A g u i la r - B r y a n  an d  
Bryan, 1999
“ A regulatoiy role in the sporulation o f B. subtilis has been suggested (Isezaki et a i ,  2001)
The multidrug transport P ghland  its resistance role in P. falciparum  has remained controversial due 
to contradictory results obtained by different authors (Bray et a i ,  1992; Ginsburg and Krugliak, 1992, 
Krogstad et a i ,  1987, 1992)
Antigen processing 
 ^Potassium channels ATP dependent
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1.6 The drug-efflux system of Streptomycespeucetius
1.6.1 Actinomycetes
The Actinomycetes are a group of microorganisms that show characteristics of 
both bacteria and fungi. The growth habit of Actinomycetes is hyphal and may form 
a mycelium characteristic of fungi, although hyphae are always of smaller diameter 
and usually do not exceed one micrometre (Alexander, 1961). Additionally, 
Actinomycetes are able to produce an aerial mycelium and conidia characteristic of 
fungal species. When they are grown in pure liquid culture, the turbidity usually 
associated with bacterial growth is absent, and in many species the growth rate is not 
exponential as it is in bacteria (Alexander, 1961). However, unlike fungi, 
actinomycetes are prokaryotes. They have been placed in the bacterial group of 
Gram^, and in the order Actinomycetales. Actinomycetes play both detrimental and 
beneficial roles in nature. Among their negative attributes is their ability to cause 
opportunistic diseases in animals, humans, forestry and plants, and spoilage of hay, 
straw, cereal grains, seeds, bagasse, plant fibres, wood, pulp, paper, wool, 
hydrocarbons, rubber and plastic. Biodégradation by these organisms, on the other 
hand, plays an extremely useful role in waste removal and as an integral part of the 
recycling of materials in nature. Actinomycetes are numerous in soil, where they 
have three important environmental roles: decomposition of the organic matter; 
binding clay particles to their filaments that is conducive to crop production; and 
responsible in part, for the earthy odour of soil. Many Actinomycetes are also good 
chitin degraders because Actinomycetes are "late colonisers" and play vital roles in 
degradation processes and the formation of humus (Schrempf, 1995). Actinomycetes 
decompose lignocellulose from plant residues and have potential for bioconverting 
waste materials into chemicals. Mesophilic and thermophilic species produce 
celiulases, xylanases, amylases, proteases and ligninases. Thermotolerant and 
thermophilic species are active in composts degrading plant polymers and generating 
heat. The ability o f certain Actinomycetes to degrade lignin and/or cellulose is 
potentially important in the production of liquid fuel and chemicals from 
lignocellulose (Piret and Demain, 1988).
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Aerobic Actinomycetes that are frequently found in environmental 
microbiology include Streptomyces, Rhodococcus, Nocardia, Mycobacterium, Actino- 
madura, Nocardiopsis, and Dermatophilus (Grant and Long, 1981). Most attention 
has been focused on the ability of Actinomycetes to synthesise antibiotic compounds. 
Thus, the search for novel species and the mass screening of species for secondary 
metabolites has been a major focus of pharmaceutical companies worldwide.
Natural antibiotics, particularly those from the genus Streptomyces, are as 
important as the -lactam antibiotics, which are derived from chemical modification 
of existing antibiotics.
Actinomycetes are rather difficult to identify at the species level but cell wall 
type, extracted sugars, morphology and the colour of mycelia and sporangia, G + C 
content, membrane phospholipid composition, and the heat resistanee of spores are all 
useful in this regard. Comparison o f 16S rRNA sequences and pulse-field 
electrophoresis o f large DNA fragments produced by restriction endonuclease 
digestion are also used for classification purposes.
1.6.2 Streptomyces
The oxàQV Actinomycetales is divided into 10 suborders. The Streptomycineae, 
is the most relevant suborder as it contains the Streptomyces genus, many species of 
which are ecologically and medically important. Research on Streptomyces indicates 
that they, along with other fungi, may play an important role in the degradation of 
lignin. They play important roles in degradation in compost piles. Streptomyces are 
also important agents in the degradation of organic matter in soil and contribute to the 
formation of stable humus (Metting, 1992). A few species are pathogenic for animals 
and humans (McNeil and Brown, 1994); Streptomyces somaliensis is known to be 
pathogenic in humans, causing actinomycetoma (Nasher and Hay, 1998), which is an 
infection of subcutaneous tissues that produces swelling, abscesses and even bone 
destruction. Other species are phytopathogens.
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The Streptomyces genome is about twice the size o f E. coli, and the organism 
is characterised by the presence of L,L-diaminopimelic acid (L,L-DAP) in its cell wall 
peptidoglycan. It also possesses complex polar lipids that typically contain 
diphosphatidylglycerol. Members of the genus are aerobes and chemoorganotrophic, 
having an oxidative type o f metabolism. They are catalase positive and generally 
reduce nitrates to nitrites, degrade adenine, esculin, casein, gelatin, hypoxanthine, 
starch and L-tyrosine, and use a wide range o f organic compounds as sole sources of  
carbon for energy and growth (Goodfellow and Cross, 1974). Streptomyces albus is 
the species prototype and the differentiation o f species in this genus is difficult. There 
are over 50 named species, and their differentiation is based on a combination of 
pigmentation, morphological and physiological traits.
On isolation, colonies are discrete and lichenoid, leathery or butyrous; initially 
relatively smooth surfaced but later they develop a wide variety o f aerial mycelia that 
may appear granular, powdery, velvety or floccose (Alexander, 1991). Streptomyces 
produce a wide variety of pigments responsible for colours o f the vegetative 
mycelium, aerial mycelium and substrate, being the colour of mature sporulated aerial 
mycelia, white, grey, yellow and some other colours in between. Streptomyces are 
slow growing organisms and isolation plates are often incubated for 1 to 2 weeks to 
allow differentiation and adequate growth o f the colonies (Fig. 1.14).
%
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Figure 1.14 Streptomyces colonies on agar (reproduced from
http://rilefaox.\'t.cdii/iiscrs/chaucdor/biol 4684/M icrobcs/strcp.htinl)
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Besides producing many secondary metabolites, extracellular enzymes, 
enzymatic inhibitors and pigments (Schrempf, 1991), the bacterial genus 
Streptomyces is noted for the production of antibiotics, as much in volume as in 
diversity. Practically all the different chemical families of antibiotics active against 
bacteria, fungi, algae, viruses or tumours are produced by some representative from 
Streptomyces.
1.6.3 Drug export as self-protection mechanism in antibiotic producing 
organisms
Diverse mechanisms to protect antibiotic-producing organisms have been 
described (Ohnuki et aL, 1985; Levy, 1992). In tetracycline producers, cytoplasmic 
resistance determinants (e.g. TetM, OtrA) are associated with the ribosome and 
prevent its interaction with the antibiotic (Roberts, 1994; B hal and Hunter, 1995). 
The microorganism may lack the target site for the antibiotic it produces (Vining, 
1979). Modification of the antibiotic or its target site in the producing organism and 
active transport out of the cell seem to be the most common mechanisms to avoid the 
effect of these autotoxic compounds. A resistance mechanism implied for producers 
of antibiotic peptides (e.g. subtilin, nisin, lacticin) seems to require the presence of a 
couple of ABC transporters, one of them being necessary for the re-translocation of 
exported peptides that have penetrated the membrane from the external media (Abee,
1995). Another ABC peptide exporter also involved in producer self-protection is the 
bacitracin transporter (Bcr) of B. licheniformis (Podlesek et al., 1995). Both proton- 
dependent transmembrane electrochemical gradients and ABC pumps are represented 
in Streptomyces self-resistance mechanisms. The self resistance of S. peucetius to the 
anti-tumour anthracycline compounds daunorubicin and doxorubicin, is one of the 
known examples that involves active transport of antibiotic compounds out of the 
producing cell to avoid its toxicity (Guilfoile and Hutchinson, 1991; Kaur, 1997). 
Other Streptomyces species possess self-resistance mechanisms that involve ABC 
transporters; some examples include the tylosin-resistance protein TlrC from 
Streptomyces fradiae (Rostek et a l, 1991), which is similar to the DrrA protein; the 
oleandomycin transporter OleC from Streptomyces antibioticus (Olano et ah, 1996); 
the Streptomyces argillaceus mithramycin resistant-determinant (Fernandez et a l,
1996); the Cb carbomycin-resistance determinant in Streptomyces thermotolerans
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(Epp et al, 1987); and Streptomyces rochei msr that is another gene that would 
encode a multidrug ABC transporter (Fernandez-Moreno et al., 1998).
A summary of some examples of ABC transporters responsible for antibiotic 
resistance mechanisms in antibiotic producing microbes can be seen in Table 1.6. As 
many ABC transporters have been located in antibiotic biosynthetic gene clusters, it is 
logical to link their presence to some natural function for the export of the product 
across the cellular membrane to avoid their autotoxic effects (Mendez and Salas, 
2001).
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Table 1.6. ABC transporters in antibiotic-producing actinomycetes
Synthesised Producer ATP Membrane References
antibiotic
Type I
organism binding
protein
protein
Daunorubicin S. peucetius DrrA DrrB G u i l f o i l e  a n d  
Hutchinson, 1991
M ithramycin S. argillaceus MtrA MtrB Fernandez et al., 1996
Oleandomycin S. antibioticus OleC 01eC5 Rodriguez et al., 1993
Tetronasin S. longisporoflavus TnrB2 TnrB3 Linton et al., 1994
Macrotetrolide S. griseus Non-orf5 Non-orf6 Smith et al., 2000
Kasugamycin S. kasugaensis KasK KasL, KasM Ikeno et al., 2000
Rapamycin S. hygroscopicus OrfX Schwecke et al., 1995
Type II
Carbomycin S. thermotolerans CarA - Schoner ef a/., 1992
Spiramycin S. ambofaciens. SrmB - Schoner e/fl/., 1992
Tylosin S. fradiae TlrC - Rosteck et a/., 1991
Oleandomycin S. antibioticus OleB - Olano et al., 1996
A201A S. capreolus A rdl - Barrasa et al., 1995
Lincomycin S. lincolnensis LmrC - Peschke et al., 1995
Frenolicin S. roseofulvus FnrD - AF058302
Virginiamycin S. virginiae VarM - Kawachi et al., 2000
Type III
Bleomycin Stv. Verticillum BIe-0rf7 In ty p e  III 
transport both
C a lcu tt and S chm idt, 
1994
Streptomycin S. glaucescens StrV, StrW dom ains are Beyer et al., 1996
Chloroeremomycin A. Orientalis OrfZ fused Wageningem et al., 1998
Novobiocin S. sphaeroides NovA Steffensky et a l ,  2000
Nystatin S. noursei NysG and 
NysH
Brautaset et al., 2000
In p roducer o rganism  colum n; A is A m yc o la to p a to p sis \ S is S trep to m yces  and; Stv is 
Streptover tic ilium. In type I transporters, ATP-binding domains and membrane domains are produced 
in separate proteins. In type II transporters, membrane domains have not been reported. In type III 
transporters, ATP-binding domains are fused to membrane domains in a single protein. This table is an 
adaptation o f  the table presented by Mendez and Salas, 2001.
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1.6.4 The DrrAB pump system
In addition to antibiotics like aminoglycosides, tetracyclines, chloramphenicol, 
and some p-lactams that are produced by members of the genus Streptomyces, S. 
peucetius produces the antibiotics doxorubicin and daunorubicin (Guilfoile and 
Hutchinson, 1991). These compounds are classified into the anthracyclines and 
possess antitumoral activity (Arcamone, 1981), expanding the arsenal of compounds 
with different activities produced by Streptomyces.
The way in which S. peucetius avoids the effects of the anthracyclines they 
produce, is by pumping them out of the cell (Guilfoile and Hutchinson, 1991) using 
an ABC transporter (Gottesman and Pastan, 1993). Two subunits are present, one of 
them, DrrA, is a peripheral membrane protein that acts as the energy-transducing 
component, and the other, DrrB, is the membrane carrier. This type of permease 
cames out export of antibiotics in an ATP-dependent mamier.
In 1991, Guilfoile and Hutchinson cloned, sequenced, and transcribed the 
genes that confer resistance to the daunorubicin and doxorubicin compounds. The 
transformation of Streptomyces lividans allowed the analysis and recognition of the 
drrAB locus by resistance selection to the anthracyclines (Guilfoile and Hutchinson, 
1991). Transcription of both genes could not be detected early in growth, suggesting 
that drrA B  transcription might be co-regulated with the genes for antibiotic 
production.
Having identified start and stop codons for each reading frame of the operon, 
they could predict that drrA would encode a predominantly hydrophilic protein 
containing 330 amino acids with a molecular mass of 35,668 Da and a pi of 5. 
Similarly, drrB would encode a very hydrophobic protein, composed of 283 amino 
acids, a molecular mass of 30,614 Da and a pi of 7.5. They concluded that the 
sequence of the predicted product of the drrA gene was similar to the products of 
other transport and resistance genes, notably with P-glycoprotein from mammalian 
tumour cells and that it was probably involved in the transport of the same substrates. 
DrrB, on the other hand, showed no significant similarity to other known proteins. 
Later investigations reported that DrrB exhibited statistically significant sequence
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homology to integral membrane components of four bacterial ABC transporters, such 
as NodJ from NodlJ, involved in oligosaccharide export in R. leguminosarum (Evans 
and Downie, 1986), KpsM from KpsTM, involved in capsular polysaccharide export 
in E. coli (Smith ei aL, 1990; Pavelka et a l,  1991), and its capsular polysaccharide 
export homologues BexB from H. influenzae Bex ABC (Kroll and Moxon, 1990) and 
CtrC from N. meningitidis CtrDCB (Frosch et al., 1991). In conjunction with the 
homology that DrrA presents with the ATP binding constituents o f these four 
transporters, suggested a novel subclass of transporters to be named the ABC-2 family 
(Reizer et aL, 1992).
The open-reading frames of the drrrA and drrB genes were sub-cloned and 
expressed in E. coli expression vectors as single or coupled gene constructs (Kaur,
1997). Both gene products showed a molecular mass that corresponded to that 
predicted from their nucleotide sequences (36 kDa for DrrA and 31 kDa for DrrB), 
The DrrA protein was present in the cytosolic fraction and was also located in the 
membrane. The DrrB protein was scarcely expressed in the absence of the drrA gene, 
and was shown to be toxic for E. coli growth. DrrA was shown to bind ATP and GTP 
in the presence of magnesium ions in a UV cross-linking assay. The binding of 
nucleotide to DrrA was enhanced by the presence of doxorubicin, indicating that the 
activity of the pump was regulated by its substrate (Kaur, 1997; Kaur and Russell,
1998).
It has been suggested that a very close relationship between both subunits is 
required for the activity of this system, and subsequently, for the resistance of S. 
peucetius towards its own antibiotic. DrrA was expressed as an active form that could 
bind ATP only when it was in complex with DrrB. UV cross-linking studies with 
^^P] ATP showed that only the membrane-bound form of DrrA in cells containing 
both DrrA and DrrB, was in a conformation competent to bind and/or hydrolyse ATP 
(Kaur and Russell, 1998). Kaur and Russell’s work emphasised that ATP interacted 
with membrane-bound DrrA and not with DrrA present in the cytoplasmic fraction, 
irrespective of whether or not it was over-expressed in the presence of DrrB.
Although DrrB seems to be translated in the absence of DrrA, it was only 
detected after translation of both the drrA and drrB  genes (Kaur, 1997; Kaur, and
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Russell, 1998) indicating a requirement upon the drrA gene product for stabilisation 
of the DrrB protein. Chemical cross-linking studies also suggested a direct interaction 
between DrrA and DrrB with a probable stoichiometry of the complex as DrrAzDrrBz. 
The authors proposed that DrrA is an allosteric protein that acquires different 
conformations depending on the presence or absence of DrrB and the ligand 
doxorubicin.
Another gene, drrC, is also involved in S. peucetius resistance to anthiacycline 
antibiotics, specifically daunorubicin (Dm). However, DrrC is not part of the DrrAB 
pump; it is proposed to protect DNA from Dnr as soon as its production starts, and 
that DrrA and DrrB work to export the antibiotic after its concentration rises in the 
cell (Fur ay a and Hutchinson, 1998). A regulatory role for the dnr I  gene product in 
the production of DrrC, DrrA, and DrrB proteins has been proposed by these authors.
An equivalent DrrAB(C) system was also reported and characterised for M  
tuberculosis (Choudhuri et aL, 2002; Nash, 2003), although its role in this 
microorganism is not yet clear. DrrA, particularly, shares some features with other 
NBDs, notably its preference for ATP as substrate and its dependence upon divalent 
cations like magnesium. When purified in isolation and assayed, ATPase activity is 
not affected by the presence of the transport substrate and interaction with membrane 
components does not take place unless the protein is reconstituted into 
proteoliposomes.
Most ABC transporters consist of two nucleotide-binding domains (NBDs) 
and two transmembrane spanning domains (TMDs) of six-helices each. DrrAB 
consists of one NBD and one TMD, equivalent to a half transporter, and it is thought 
further association is required to form a full transporter structure. A seven-helix 
topology had been suggested for DrrB, different from the six-helix reported in the 
transmembrane domains of many other transporters. Recent experiments (Gandlur et 
aL, 2004), support an eight-helix topology (Fig. 1.15). Fusion of DrrB to several 
reporter genes indicated the presence of the N- and C-termini in the cytoplasm.
58
Periplasm
ATP ADR + Pi
CytoplasmN-
Flgure 1.15 Diagrammatic presentation of the membrane topology of the two 
transport domains from S. peucetius DrrAB transporter.
Two polypeptides are encoded by different genes; the membrane domain (eight a-heiices) by drrB, and 
the nucleotide-binding domain, by drrA. The figure above represents a half transporter. Two TM and 
two NB domains would form the canonical structure for the ABC transporters.
New experiments from Kanr’s group (Kaur et al., 2005), have used single­
cysteine DrrB mutants in chemical cross-linking experiments. Single cysteine 
residues were created in the transmembrane and cytosolic loops by site-directed 
mutagenesis, and subsequently attempts were made to link the DrrB proteins to a 
primary amine in DrrA. This was used to map possible sites o f  DrrA DrrB 
interaction. Interestingly, a motif that might be equivalent to the EAA sequences 
reported in ABC importers was identified in the N-terminal cytoplasmic tail o f DrrB, 
and shown by sequence analysis to be also present in exporters.
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1.7 Aims of the project
The goal of this project is to determine the molecular mechanisms of 
antibiotic binding and translocation for the doxorubicin pump, DrrAB, from S. 
peucetius.
Principally, the approach will be to prepare proteins for transient kinetic 
experiments to provide mechanistic information. If sufficient protein can be 
obtained, it might also be used for crystallisation trials to provide structural 
information. An additional potential goal would be to use the DrrA protein as a 
component of a biochip to screen for inhibitors of the antibiotic pump.
If the ATP binding domain can be functionally separated from the membrane 
domain of the transporter it may then be possible to overproduce these domains 
separately for detailed structure-function studies. Knowledge of the structure of DrrA 
will be important in elucidating the architecture of the antibiotic binding-site. As such, 
Drr is an important model system for the study of the molecular mechanism of 
resistance pumps. Understanding the structure and function of one of these pumps 
will be vitally important in combating the escalating threat posed by multidrug 
resistant pathogens and in cancer chemotherapy.
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Chapter 2
MATERIALS AND METHODS
2.1 Reagents and materials
2.1.1 Source of reagents and materials
Chemicals were mainly acquired from Sigma and BDH, but as well from 
Aldrich, Riedel-de Haen, and Fischer. Difco and Oxoid supplied microbial growth 
media. Enzymes used in molecular biology were obtained from Promega, Roche, or 
Gibco. Additional reagents or materials for special applications are noted in the 
respective section in this chapter.
2.1.2 Preparation of chemical and media solutions
General chemicals were weighed on an AND digital balance and dissolved in 
distilied/de-ionised water. Small amounts were weighed on a Metier Toledo digital 
fine balance.
2.1.3 Sterilisation of reagents and materials
Reagents and media to be sterilised were either autoclaved or filter sterilised, 
depending on their stability to heat. Sterilisation by autoclaving was performed at 
121 °C for 15 minutes at 4 atmospheres pressure. Filter sterilisation was used for heat 
labile liquid reagents by filtration tlmough a 0.2 pm Millipore syringe filter.
2.1.4 Centrifugation
Routine room temperature centrifugation of 1.5 ml microcentrifuge tubes was 
performed in a MSB MicroCentaiir benchtop microcentrifuge, fitted with a 24 place 
fixed angle rotor. When cooling was required, a Jouan CRi benchtop refrigerated 
centrifuge was used. Larger volumes of liquids were processed in a Beckman-Coulter 
Avanti J-E refrigerated centrifuge accommodating several different fixed angle rotors. 
A Beckman JA-10 rotor was used to process volumes up to 3 litres in 500 ml plastic 
containers, whilst a Beckman JA-21 rotor was used to process up to 400 ml in 50 ml
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tubes. High-speed ultracentrifugation was performed in a Beckman L8M 
ultracentrifuge using a Beckman Ti50 fixed angle rotor.
2.2 Microorganisms; growth and storage
A list of all bacterial strains used in this thesis is presented in the Table 2.1.
2.2.1 Growth media
Basic liquid cultures for propagation of E. coli strains used two main types of 
growth media:
Luria-Bertani (LB) medium:
NaCl lOg/L
Tryptone lOg/L
Yeast extract 5 g/L
2X YT medium:
NaCl 5 g/L
Tryptone 16 g/L
Yeast extract 10 g/L
62
Table 2.1 Bacterial strains used in this study
Microorganism Genotype Origin Application
Escherichia coli enclAl hsdR17(ric]2~ V supE44 th i-1 Novagen General cloning
Novablue re c A I  g y rA 9 6  r e lA l  la c  [ F ’ 
proA 'B 'laéZJA Î5::TnlQ (tei^)]
Escherichia coli X L l- r e c A l  e n d A l g y r A 9 6  (h i —I Stratagene General cloning
Blue h sd R 1 7 su p E 4 4  r e lA l  la c  [ f  
pro  A *B^laéZ_MÎ5TnlO(tei^)]
Escherichia coli XL 10 Tef' __(tncrA) 183 (mcrCB-hsdSMR- Stratagene General cloning
Gold mrr)173 end A1 suoE44 thi-1 recA l 
gyrA96 re lA l lac The[F’ proAB lad’Z 
_M15 TnlO (Tei'^ ) Amy Cam'
Escherichia coli TOP 10 F  m crA  _(mrr-hsdRMS-mcrBC) 
_80lacZ_M 15 _lacX74 recA l deoR  
araD 139 _(ara-leii)7697  g a lU  galK  
t'psL (Str’^ ) endAlnupG
Invitrogen pBADTOPO 
cloning and 
mediated 
recombinant 
expression
Epicurian coli B L21 E. coli B F  omp had S (rjf mF) dcm' Stratagene pET21-a mediated
(DE3) Tef g a l EndA The[argU  ileY  leiiW  
Cam']
recombinant
expression
Epicurian coli BL21 AI F  ornpT h sdS ^  (rFmF) g a l dcm 
araB:: T7RNAP-tetA
Invitrogen pET21-a mediated 
recombinant 
expression
Escherichia coli BMH Thi, siipE, _(lac-proAB, [/?m/S:TnlO] Promega Site-directed
mutS [F’, proP4Q, la c j\Z _ M  15 mutagenesis
Escherichia coli _80lacZ_M l5 recA l endAl gyrA96 thi- Promega General cloning
DH5_pro 1 hsdR17(rir mF) supE44 re lA l deoR 
JlacZYA-argF) V I69
Escherichia coli F  mcrA _lacX74 gal E thi rpsL _phoA Invitrogen pBADTOPO
LMG194 (Pvu 11) _ara714 leii::TnlO cloning and 
mediated 
recombinant 
expression
Escherichia coli N a t StF R i f  Thi Lac Ara" G a t  M tt F Qiagen Protein expression
M15[pREP4] RecA'  ^ Uvr'' Lon
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2.2.2 Growth of bacteria
Escherichia coli strains were routinely cultured in Luria-Bertani (LB) 
broth, supplemented with the appropriate antibiotic where necessary. When solid 
media were prepared, agar was added at 1.5% w/v prior to autoclaving. To provide 
higher cell densities when large volumes of cells were required for expression 
cultures, 2X YT broth was used. Other media such as SOC and NZY^ were used 
in some specific cases according to the requirements of the particular protocol.
Inoculation in liquid broth was achieved by transferring a single colony from a 
plate to an appropriate volume of medium. The culture was incubated, with rotary 
shaking at 200 rpm and 37 °C, in a 25-ml conical bottomed universal container.
Culture on solid media was achieved by streaking or spreading organisms onto 
the agar surface, using a sterile microbiological loop or sterile spreader. Plates 
were placed in a 37 °C incubator, in an inverted position, for 18 hours,
2.2.3 Storage of bacteria
Stock cultures of each bacterial strain used were prepared in order to maintain 
their long term integrity and viability. Stocks were typically prepared by mixing 800 
111 of an overnight liquid culture with 200 jal of sterile 80% glycerol, and stored at -80 
°C. These strains were retrieved by scraping a small amount of the frozen stock using 
a sterile loop, and then streaking this material onto solid growth medium for 
overnight incubation at 37 °C.
2.2.4 Antibiotics
The use of antibiotic markers in a culture is a useful tool to ensure the 
presence of plasmids and the selection of strains that carry specific genetic markers 
such as antibiotic resistance genes, avoiding contamination by other microorganisms. 
Antibiotics were made up at the following final concentrations unless otherwise stated 
and filter sterilised before use: ampicillin 100 mg/ml; carbenicillin 100 mg/ml; 
kanamycin 50 mg/ml; doxorubicin 2 mg/ml in DMSO.
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2.3 Isolation and analysis of nucleic acids
2.3.1 Agarose gel electrophoresis
Electrophoresis in horizontal gel slabs was used for analysis of DNA. 
Agarose was dissolved at 0.9-1% (w/v) in TAE buffer by boiling the mixture in a 
microwave. The solution was allowed to cool slightly before the addition of the DNA 
staining reagent ethidium bromide at a final concentration of 0.1 pg/ml. The mixture 
was poured into a horizontal gel-tray and allowed to set solid by cooling. Wells for 
sample loading were created in to the agarose slabs by fitting a comb into one end of 
the molten agarose solution. The agarose slabs were then placed into electrophoresis 
tanks and submerged in TAE buffer prior to sample loading.
The DNA samples were mixed with 6X loading buffer and applied to the gel 
wells, whilst a 1 kb DNA ladder (Roche Molecular Diagnostics; 5 pg) was used for 
reference. Gels were typically run at 110 V.
The presence of the dyes bromophenol blue and xylene cyanol in the loading 
buffer, allowed the progression of the samples through the gel to be observed so that 
we could determine when the DNA had migrated a sufficient distance. Then the gel 
was examined on an ultraviolet light transilluminator to visualise the DNA. If 
necessary, the gel was photographed using a Polaroid MP4 instant camera system or a 
SynGene Bio Imaging system.
Buffer compositions:
IX TAE:
4.84 g Tris base
1.142 ml glacial acetic acid
2 ml 0.5 M EDTA
Made up to 1 L in distilled water
6X DNA loading buffer:
100 mM EDTA (pH 8.0)
1% w/v SDS
0.1% w/v bromophenol blue
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0.1% w/v xylene cyanol 
50% glycerol
2.3.2 Small scale preparation of plasmid DNA
Bacterial strains harbouring plasmids were cultured in 5 ml LB broth, 
containing appropriate antibiotics, and harvested by centrifugation. Plasmid DNA 
was then isolated using the QIAprep Spin Miniprep Kit (Qiagen), according to the 
manufacturer’s instructions. The procedure uses the modified alkaline lysis method 
of Birnboim and Doly (Birnboim and Doly, 1979), and the lysate is subsequently 
neutralised and adjusted to high-salt conditions in one step, before centrifugation. 
The next step comprises the absorption of plasmid DNA onto a silica-gel membrane 
housed in the QIAprep spin column. The final steps comprise the washing and 
elution of purified plasmid DNA from the column.
2.3.3 Extraction of DNA from agarose gels
DNA was extracted from agarose gels for cloning. This was accomplished 
using the QIAquick Gel Extraction Kit (Qiagen) according to manufacturer’s 
instructions. The sample containing the DNA target was separated on an agarose gel 
containing ethidium bromide. After visualisation of the DNA on a UV 
transilluminator, the bands required were excised from the gel for extraction. The gel 
slices were mixed with solubilisation buffer (solution QG) at a ratio of 300 pi per 100 
mg of agarose and incubated in a water bath at 50 °C, until complete dissolution of the 
agarose had been achieved. The sample was then applied to a spin column, allowing 
DNA adsorption to its silica-membrane. Other components of the solution were 
cleared by centrifugation through the spin column. Subsequent washing removed 
traces of agarose and residual buffers. The DNA was eluted in a last step.
2.3.4 Alternative Procedure for gel extraction/purification/concentration of DNA
Alternatively, the Qiaex 11 resin (Qiagen) was also used for DNA gel 
extraction following the manufacturer’s instructions.
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2.4 DNA amplification, cloning and sequencing
2.4.1 Use of the Polymerase chain reaction (FCR)
PCR was mainly used to amplify the drrA gene for insertion into different 
vectors. Alternatively, PCR was also used for site-directed mutagenesis and 
assessment of the orientation of genes inserted in the pBADTOPO thio vector.
2.4.1.1 Template
Streptomyces peucetius drrA, or drrA and drrB, were prepared by PCR using 
the cosmid pWHM612 (the kind gift of Guilfoile and Hutchinson) as template.
2.4.1.2 Oligonucleotide primers for PCR
Oligonucleotide primers for PCR (Table 2.2) were synthesised at a 50 nmol 
scale by Life Technologies and supplied desalted and lyophilised. Primers were re­
suspended in the appropriate volume of 10 niM Tris-HCl pH 8.0 to achieve a stock 
concentration of 50 pmol per micro litre.
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Table 2.2 Oligonucleotide primers for PCR
Primer name
pET21a-(7/'rX forward 
pET21a-c//rX reverse 
F E Ïll^-dirA B  forward 
FET2\?i-dn'AB reverse 
pET33b-c//7*42J forward 
pET33b-(3'/v’/1.5 reverse
Sequence (5’ to 3’)
CAT ATG AAC ACG GAG CCG ACA CGG GCC ATC GAA
CTC GAG TGC CAC CTT CTC CTC TTC CGC CGC TTC TTC
GCT AGC CAT CAT CAT CAT CAT CAT AAC ACG CAG CCG 
ACA CGG GCC ATC
AAG CTT TCA GTG GGC GTT CTT GTT GCG GTA CAG ACG 
CAT GGT CAG CGG
GCT AGC AAC ACG CAG CCG ACA CGG GCC ATC 
AAG CTT TCA GTG GGC GTT CTT GTT GCG GTA
^B hm O B O -thiodirA  forward GTG AAC ACG CAG CCG ACA CGG GCC ATC GAA
pBADTOPO- thiodn-A reverse TGC CAC CTT CTC CTC TTC CGC CGC TTC TTC
W C l^ -drrA B  forw ard  
W C l^ -drrA B  reverse 
PQE-i^/tX forward 
^QE-drrA reverse
GAA TTC GCA CCA CCA CCA CCA CCA CAA CAC GCA GCC 
GAC ACG GGC CAT CGA
AAG CTT TCA GTG GGC GTT CTT GTT GCG GTA CAG ACG 
CAT GGT CAG CGG
GAG CTC GTG AAC ACG CAG CCG ACA CGG GCC ATC 
AAG CTT TCA TGC CAC CTT CTC CTC TTC CGC CGC
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2.4.1.3 Standard PCR
PCR was carried out using HotStarTaq^^ thermostable DNA polymerase (a 
derivative o f Thermus aquaticus DNA polymerase) (Qiagen) and its respective 
buffers. This enzyme requires a period of incubation of 15 minutes at 95 to be 
active. This characteristic of the polymerase increases the probability of specific 
priming and extension. Typical reaction composition is presented below with cycling 
parameters (Table 2.3). Particular PCR conditions will be presented in the respective 
Results section.
A one-tube format reaction was performed using the following reaction
components:
Final volume 100 pi
lOX PCR buffer 10
dNTPs (10 mM) 2
Primer 1 (50 pmol/pl) 2
Primer 2 (50 pmol/pl) 2
DNA polymerase 1
Millipore water 82
Template DNA (40 ng/pl) 1
Deoxyribonucleotides dATP, dCTP, dGTP and dTTP were obtained as 100 
mM stock solutions. A mixture of the four dNTP’s was prepared with each one at a 
concentration of 10 mM.
On some occasions the use of the proprietary reagent Q-solution (supplied 
with HotStar Taq DNA polymerase) was essential to the success of the amplification 
of the DNA target sequence. This solution alters the melting properties of duplex 
DNA.
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Table 2.3 Cycling parameters for standard PCR reaction
Segment Cycles Temperature Time
Hot Star Taq 1 95 "C 15 minutes
activation
Dénaturation 30 94 T 45 seconds
Annealing Gradient 50-60 °C 45 seconds
Extension 72 "C 1 min. 30 sec.
Final extension 1 72 °C 10 minutes
PCR was performed on either an Eppendorf Gradient Thermocycler or a 
Techne Cyclogene Thermocycler. Both machines have heated lids which prevent 
evaporation of the reaction mixes during the cycling process. These lids were set to 
105 °C, removing the need for a layer of mineral oil over each reaction.
Reactions were set up on ice and transferred to the thermocycler for PCR. 
Thin-walled PCR reaction tubes and sterile tips were used for all reactions.
2.4.2 Vectors
2.4.2.1 pGEMT-Easy (Promega)
This vector was used for the cloning of all the PCR products except for the 
product to be inserted into the pBADTOPO thiofusion vector. These vectors are 
convenient systems for cloning of PCR products as they present single terminal T 
overhangs, which not only impede the recircularisation of the vector, but also provide 
compatible overhangs for PCR products that have been generated by thermostable 
polymerases with terminal transferase activity. These enzymes often add a single 
deoxyadenosine to the 3 ’ ends of the amplified fragments.
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2.4.2.2 pET21a (Novagen)
Ndel and Xhoi restriction sites flanking the drrA gene were incorporated into 
the primers used for amplification by PCR, and these sites in the pET21a plasmid 
were used for cloning. In this vector (Fig. 2.1), the sub-cloned gene is placed under 
control of the strong bacteriophage T7 promoter. Sub-cloning of both the drrA and 
drrB genes into pET21a was also performed. For this reaction, Nhel and Hindlll 
restriction sites were used.
2.4.2.3 pET33b (Novagen)
The vector pET33b was also used to sub-clone drrA and drrB together. Nhel 
and H indlll restriction sites flanking the drrAB sequence were designed into the 5’ 
termini of the primers.
2.4.2.4 pBADTOPO thiofusion (Invitrogen)
For cloning into this vector, drrA primers did not carry any restriction sites as 
the vector carries the enzymatic machinery for ligation of the PCR product. This 
plasmid (Fig. 2.2) contains the araB AD  promoter that can be tightly regulated to 
produce recombinant protein in a more controlled fashion.
2.4.2.5 pQElOO (Qiagen)
Sacl and Hindlll restriction sites were designed into drrA primers to enable 
ligation between these sites in the pQElOO plasmid. In pQE vectors, expression of the 
sub-cloned gene is achieved from the bacteriophage T5 promoter.
2.4.3 PCR based DNA sequencing
Sequencing of DNA was carried out by BaseClear (Leiden, The Netherlands), 
and by the University of Durham. Purified DNA template and, were necessaiy, gene 
specific primers, were sent to the service providers. Sequence data were returned in 
the form of text and cliromatogram files for manipulation and analysis. Data were 
analysed using Vector NTl 6.0 bioinformatics software (InforMax Inc.).
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Figure 2.1 Map of the pET-21a vector used to clone the d/rA  and drrAB  genes
(from Novagen)
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PCR Product
HP-thioædojcrai EK site V5 epitope S B xH iS
pBAD/Thio TOPO®
4454 bp
Figure 2.2 Map of the pBADTOPO thiofusion vector used to clone the drrA 
gene (from Invitrogen)
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2.5 Enzyme mediated manipulations of DNA
2.5.1 Restriction enzyme digestion
Digestion of DNA with restriction endonucleases was performed in sterile 0.5 
ml micro centrifuge tubes at 37 °C in an incubator. Reaction mixes contained the 
appropriate enzyme buffer, restriction endonuclease and an appropriate amount of 
DNA. Sterile distilled water was added to a final volume of 20 pi. A standard 
reaction mix contained:
1 OX restriction enzyme buffer 2 pi
Experimental DNA sample 2-5 pi (up to 1.5 pg)
Restriction enzyme 1 pi (2-10 units)
MilliQ water Up to 20 pi
Digestion was allowed to proceed for 1-3 hours, depending on template 
concentration and the intended application. After the incubation period, samples were 
analysed by agarose gel electrophoresis.
2.5.2 Ligation of DNA to plasmid vectors
Vector systems used for cloning were linearised in preparation for ligation 
with the DNA of interest. For the cloning of PCR products, T-A cloning was used. 
For cloning of restriction fragments cohesive ligations were performed by cutting the 
vector to generate ends compatible with those of the DNA to be cloned.
2.5.2.1 T-A cloning:
For general propagation of PCR amplicons the pGEMT-Easy vector system 
was used (Promega). Reaction components were as follows:
pGEMT-Easy vector DNA 1 pi (50 ng)
2X rapid ligation buffer 5 pi
Gel purified PCR amplicon 3 pi (2:1 insert to vector ratio)
T4 DNA ligase 1 pi (5 Units)
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Ligation was allowed to proceed for 1 hour at room temperature or overnight 
at 4 prior to transformation.
2.5.2.2 pET cloning
PCR products amplified from S. peucetius were cut out of the pGEMT-Easy 
vector and ligated into different E. coli expression vectors (particularly pET21a). 
DNA excised from pGEMT-Easy by restriction enzyme digestion was ligated into 
linearised expression vectors that had been digested with the same enzymes, such that 
the two DNA fragments possessed complimentary ends. Components were;
Digested pET vector DNA 1 pi (50 ng)
Digested DNA to be cloned 3 pi (3:1 insert to vector ratio)
5X ligase buffer 4 pi
T4 DNA ligase 1 pi (5 Units)
Sterile distilled water to 20 pi
Ligation was allowed to proceed for 1 hour at room temperature prior to
transformation, or incubated at 16 °C overnight to guarantee a high number of
recombinant DNA molecules.
2.5.2.3 pBADTOPO thio cloning
For the construction of a recombinant protein expression system using the 
pBAD fusion vector, the drrA PCR product was ligated using an activation factor 
(Topoisomerase I) and the single overhanging 3’ deoxythymidine (T) residues 
contained in the vector. Reaction components were:
Fresh PCR product 3 pi
Salt solution 1 pi
Sterile water to a total volume of 5 pi
TOPO^ vector 1 pi
Final volume 6 pi
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The reaction mix was incubated for 5 minutes at room temperature for ligation. 
Subsequently, 2 pi of this reaction mixture was used to transform chemically 
competent LMG 194 E. coli cells according to standard protocols. The transformed 
bacteria were plated onto solid LB agar media supplemented with 100 pg/ml 
carbenicillin, and recombinant cells were isolated after incubation overnight at 37 °C.
2.6 Transformation of E. coli with DNA plasmid
2.6.1 Transformation of chemically competent E. coli cells
Chemically competent E. coli strains were acquired from various commercial 
sources, or produced in the laboratory. Transformation protocols were followed 
according to the manufacturer’s instructions. A typical protocol is described below.
Ligation reactions or plasmid preparations (2.5 pi) were added to 50 pi of 
thawed competent cells on ice and gently mixed. The mixture was then incubated on 
ice for 30 minutes. Heat shock was applied by immersion of the tube in a 42 °C water 
bath for 45 seconds. Tubes were rapidly restored to an ice bath for two minutes, 250 
pi of SOC medium (or equivalent) was added to each tube, and the suspension was 
shaken at 220 rpm and 37 °C for 1 hour. Cells were then plated onto LB agar 
containing the appropriate antibiotic and incubated at 37 °C overnight.
When fresh competent cells were prepared, the CaCb method was used. In 
this procedure, cells from an overnight culture are diluted 50 fold into a volume of 10 
ml and grown until an ODeoonm of 0.6 is reached. An aliquot of 1 ml is centrifuged 
(30-60 secs), the supernatant is discarded, and the pellet, kept on ice, is re-suspended 
in 0.5 ml of cold 50 niM CaCb for 10 minutes, or overnight at 4 ®C. After a second 
short spin, the pellet is again re-suspended in 0.3 ml of CaCb and kept on ice for 30 
minutes, or again overnight at 4 °C. At that stage, cells are ready for transformation.
2.6.2 Selective screening of recombinant bacterial clones
The presence of one or several antibiotic resistance determinants was a feature 
of all the plasmid vectors used in this work. This ensured that only successfully 
transformed bacteria could grow on media supplemented with antibiotics. DNA from
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these clones was then screened for the presence of insert using restriction digestion 
and/or sequence analysis. Ampicillin resistance was a feature of almost all the vectors 
used in this study.
Blue/white screening of recombinant pGEMT-Easy clones
Identification of pGEMT-Easy is aided by insertional inactivation of a - 
galactosidase reporter gene and the loss of hydrolysis of the substrate analogue X-gal 
(5-bromo-4-chloro-3-indolyl-_-D“galactoside). Expression of the -galactosidase 
gene is under the control of the lac promoter and successful transcription requires the 
presence of the inducer IPTG (isopropyl-_-thiogalactopyranoside). Colonies with 
non-recombinant plasmids appear blue on the indicator plates because the - 
galactosidase gene has not been disrupted and the X-gal substrate can be digested. In 
contrast, cells that carry recombinant plasmid remain white under these conditions.
To make indicator plates, LB agar plates containing 100 pg per ml ampicillin 
were spread with 100 pi of sterile 100 mM IPTG. Prior to inoculation, 100 pi of 2% 
(w/v) X-gal in dimethyl formamide, was spread onto the agar surface. These 
components were allowed to diffuse and dry on the plates for at least 1 hour before 
use. Plates were incubated in an inverted position, at 37 °C for 18 h, and white 
colonies picked and propagated for further analysis.
2.7 Heterologous expression of recombinant proteins
2.7.1 Expression of recombinant proteins from pET21a in Epicurian coli BL21 
(DE3)
Epicurian coli BL21 (DE3) cells were used for the production of recombinant 
proteins derived from pET21a carrying the S. peucetius DrrAB system. This bacterial 
strain is lysogenic for the lambda bacteriophage and carries an IPTG-inducible 
bacteriophage T7 RNA polymerase that is required for transcription from the T7 
promoter. Bacterial strains harbouring expression constructs were streaked onto an 
LB agar plate containing 100 pg per ml carbenicillin. Following overnight incubation 
and growth, a single colony was used to inoculate a starter culture. This culture was 
grown at 37 “C and 200 rpm overnight and used to inoculate a larger expression
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culture at a 1/1000 dilution. All expression cultures were grown in baffled flasks with 
rotaiy shaking at 200 rpm to promote aeration, and supplemented with the appropriate 
antibiotic to maintain the retention of the pET plasmid. Growth continued until the 
culture reached an approximate ODeoo of 0.6. Expression was then induced by 
addition of IPTG to a final concentration of 1 mM, and was allowed to proceed for 3- 
4 hours. Tlu'ough interaction with the lac repressor, this triggered de-repression of the 
chromosomal lacUV5 promoter and hence the production of the T7 RNA polymerase, 
required for transcription of the target gene from the T7 promoter.
To assess the extent of heterologous protein expression, 1 ml aliquots were 
removed from the expression culture prior to induction and at Ih intervals thereafter. 
The cells were harvested by centrifugation at 16,600 x g  for 1 minute, and the cell 
pellet was prepared for analysis by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE), as described later.
Alternatively, the expression culture was grown until the cells reached an 
ODôoo of approximately 0.25. The temperature was then gradually reduced about 5 
degrees each 15 minutes until it reached 19“C. When an OD^oo of 0.6 was reached, 
cultures were induced by addition of IPTG. The reduction in temperature was 
continued to 17 °C, and the culture was then grown overnight.
2,7.2 Expression of recombinant proteins from pBADTOPO thiofusion in E. coli 
LMG 194 and Top 10 cells.
Single colonies of transformed E. coli LMG 194 or E. coli TOP 10 cells were 
picked to liquid medium and grown at 200 rpm and 37 °C overnight. Expression 
cultures were prepared by inoculation with a 1/1000 volume of overnight culture. 
Cultures were grown until the cells reached an approximate ODeoo of 0.6-0.7 before 
induction with arabinose.
To find the appropriate concentration of inducer, a pilot experiment was 
carried out using different concentrations of arabinose to induce protein expression at 
37 °C in 10 ml cultures that had reached mid-log phase. Arabinose concentrations 
were varied from 0.0002% to 2% (w/v) to identify the optimal concentration required
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for expression of soluble protein. Protein expression was induced for 4 hours and 
monitored at intervals by withdrawing 1 ml samples for centrifugation and re­
suspension of cell pellets in 100 pi of 4X SDS-PAGE buffer. Samples (10 pi) were 
then analysed by SDS-PAGE.
Having explored the influence of arabinose concentration on protein 
expression, larger scale expression cultures were induced by addition of arabinose to a 
final concentration of 0.002%. Induction was allowed to proceed for 3-4 hours.
Similar to work with pET vectors, low temperature expression was used. 
Cultures were grown to an OD^oo of approximately 0.25, and the temperature was then 
dropped about 5 degrees each 15 minutes. When the temperature reached 19 °C and 
the cultures were at an ODôoo of 0.7, protein expression was induced by addition of 
0.002% arabinose. The temperature continued to be reduced to 17 °C, and the culture 
was induced overnight under these conditions.
2.7.3 Electrophoresis under denaturing conditions by Sodium Dodecyl Sulfate
(SDS) Polyacrylamide Gel Electrophoresis (PAGE)
Analysis of protein derived from expression experiments was achieved by 
separation of the proteins by electrophoresis. Pre-cast polyacrylamide mini-gel 
systems NuPAGE® Bis-Tris (Invitrogen) were employed under denaturing conditions. 
These gels were buffered at pH 6.4 and contained 12% aery 1 amide. Although they do 
not contain SDS, they are intended for denaturing gel electrophoresis. NuPAGE 
MOPS SDS was used as running buffer.
2.7.4 Electrophoresis of protein by Polyacrylamide Gel Electrophoresis
(PAGE) under native conditions
Pre-cast polyacrylamide mini-gel systems NuPAGE® Bis-Tris-Acetate 
(Invitrogen) were employed. These gels were buffered at pH 8.0 and had 3-8 % of 
acrylamide. NuPAGE Tris Glycine was used as running buffer, whilst NuPAGE SDS 
sample buffer from which SDS had been omitted, was used as sample buffer.
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2.7.5 Preparation of samples for SDS-PAGE
Samples for SDS-PAGE were prepared from bacterial pellets or from fractions 
collected during the purification of protein from disrupted bacterial cells. In the first 
case, for direct analysis, cell pellets were re-suspended in an appropriate volume of 
concentrated SDS-PAGE loading buffer, heated at 70 °C for 5 minutes and placed on 
ice until required.
In the second case, fractions from affinity chromatography were mixed at a 
3:1 ratio with SDS-PAGE loading buffer, and then heated at 70 for 5 minutes.
2.7.6 Preparation of samples without SDS for PAGE
In this case, samples purified by affinity cliromatography were mixed 3:1 with 
PAGE loading buffer, and then applied directly to the gel. Running buffer and the 
pre-cast gel did not contain SDS.
2.7.7 Electrophoresis protoeol
To each sample well of the gel, 10-20 pi of protein sample was added using a 
20 pi capacity Gilco micropipette or equivalent. Each gel included a lane of 
molecular weight markers (pre-stained SeeBlue standards from Invitrogen). A 
voltage of 200 V was applied and electrophoresis was allowed to run for 45 minutes.
2.7.8 Analysis of SDS-PAGE gels
Polyacrylamide gels were usually stained using Gelcode® Blue Protein Stain 
(Pierce). The gel was removed from its container and transfered into a 10 cm x 10 cm 
petri dish filled with distilled water. It was washed twice (10 minutes each wash) 
with gentle agitation to remove SDS, which could inhibit the staining process. After 
the second wash, 20 ml of protein stain was added and the staining was allowed to 
proceed for 1 hour. After this, the stain was discarded and replaced with water. 
Protein bands could be visualised after 15 minutes. The longer the gel remained in 
water, the greater the resolution of the bands.
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2.7.9 Analysis of non SDS-PAGE gels
Analysis of these gels was performed in a similar way but the initial washing 
was omitted.
2.8 Analysis of recombinant expression by Western blotting
Western immunoblotting was used to confirm the presence of recombinant 
proteins carrying a histidine tag (Hise).
2.8.1 Western transfer of proteins onto PVDF membranes
Western blotting, also called immunoblotting, is one of the best methods for 
detecting a particular protein in a complex mixture. Its three-steps comprise the 
separation of proteins through an SDS gel, the reaction of the target protein with 
specific antibodies, and detection by enzyme conjugates.
Electrophoresis was carried out as previously described for SDS-PAGE. Gels 
were run in duplicate, one for transfer and the other for direct analysis by staining. 
Proteins were transferred electrophoretically to a polyvinylidene fluoride (PVDF) 
membrane using a constant voltage of 30 V for 1 hour 30 minutes. The membrane 
was subsequently blocked by washing with a solution of non-fat milk powder and 
then probed with primary antibody (1:300 dilution of mouse anti-Hisg monoclonal 
antibody (Bio-Rad)), secondary antibody (1:1000 dilution of goat anti-mouse alkaline 
phosphatase conjugated antibody), and substrate (BioRad GDP-Star® 
chemiluminescent substrate). The membrane was thoroughly washed after each 
antibody incubation to remove unbound protein. The enzyme (AP) conjugated to the 
secondary antibody catalyses a light-emitting reaction when substrate is added, 
resulting in the exposure of X ray film.
2.9 Purification of DrrA
Recombinant DNA techniques usually permit the construction of fusion 
proteins in which specific affinity tags are added to the protein sequence of interest. 
These tags simplify the purification of recombinant fusion proteins by employing
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affinity chromatography methods. All heterologous expression constructs were 
designed in such a way as to encode six consecutive histidine residues at either the N- 
or C- terminus of the recombinant protein. This sequence enables the expression of 
the recombinant protein to be monitored by immunochemical methods, and 
purification by affinity cluomatography. The residues bind strongly to certain divalent 
cations, particularly Ni^ "^ , allowing an efficient purification of the recombinant protein 
using “Immobilised Metal Affinity Chi'omatography” (IMAC). Nickel-nitrilotriacetic 
(Ni^'^-NTA) affinity chromatography was used.
Usually a 10 L culture in 2X YT medium containing carbenicillin (100 pg/ml) 
was induced to overexpress the target protein. The induction was accomplished with 
IPTG for the pET constructs carrying DrrA, or DrrA and DrrB. Arabinose was used 
to induce pBAD constructs to overexpress the Thio-DrrA fusion. In all the constructs 
DrrA was produced with a histidine tag, to aid further purification.
Cells were collected by centrifugation at 4,000 x g  for 8 min at 4 °C, the 
supernatant discarded, and the pellet placed on ice. The cells were re-suspended in an 
appropriate volume of re-suspension buffer (usually 30 ml Tris buffer pH 8.0 per L of 
culture) to allow for a concentration factor of 34 with respect to the original culture 
volume. The cell suspension was sometimes treated with lysozyme (1 mg/ml final 
concentration) and incubated for 1 hour before disruption in a homogeniser at 20 PSI. 
Cells were forced under high pressure through a small aperture in the base of a cell 
disrupter cup and passed twice through the chamber to assure they were successfully 
broken. The disrupted material was recovered from the disrupter cup and debris and 
insoluble proteins were harvested by centrifugation at 22,000 x g  for 20 minutes.
In an alternative protocol, cell disruption was performed using an Ultrasonic 
disintegrator (Sanyo Soniprep 150). Batches of 30-40 ml of cells were processed 
individually with 6 sonication pulses of 15 seconds and an interval of resting of at 
least 45 seconds between each pulse. The amplitude was maximised using the power 
control and the process was performed manually for the indicated times. The sample
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vessel (usually plastic Universal tubes were employed) was immersed on ice to avoid 
damage to the protein due to the heat generated.
2.9.1 DrrA purification under native conditions
2.9.1.1 DrrA purification from the soluble fraction
Affinity chromatography
The supernatant from the 22,000 x g  centrifugation step was decanted into 20 
ml ultracentrifuge tubes (Sorvall or Beckman) and ultra-centrifuged at 149,000 x g  for
1.5 hours to remove cell membranes. The supernatant thus obtained (representing the 
soluble fraction of the cell extracts), was used in Nickel affinity chromatography. 
This fraction was shaken gently at 4 °C for 1 hour or overnight, with NP'*'-NTA 
agarose affinity resin (Qiagen; 1 ml per 10 L of culture), and the slurry was loaded into 
a 0.8 cm diameter gravity fed chromatography glass column (Bio-Rad). The nickel 
cation in the Ni^^-NTA complex interacts with the histidine tag present in the DrrA 
protein derivative. The pellet collected during ultracentrifugation comprised the 
membranes and insoluble proteins. This was dissolved in a buffer containing an 
appropriate detergent before Nickel affinity clu'omatography (see next section).
After allowing the slurry to accumulate in the column (a batch usually 
corresponding to 2 or 2.5 L of culture), it was washed with increasing imidazole 
concentrations up to 50 mM prepared in the same buffer as the sample. Then, 10 ml 
of elution buffer (300 mM imidazole) was loaded onto the column in 1 ml aliquots, to 
elute the protein. The recovery of protein at stages through the purification process 
was assessed by SDS-PAGE.
Solubilisation buffers:
Phosphate buffer: 50 mM NaiHPO#, 300 mM NaCl, 10% (v/v) glycerol, 10 
mM imidazole, pH 8.0
Tris buffer: 50 mM Tris-HCl, 150 mM NaCl, 10% (v/v) glycerol, 10-20 mM 
imidazole, pH 8.0. Specific adjustments were made for particular assays, such as
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NaCl concentration adjusted to 400 mM, higher and lower glycerol concentrations, 
the addition of detergent and reducing agent. These are presented in the respective 
Results chapter.
MOPS buffer and a different Phosphate buffer formulation (pBADTOPO 
thiofusion manual) were also tested and are presented in the respective Results 
chapter.
2.9.1.2 DrrA purification from the membrane fraction
The purification of recombinant proteins from the membrane fraction followed 
the general procedure stated above. Cell membranes were separated from the soluble 
fraction after the 149,000 x g  centrifugation step. To solubilise these membranes 
(membrane pellet obtained from a 10 L culture), 50 mM Tris-buffer (200 ml) with 2% 
of dodecyl maltoside (DDM), was used. The membrane solubilisation proceeded for 
14 hours at 4 with gentle shaking. After that period, the mixture was ultra- 
centrifuged at 149,000 X g  for 30 minutes at 4 °C and non-solubilised material was 
discarded. The supernatant was then ready for affinity chromatography following the 
standard procedure already described, with the addition of 0.2% DDM in the wash 
buffers.
2.9.2 DrrA purification under denaturing conditions. Protein 
refolding
When heterologous proteins expressed in E. coli are present only as insoluble 
protein in inclusion bodies, solubilisation and refolding of the protein under 
denaturing conditions has been successful for some proteins.
In this procedure, the disrupted cell pellet was collected and solubilised in 
Tris-HCl lysis buffer with 8 M urea. Phosphate buffer was also tested. The suspension 
was shaken for 2 h at 4 °C. A further round of centrifugation at 6,000 g  removed 
material that remained insoluble. Tris-urea buffer was 50 mM Tris-HCl, 150 mM 
NaCl, 10% (v/v) glycerol, 10 mM imidazole, 8 M urea, pH 8.0.
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2.9.2.1 Refolding with Urea
Refolding of DrrA solubilised from inclusion bodies was done using a 
decreasing urea gradient from 8 to 0 M. This was carried out on a column. To 
accomplish this, 200 pi of disrupted cell pellet was mixed in 10 ml of binding buffer 
for 1 hour, on ice. Five hundred pi of Ni^’^ -NTA agarose was added to the column, 
and washed with 10 ml binding buffer to pre-equilibrate. The sample was then added, 
and the flow-through collected slowly over 15 min. The column was washed with 10 
ml of binding buffer containing 8 M urea, and 5 mM imidazole, followed by 10 ml of 
washing buffer containing 8 M urea, 20 mM imidazole. Flaving immobilised the 
protein onto the column, re-naturation was attempted by running a 20 ml gradient 
comprising 8 to 0 M urea through the chromatography medium. After a final wash 
with 20 ml binding buffer without urea, the re-natured protein was eluted with 3 ml 
elution buffer (0 M urea, 0.3 M imidazole), and collected in 500 pi aliquots, followed 
by a single pulse of 5 ml of elution buffer.
All the buffers were 20 mM Tris, 0.5 M NaCl and pH 8.0. Binding buffer was 
5 mM imidazole and 8 M urea. Washing buffer was the same as binding buffer 
except imidazole was 20 mM. Elution buffer was 300 mM imidazole. This protocol 
was also employed using 50 niM Tris and 0.15 M NaCl in the buffer recipe.
2.9.2.2 The Foldit Screen Refolding
The Foldit Screen Refolding kit (Hampton Research) was also used in an 
attempt to find conditions for refolding of the DrrA protein under denaturing 
conditions. Foldit is a fractional factorial-folding screen designed for use with 
proteins expressed from E. coli. In this protocol, inclusion bodies were solubilised in 
4 M Guanidine-HCl, 0.1 M Tris and 0.1 M NaCl, and a set of 16 different 
experimental conditions were assayed. Parameters included the type and 
concentration of buffer, salt, presence and absence of denaturing agents, type of 
cation chelator, polar and non-polar additives, presence and type of detergent, 
reducing agents, ligand addition, and protein concentration (Tables 2.4 and 2.5). 
Treated protein preparations were dialysed, checked on gels, and their activity was 
evaluated in ATPase activity assays and fluorescence spectroscopy.
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2.9.3 Dialysis of purified protein
Those eluted fractions which had the highest concentrations of protein as 
visualised on polyacrylamide gels, were collected and pooled to be dialysed against 
solubilisation buffer without imidazole.
Purified DrrA was dialysed before quantification and further experiments, as 
imidazole interferes with the BCA protein determination. Dialysis cassettes (Pierce 
Slide-A-Lyzer®) of different sizes were employed according to the volume of the 
sample. Occasionally dialysis tubing was used as well. For this, membrane (12-14 
kDa cut off) was cut into 8 cm sections and boiled for 10 minutes in water before use.
Dialysis of the protein was performed in 3 L Tris buffer pH 8 (50 mM Tris- 
HCl, 150 mM NaCl, and 10% glycerol) or equivalent, usually over 4 hours if the 
sample volume was less than 6 ml. The process was run at 4 °C with gentle stirring in 
a volume of 800 ml of buffer, being the buffer replaced each hour. If necessary, 
fractions were concentrated using a centrifugal concentrator (Amicon Centricon A 10) 
or a Stirred Ultrafiltration Cells device (Millipore) according to the protein volume.
2.9.4 Size exclusion chromatography
Purification by size exclusion was tested as a method for separation of Thio- 
DrrA from contaminating proteins. The ÂKTA purification system of Amersham 
Pharmacia Biotech was used for this purpose, and 16/60 Superdex 75 and 200 
columns were employed to run the chromatography. Each of these columns was 
equilibrated with 50 mM Tris-HCl buffer pH 8, 150 mM NaCl, and loaded with 1 ml 
of sample. A flow of 0.5 ml/min was set for the run and 1.5 X the 
volume of the column was used to elute the samples.
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Table 2,4 Foldit Screen Formulations
Buffeir Sait PEG Guanidine Cation/Che­ Polar and
(NaCl, KCl) 3350 HCl lator Nonpolar
(% ) Additives
1) Tris pH 8.2 264 mM, 11 mM 0.055 0 mM EDTA None
2) M ES pH 10.56 mM, 0.44 mM None 550 mM M gC f, CaCl2 None
6.5
3) M ES pH 10.56 mM, 0.44 mM 0.055 550 mM EDTA Sucrose, L-Arginine
6.5
4) Tris pH 8.2 264 mM, 11 niM None 0 mM M gCh, CaCb Sucrose, L-Arginine
5) M ES pH 264 mM, 11 mM None 0 mM M gCb, CaCb Sucrose
6.5 1
6) Tris pH 8.2 10.56 mM, 0.44 mM 0.055 550 mM EDTA Sucrose
7) Tris pH 8.2 10.56 mM, 0.44 mM None 550 mM M gCh, CaCb L-Arginine i
8) M ES pH 264 mM, 11 mM 0.055 0 mM EDTA L-Arginine
6.5
9) M ES pH 264 mM, 11 mM 0.055 550 mM MgClz, CaCh Sucrose
6.5
10) T ris pH 10.56 mM, 0.44 mM None 0 mM EDTA Sucrose
8.2
I I )  T ris pH 10.56 mM, 0.44 mM 0.055 0 mM MgClz, CaClz L-Arginine
8.2 ■it
12) MES pH 264 mM, 11 mM None 550 mM EDTA L-Arginine t
6.5
13) T ris pH 264 mM, 11 mM None 550 mM EDTA None i
8.2 *
14) MES pH 0.56 mM, 0.44 mM 0.055 0 mM MgClz, CaCl2 None
6.5
15) M ES pH 0.56 mM, 0.44 mM None 0 mM EDTA Sucrose, L-Arginine
6.5
16) T ris pH 264 mM, 11 mM 0.055 550 mM MgClz, CaCl2 Sucrose, L-Arginine
8.2
All buffers were 55 mM.
EDTA was 1.1 mM; M gCb and CaCh were 2.2 mM. 
Sucrose was 440 mM, and L-arginine was 550 mM
87
Table 2.5 Foldit Additions -  Pipetting and dilution table for Foldtit
Reagent Reagent 0.1 M 30 mM 100 10 mM Ligand Protein Final
# volume DTT Lauiyl mM GSSG (mM) (pL) [Prot.]
(pL) (pL) Maltoside
(pL)
GSH
(pL)
(pL) (mg/ml)
1 950 10 - - Up to 10 50 0.1
2 950 - 10 10 10 “ 50 0.1
3 950 - - 10 10 Up to 10 50 0.1
4 950 10 10 - - - 50 0.1
5 950 - - 10 10 Up to 10 50 1.0
6 950 10 10 - - - 50 1.0
7 950 10 “ - - Up to 10 50 1.0
8 950 - 10 10 10 - 50 1.0
9 950 10 - - - - 50 0.1
10 950 - 10 10 10 Up to 10 50 0.1
11 950 - - 10 10 - 50 0.1
12 950 10 10 - - Up to 10 50 0.1
13 950 - - 10 10 - 50 1.0
14 950 10 10 - - Up to 10 50 1.0
15 950 10 - - - - 50 1.0
16 950 - 10 10 10 Up to 10 50 1.0
Ligand was doxorubicin 30 pg/ml.
2.10 Protein determination
Protein concentrations were determined using the BCA Protein Assay Kit 
(Pierce Chemical Co.) with bovine serum albumin as standard. In this colorimetric 
assay, the protein reacts with the BCA reagent to give a violet colour of intensity 
equivalent to its concentration in a range between 20-2000 pg/ml, and that is 
measured at an absorbance of 562 mn. The Pierce BCA assay is a formulation based 
on bicinchoninic acid and combines the well-known reduction of Cu^ "*" to Cu^^ by 
protein in an alkaline medium (Biuret reaction) with the colorimetric detection of the 
cuprous cation (Cu"^ )^ using a special reagent containing bicinchoninic acid. The 
colour is the product of the chelation of two molecules of BCA with one cuprous ion.
Protein concentration was determined with reference to standards of bovine 
serum albumin (BSA), and although the test tube procedure was the most accurate 
method to determine protein concentration, the microplate procedure was chosen for 
routine use since only 25 pi of sample was required. In this procedure, 25 pi of the 
protein sample was added to a well into the microplate followed by 200 pi of the 
BCA reagent. The solutions were mixed, and incubated at 37 °C for 30 minutes. After 
the incubation period, sample absorbance values were measured in a microplate 
reader at 610 nm. The absorbance values were compared with those of a protein 
standard curve, and related back to protein concentration.
2,11 Characterisation of Thio-DrrA
2.11.1 DrrA protein sequence analysis
Protein analyses based on sequence were performed using NTI Vector and 
Wabim programs.
2.11.2 ATPase Activity
2.11.2.1 EnzCheck Phosphate Assay (Molecular Probes)
This method is based on a method described by Webb (Webb, 1992). The 
EnzChek Phosphate Assay System was used to run a number of ATPase activity 
assays to evaluate the success of the refolding procedures for DrrA prepared from
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inclusion bodies (see sections 2.9.2 and 2.9.2.2). The system relies upon the 
spectrophotometric detection o f inorganic phosphate ( P j )  released into the assay 
medium by the activity of ATPase enzymes. Phosphate release is enzymatically 
coupled to phosphorolysis of the artificial substrate 2-amino-6-mercapto-7- 
methylpurine riboside (MESG). The phosphorolysis reaction produces a molecule 
with a strong absorption at 360 nm that can be monitored in real-time. The reaction 
was initiated by the addition of MgCb and the ATPase activity was monitored as an 
increase in absorbance of the reaction mixture at 360 nm over time.
To follow the kinetics of Pj release, an enzyme reaction was set up with the 
following components in a total volume of 1 ml of reaction mixture:
20X reaction buffer 50 pi
MESG substrate solution 200 pi
Purine nucleotide phosphorylase 10 pi (1 Unit)
ATP X pi
MgCb y pi
Experimental enzyme z pi
Tris-HCl buffer (50mM) 740 -  x -  y -  z pi
It is the purine nucleotide phosphorylase component of the reaction mixture 
which couples release of Pj by the ATPase enzyme to phosphorolysis of the MESG 
substrate.
2.11.2.2 Malachite green Assay
A colorimetric assay to determine free phosphate, based on the use of the 
ammonium molybdate/malachite green reagent (Nash, 2003; Maehatma, 2001; Harder 
et aL, 1994), was used in microplates. Malachite green in the presence of molybdate 
binds inorganic phosphate, which gives rise to a complex that can be measured
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between 620-660 nm (Ekman and Jager, 1993). A total reaction volume of 500 pi was 
used for each sample. This included the DrrA protein (DrrA or Thio-DrrA), ATP, and 
assay buffer. The mixture was pre-incubated for 5 minutes at 37 °C. The reaction was 
then initiated by addition of MgCh. Immediately after the induction of ATPase 
activity, and at various time points thereafter, 45 pi of sample were withdrawn and 
pipetted into each well of the microplates, where 5 pi of 0.5 M EDTA had been 
previously added to sequester Mg^ "^  ions and stop the reaction. At the end of the 
reaction time course, 100 pi of Malachite green assay solution was added to each 
sample in the well, and the microplate was immediately read at an absorbance of 610 
nm. Two experiments were run simultaneously, and protein of 1 pM concentration 
was usually sufficient to follow the development of colour in the reaction with 
malachite green in standard conditions. Routine experiments and characterisation 
were performed with this method and using 450 pM Mg^^ and 250 pM of ATP, final 
concentrations.
Preparation of Malachite green Assay solution
1. - Solution A: 4.2% (w/v) anunonium molybdate in 4 N HCl.
2. - Solution B: 0.045% (w/v) Malachite green solution in H2O.
3 . - 1  part of A is mixed with 3 parts of B.
4. - The resultant solution is filtered, giving a yellow colour.
Assay buffer was usually 50 mM Tris-HCl, 150 mM NaCl, glycerol 10%, pH 8.0.
2.11.3 Dependence on ATP concentration
ATP concentrations between 0.1 to 2 mM (prepared in assay buffer), were 
assayed as described in section 2.11.2.2 to find the concentration that induced the 
highest ATP-ase activity in recombinant DrrA proteins, enabling calculation of Km.
2.11.4 Dependence on divalent cation concentrations: Mn^\ Co^ ,^ Zn^  ^
and Ca^ ^
Concentrations of divalent cations between 0.1 and 2 mM (prepared in assay 
buffer), were assayed as described in section 2.11.2.2 substituting for Mg^ "^ , to 
determine the efficiency of their stimulation upon the DrrA ATPase activity.
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2.11.5 Dependence on pH
A range of pH between 6.0 and 9.0 was tested to assess the optimum for DrrA 
proteins ATPase activity. MES/Na buffer was used for pH values between 6.0-6.5. 
MOPS/Na was used for pH range 6.6-7.5. Tris/Cl for pH range 8.0-9.0. All buffers 
were 50 mM.
2.11.6 Substrate specificity and inhibitors
The nucleotides triphosphate CTP, GTP, and TTP (prepared in assay buffer), 
were evaluated as substrates for Thio-DrrA. Forty pi of 3.125 mM stocks of each of 
the NTPs, were added to the reaction mix to obtain a final concentration of 250 pM. 
Reactions were initiated by addition of Mg^ "*" as described above. The effect of ADP 
on the ATPase activity of Thio-DrrA was also assayed. A final concentration of 250 
pM was used.
Ortho-vanadate and NaCl were assayed as inhibitors of the DrrA ATPase 
activity. Vanadate concentrations between 10-1000 pM were added to a standard 
DrrA assay for ATPase activity and its kinetics were followed. NaCl concentrations 
between 150-2000 pM were evaluated to determine if NaCl inlribited the Thio-DrrA 
ATPase activity. The conditions in these experiments were standardised with 250 pM 
ATP and 450 pM MgCb.
2.11.7 Dependence on DrrB presence
DrrA and Thio-DrrA were assayed for ATPase activity in presence of the 
DrrB protein (the kind gift o f Dr. McKeegan, Wolfson Institute, University of 
Durham). Protein concentration was 1 pM, and ATPase kinetics between 25 and 
2000 pM ATP was estimated. MgCh concentration was 450 pM. The assay buffer 
contained 0.2% DDM detergent.
2.11.8 Dependence on the presence of Doxorubicin or Daunorubicin
The effect of the presence of doxorubicin was assayed for both DrrA and 
Thio-DrrA. Concentrations of doxorubicin of 2, 10 and 20 pg/ml (~3, 17 and 34 
pM, respectively) were used in reaction mixtures with DrrA 37 pg/ml (~1 pM), to
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follow ATPase kinetics. The effect of the presence of daunorubicin (3 pM) was 
also assayed on Thio-DrrA ATPase activity.
2.11.9 Dependence on the presence of DrrB and Doxorubicin
The effect of both DrrB and doxorubicin on the ATPase activity of DrrA was 
evaluated. These two components were added to a reaction mixture containing DrrA 
protein and the kinetics of ATP hydrolysis was followed. DrrA and DrrB were 1 pM, 
whilst doxorubicin was 2 pM.
2.12 DrrA Site-Directed Mutagenesis
Site-directed mutagenesis is a valuable tool for the study of DNA function as 
well as for the analysis of protein structure and function. It is accomplished by 
hybridisation and extension of a synthetic oligonucleotide that is complementary to 
the target template except for a region of mismatch near the centre, and also by PCR 
methods. This mismatched region contains the desired mutation. In both cases, 
double-stranded DNA is obtained and used to transform an E. coli host.
2.12.1 GeneEditor protocol (Promega)
This protocol was used to obtain a single amino acid mutation in the protein 
Thio-DrrA for stopped-flow experiments based on the fluorescence of the amino acid 
tryptophan. This system uses antibiotic selection to obtain high frequency mutants. 
Oligonucleotides provided with the system encode mutations that alter the ampicillin 
resistance gene, creating a new additional resistance to the GeneEditor antibiotic 
selection mix. The selection oligonucleotide is annealed to a single or double­
stranded DNA template at the same time as a mutagenic oligonucleotide. Subsequent 
synthesis and ligation of the mutant strand links the two oligonucleotides. The 
resistance to the GeneEditor antibiotic selection mix encoded by this mutant DNA 
facilitates selection of the desired mutation. A summary of the procedure is presented 
here.
93
As single stranded DNA (ssDNA) was required as template for mutagenesis 
reactions, alkaline dénaturation of double stranded DNA (dsDNA) was achieved in a 
reaction that included plasmid DNA (dsDNA; 0.5 pmol ~2pg), 2 M NaOH, 2 mM 
EDTA (2pl), and dIÎ20. The DNA was precipitated with 2 M ammoniiun acetate (2 
pi) and 100% ethanol at -70°C (75 pi) for 30 minutes, and pelleted by centrifugation. 
The ssDNA pellet was washed in 70% ethanol (200 pi), re-collected by 
centrifugation, air-dried, dissolved in TE buffer (lOOpl), and a 10 pi aliquot was 
analysed by agarose gel electrophoresis in order to estimate the reaction success and 
yields.
ssDNA template (10 pi) was mixed with the phosphorylated selection 
oligonucleotide (1 pi; 0.25 pmol), the phosphorylated mutagenic oligonucleotide, 
(1.25 pmol), lOX amiealing buffer (2 pi), and dH20 up to 20 pi. The mixture was 
heated at 75 °C for 5 minutes, and slowly cooled to 37 (1.5 "C per minute). During
this period the oligonucleotides anneal to the template DNA.
Synthesis of the mutant strand and ligation was accomplished in a reaction 
containing dfUO (5 pi), lOX synthesis buffer (3 pi), T4 DNA polymerase (5-10 U; 1 
pi), and T4 DNA ligase (1-3 U; 1 pi). The reaction mixture was incubated at 37 °C 
for 90 minutes to allow mutant strand synthesis.
The DNA was then transformed into competent E. coli BMH 71-18 mutS ceils. 
This strain has a mutation in the mutS DNA repair gene which allows the cells to 
tolerate plasmids with small double strand mismatches. The cells were transformed 
with 3 pi of the mutant plasmid mixture prepared in the previous step. Transformation 
was performed by a standard heat-shock protocol. The entire mixture was incubated 
in 4 ml of LB medium containing the proprietary selection antibiotic overnight (37 
°C), allowing time for plasmid replication and segregation in such a way as to 
enliance the number of cells carrying the mutated plasmid.
Mutant plasmids obtained from the previous step were then transformed into 
competent E. coli JM109 cells, and selected on solid LB-agar medium containing the 
selection antibiotic. JM109 clones resistant to the antibiotic selection mixture were
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used to prepare plasmid DNA. The successful introduction of specific mutations was 
determined by DNA sequencing.
2.12.2 QuickChange Site-Directed Mutagenesis (Stratagene)
The QuikChange site-directed mutagenesis protocol (Stratagene), was also 
used for the same purpose. This method uses a supercoiled double-stranded DNA 
vector with an insert of interest as template, and two synthetic oligonucleotides 
primers containing the desired mutation. It is performed using Pfu Turbo® DNA 
polymerase and a temperature cycler. This enzyme replicates both plasmid strands 
with high fidelity and without displacing the mutant oligonucleotide primers, each 
complementary to opposite strands of the vector. Incorporation of oligonucleotide 
primers generates a mutated plasmid containing staggered nicks. After temperature 
cycling, the product is treated with Dpn  I endonuclease, which is specific for 
methylated and hemimethylated DNA, to digest the parental DNA template. The only 
DNA left is the newly synthesized DNA containing the mutation. This nicked vector 
containing the desired mutation is then transformed into XL 1-Blue supercompetent 
cells. A summary of the procedure is presented here. Two complementary 
oligonucleotides containing the desired mutation, flanked by unmodified nucleotide 
sequence, were synthesised for the mutagenesis experiment (Table 2.6).
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Table 2.6 Primers used for Site-directed mutagenesis in pBADTOPO thio-drrA
Primer name Mutation in Thio-DrrA Sequence (5’ to 3 ’)
drrA Y 140 forward Original Y was replaced by W in the CGG CTC CTG AAG ACC TG G
(Y140W) ABC signature region TCC GGT GGC ATG CGG
drrA Y 140 reverse Same CCG CAT GCC ACC GGA C C A
(Y140W) GGT CTT CAG GAG CCG
drrA Y37 forward Original Y position 37 in the DrrA CCG GCC GGT CTC GTC T G G
(Y37W) sequence, was mutated to W GGG ATC CTG GGG CCG
drrA Y37reverse Same CGG CCC CAG GAT CCC CC A
(Y37W) GAC GAG ACC GGC CGG
drrA A45 forward A in position 45 in the W alker A CTG GGG CCG A A C GGC
(A45W) motif, was mutated to W TG G  GGC AAG TCC ACC ACC
drrA A45 reverse Same GGT GGT GGA CTT GCC C C A
(A45W0 GCC GTT CGG CCC CAG
drrA-T50 forward T position 50 beside the W alker A GCC GGC AAG TCC ACC TG G
(T50W) motif, was mutated to W ATC CGC ATG CTG GCG
drrA T50 reverse Same CGC CAG CAT GCG GAT C C A
(T50W) GGT GGA CTT GCC GGC
Thio forward T he 2 o rig in a l W p rese n t in ATC CTG GTT GAT TTC G G G
Thioredoxin, were mutated to G GCA CAC G G G  TGC GGT CCG 
TGC AAA
Thio reverse Same TTT GCA CGG ACC GCA C C C  
GTG TGC C C C  GAA ATC AAC 
CAG GAT
PBAD forward priming site To check m utations in thioredoxin ATG CCA TAG CAT TTT TAT
gene CCA
drrA-T50 -forw ard T50 mutation was cancelled, and the GCC GGC AAG TCC ACC A C C
(W50T) original T  replaced the mutation W ATC CGC ATG CTG GCG
drrA-T50 -reverse Same CGC CAG CAT GCG GAT G G T
(W50T) GGT GGA CTT GCC GGC
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The sample reaction was prepared according to the following indications:
5 pi of lOX reaction buffer
X pi (5-50 ng) of dsDNA template
X pi (125 ng) of oligonucleotide primer #1
X pi (125 ng) of oligonucleotide primer #2
1 pi of dNTP mix
ddHiO to a final volume of 50 pi
One pi of PfuTurbo  DNA polymerase (2.5 U/pl) was added. A control 
reaction was performed as well. The reaction was cycled using the parameters 
outlined in the Table 2.7,
The reaction mixture was placed on ice for 2 minutes and allowed to cool to 
37 °C. One pi of the Dpnl restriction enzyme (lOU/pl) was added to the amplification
reaction, and this was thoroughly mixed by pipetting, briefly centrifuged, and
incubated for 1 hour at 37 °C to digest the parental supercoiled dsDNA.
One pi of the I-treated DNA was added to 50 pi o f XL 1-Blue 
supercompetent cells, previously thawed on ice, and the mix was incubated on ice for 
30 minutes. The transformation reaction was heat-shocked for 45 seconds at 42 °C, 
and then placed on ice for 2 minutes. NZY"  ^broth (0.5 ml) preheated to 42 °C was 
added to the transformation reaction, and this was incubated at 37 "C for 1 hour with 
rotary shaking at 225 rpm. The transformation reaction (250 pi) was subsequently 
plated on agar plates containing the appropriate antibiotic for the plasmid vector.
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Table 2.7 Program for DNA amplification designed for QuickChange site- 
directed mutagenesis
Segment Cycles Temperature Time
1 1 95 T 30 seconds
2 12-18 95 °C 30 seconds
55 °C 1 minute
68 °C 1 m inute/kb o f
plasmid length
For single amino acid changes segment 2 was adjusted to 16 cycles, as suggested per manufacturers.
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2.13 Ligand Binding Analysis
2.13.1 Steady-state protein fluorescence measurements
Protein fluorescence measurements were assayed at room temperature using a 
Jasco FP-750 fluorescence spectrophotometer. The excitation light was set to 285 nm 
via a series of eliromating mirrors and the protein fluorescence was measured at right 
angles to the direction of the ineident light using the amplified signal provided by a 
photomultiplier tube.
Volumes of 200 pi of sample were prepared to load a Helma Suprasil quartz 
fluorescence cuvette and protein fluorescence spectra were obtained at wavelengths 
between 295 and 400 nm. Excitation and emission bandwidths were selected to be 5 
nm, and usually, the detection sensitivity of the photomultiplier tube was set to 
medium.
Changes in the fluorescence protein spectra would be measured when small 
volumes of ligand binding components were added at a high concentration to the 
protein solution. DrrA proteins, ATP, MANT-ATP and Mg were the basic 
components involved in the ATP system that was assayed.
2.13.2 Stopped-flow analysis of nucleotide protein interactions
Nucleotide interactions can produce transient changes in the fluorescence of 
proteins. Interactions involving the nucleotide-binding domain (NBD) of the pump 
DrrAB were assessed in a stopped-flow device from Applied Photophysics SMV 18. 
The stopped-flow system allows the rapid mixing of the protein with the ligand and 
enables one to time-resolve changes in the fluorescence on a millisecond time scale. 
Protein and ligand were injected in different channels that were directed in equal 
volumes to a mixing chamber at room temperature, by nitrogen-driven hydraulic 
plungers. Light excitation at 285 mn was provided by a xenon lamp and two serial 
monochromators, whilst a photomultiplier tube (PMT) was used to detect the emitted 
light.
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Tryptophan excitation light was fixed at 280 nm and emission light was 
filtered to select for the appropriate wavelength with 335 or 420 nm eut-off filters 
placed in front of the detection photomultiplier tube, where fluorescence data were 
collected. Alterations in the level of fluorescence were visualised as alterations in the 
voltage output of the tube. Ligand-binding experiments were set up to be performed 
under pseudo first-order conditions, having the ligand concentration in excess over the 
protein concentration. In that way, an exponential change in the fluorescence of the 
protein could be fitted by non-linear regression to an exponential equation defining a 
first order binding process.
The protein samples corresponding to the S. peucetius DrrAB NBD were 
assayed by this technique. For the assays, protein samples, Mg '^ ,^ and ATP or MANT- 
ATP in 50 mM Tris-HCl buffer with 150 mM NaCl and 10% glycerol, were used.
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Chapter 3 
Cloning and sequence analysis of genes in  the Streptomyces peucetius 
drrAB operon
The drrAB operon of Streptomyces peucetius was originally recognised by 
Giiilfoile and Hutchinson (1991). Sequence analysis showed the presence of two 
genes, drrA and drrB, which could encode the ATP-binding and transmembrane 
domains of an ABC transporter, respectively, and mediate self-protection against the 
anthracyclines compounds daunorubicin and doxorubicin. These compounds are 
important in cancer treatment as they show anti-tumour activity. The drrA gene was 
predicted to express a product with similar sequence to the products of other transport 
and resistance genes, such as P-glycoprotein from mammalian tumour cells.
3.1 PCR amplifîcatioii of the drrA and drrB genes.
Oligonucleotide PCR primers were designed for the spécifié amplification of 
the S. peucetius drrA and drrB  genes from the cosmid pWHM612 (Guilfoile and 
Hutchinson, 1991). The published drrA and drrB genes sequences (NCBI site) present 
in the GenBank database under the accession number M73758 were used in primer 
design. The drrAB  operon is 1,841 bp long. The drrA ORF is 993 bp long, and 
extends from position 471 to 1,463. The drrB ORF is 852 bp long and its beginning 
overlaps the drrA stop codon; it extends from position 1,460, to 2,311.
Additional nucleotides at the 5’ and 3’ ends of the gene(s) were included in all 
the primers except in those used to amplify the gene for ligation into the pBADTOPO 
thiofusion veetor (section 2.4.1.2. in Methods). This step was necessary to allow 
excision of the sequences from the initial cloning vector. A two-step strategy was 
planned to simplify the process of sub-cloning from the initial cloning vector into the 
expression vectors chosen for over-expression studies. To sub-clone drrA into 
pET21 a, the 5’ primer contained an ATG star t codon as part of an Ndel site that was 
substituted for the original GTG drrA start codon. In this construct, the original drrA 
stop codon was omitted from the 3 ’ end to allow the incorporation of a six-histidine 
tag in the C-terminus of the DrrA protein. A X h o l site was also incorporated at the 3’ 
terminus to enable subcloning.
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The amplification of drrA was successful using QIAGEN Q solution and a 
gradient between 50-60 °C (Table 3.1; Fig. 3.1). When the temperature gradient was 
not used, the temperature was set to 55 °C to amplify the gene. The amplification of 
the drrAB operon for other vectors was also successful with similar programs (Fig. 
3.2).
Table 3.1 Standard PCR program (Cycling parameters)
Segment Cycles Temperature Time
Hot Star Taq 
activation
1 95 °C 15 minutes
Dénaturation
Annealing
Extension
30 94 "C 
Gradient 50-60 °C 
72 °C
15-60 seconds 
30-60 seconds 
1 mill. 30 seconds
Final extension 1 12 °C 10 minutes
For the amplification o f the drrA gene, 15 and 30 seconds were set for dénaturation and annealing, 
respectively. A time o f 60 seconds was used in the same stages for amplification o f drrAB.
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Figure 3.1 PCR amplification of the drrA gene
The drrA gene was amplified from pWHM612 using 30 cycles under the following reaction conditions; 
94 °C dénaturation for 15 sec, annealing for 30 sec at temperatures ranging between 50 and 60 °C, 72 
°C extension for 90 sec. Lane M: 1 kb DNA molecular markers. Lanes 1-4: drrA PCR product from 
replicated reactions with identical conditions.
1.8 kb
IM 1 2
Figure 3.2 PCR amplification of the drrAB operon
The genes drrA and drrB were amplified from pWHM612 using 30 cycles under the following reaction 
conditions: 94 °C dénaturation for 1 min, annealing for 1 min at temperatures ranging between 50 and 
60 °C, 72 °C extension for 1 min. Lane M: 1 kb DNA molecular markers. Lanes 1-2: drrAB  PCR 
product from replicated reactions with identical conditions.
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3.2 Cloning of the drrA gene
The amplified drrA gene was purified from an agarose gel and cloned into the 
pGEMT-Easy vector (Fig. 3.3) (Section 2.3 in Methods). Ndel and X h o l  
endonuclease restriction sites had been designed to form part of the drrA gene at its 
ends, for sub-cloning in the pET21a vector. S a d  and Hindlll endonuclease restriction 
sites were present instead when the sub-cloning was intended for the pQElOO vector. 
No endonuclease restriction sites were designed into the ends of drrA for cloning into 
the pBADTOPO thiofusion vector (Table 2.2 in Methods). For cloning into pBAD, 
PCR products were isolated from several bands cut from analytical gels, and pooled 
into a single, large well, to get a high concentration of the PCR product for further 
TOPO ligation (Fig. 3.4).
3.3 Cloning of the drrAB operon
Several PCR products bearing the sequence of the drrA and drrB genes were 
also obtained (Fig. 3.2) to allow future co-expression with different vectors (e.g. 
pET21 a, pET33b). In this case, Nhel and Hindlll restriction sites were incorporated 
into the primers, an Nhel site in the 5’ terminus of the drrA gene, and a Hindlll site in 
the 3’ terminus of the drrB gene.
The product was cloned into the pGEMT-Easy vector and insertion confirmed 
by digestion with Nhel and Hindlll (Figure 3.5). The release of bands of around 3 kb 
(pGEMT vector) and 1.8 kb {drrAB operon) confirmed the success of this cloning.
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Figure 3.3 Restriction analysis of the pGEMT Easy-i/rrA plasmid
Plasmid DNA from transformed bacteria was isolated and digested with Nde\ and Xho\ before analysis 
on an agarose gel. M; 1 kb DNA molecular markers. 1: DNA fragments after digestion with Ndel and 
Xhol showing the vector and excised drrA insert (indicated).
2 kb
1 kb
M 1
Fig. 3.4 Electrophoresis of DNA in agarose gel showing concentrated drrA PCR 
product
DNA from PCR drrA product was isolated from several bands cut from analytical gels, and pooled 
into a single, large well, to obtain a high concentration o f  the PCR product for cloning into 
pBADTOPO thiofusion. M: 1 kb DNA molecular markers. 1: concentrated drrA PCR product with no 
restriction sites at its ends
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Figure 3.5 Restriction analysis of the pGEMTEasy-</rr4^ plasmid
Plasmid DNA from transformed bacteria was isolated and digested with Nhe\ and Hind\\\ before 
analysis on an agarose gel. M: 1 kb DNA molecular markers. 1: DNA fragments before digestion with 
Nhe\ and Hind[\\ showing the undigested pGEMT-easy drrAB construct. 2: DNA fragments after 
digestion with Nhe\ and HindWl showing the vector and excised drrAB insert
106
3.4 Initial construction of pET drrA plasmids for over-expression
pET vectors were considered to be a good option to sub-clone the drrA gene 
for production of soluble protein for further assays. In particular, pET21a offered 
several immediate advantages to accomplish this objective. Apart from possessing a 
convenient resistance determinant (ampicillin), a varied multi-cloning site and a poly 
histidine-coding region suitable for affinity chromatography purification, it carries a 
powerful promoter (T7) to overexpress heterologous proteins. The E. coli RNA 
polymerase does not interact with this promoter, and hence “leaky” expression of the 
target protein is minimised in the uninduced state. The transcription of the 
heterologous gene is accomplished by transforming the expression construct into a 
host cell with a clrromosomal copy of the T7 RNA polymerase, itself under control of 
the lacUV5 promoter. The expression of the T7 RNA polymerase is induced by the 
addition of IPTG to a log phase culture. This in turn results in a very high 
transcription of the target gene sequence.
3.4.1 Sub-cloning of the drrA  gene into a suitable expression vector for
Escherichia coli.
The DNA segment of the drrA gene was obtained by digesting the initial 
pGEMT-Easy construct with Ndel and Xhol and ligation o f the small released 
fragment into pET21a (Fig. 2.1 in Methods, and Fig. 3.6). The drrA gene had been 
designed with the particular restriction sites N del and Xhol, to minimise any 
additional DNA sequence between the end of the gene and the encoded his-tag 
sequence, which could disturb the conformation of the expressed protein. As the start 
codon ATG forms part of the Ndel site, it substituted the original S. peucetius drrA 
gene start codon GTG, which was not necessaiy to include.
Transformants cariying the pETllei-drrA construct were selected on the basis 
of vector encoded antibiotic resistance. Recombinant expression plasmids were 
isolated by mini-prep and checked for the presence of the inserted drrA gene by 
restriction digest. A diagram showing the general cloning process for drrA gene (Fig. 
3.6) and a restriction analysis of recombinant pET expression plasmids (Fig. 3.7) are 
presented on the following pages.
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Nde\ PCR drrA gene insertion
Recombinant 
pGEMT-Easy 
plasmid
Isolated cloned drrA gene 
after restriction digest and 
gel extraction
Xho\
pET21a
expression
plasmid
Ligation o f  
cohesive ends 
- T4 DNA ligase
Cloning site
Isolated opened pET plasmid 
DNA after restriction digest and gel
extraction
pT 7
Recombinant pET 
expression construct
His.
Recombinant pET plasmid with drrA 
gene expression under the control of 
the T7 promoter. Inserted sequence is 
fused to a His6 purification tag
Fig. 3.6 Diagram showing the cloning of the drrA gene into the pET21a vector
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Fig. 3.7 Restriction analysis of the pET21a-</rr/l plasmid
Plasmid DNA from transformed bacteria was isolated and digested with Nde\ anà Xho\ before analysis 
on an agarose gel. M: 1 kb DNA molecular markers. 1: DNA fragments after digestion with Nde\ and 
Xho\ showing the vector and excised drrA insert (indicated).
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3.4.2 Sub-cloning of the drrAB operon into a suitable expression vector for 
Escherichia coli
To sub-clone the operon sequence corresponding to drrA and drrB for over- 
expression, a sequence coding for a histidine tag had to be added to the 5 ’ terminus of 
drrA  to make DrrA suitable for immobilised-metal affinity chromatography 
purification. When the sub-cloning was performed into pET33b, no histidine tag 
coding sequence had been included in the drrA gene, as the vector presented these 
sequences at both ends of the operon.
Additionally, some primers to clone this sequence in the vector pUC 18 were 
also prepared (Table 2.2 in Methods). Although the expression of genes in this vector 
is not high, former research with the drrAB system employed this vector (Kaur and 
Russell, 1998).
The successful sub-cloning of drrAB in pET21a can be seen in the restriction 
analysis of this plasmid (Fig. 3.8).
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Fig. 3.8 Restriction analysis of the pETZla-drr/tB plasmid
Plasmid DNA from transformed bacteria was isolated and digested with Nhe\ and Hind\\\ before 
analysis on an agarose gel. M: 1 kb DNA molecular markers. 1: DNA fragments after digestion with 
Nhe\ and Hind\\\ showing the vector and excised drrAB insert
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3.5 Initial construction of pBADTOPO thio-drrA
The pBADTOPO thiofusion vector (Fig. 2.2 in Methods and below) was also 
used to clone the drrA  gene for expression of DrrA. In this system, a fusion to 
Thioredoxin was created. No restriction sites were designed into the drrA primers as 
the pBADTOPO vector contains the enzymatic machinery to ligate PCR products. 
This vector also includes a sequence encoding a poly-histidine tag to ease protein 
purification by Immobilised metal affinity chromatography (IMAC). It was hoped 
that as Thioredoxin is a small and very soluble protein, it could help in the 
solubilisation of DrrA and minimise the production of inclusion bodies.
Insertion of drrA into the pBADTOPO thiofusion vector would create a single 
protein of 51.7 kDa. This protein would correspond to the DrrA protein (35.7 kDa) 
fused to an N-terminal HP-Thioredoxin (13 kDa) and a 6 histidine tag at the C- 
terminus (3 kDa). Some problems were experienced encountered in obtaining the 
construct, as it was difficult to discern if the constructs had the drrA gene inserted 
with the proper orientation. Uncommon single restriction sites were present in both 
the plasmid and the drrA gene, and it was difficult to assess the orientation of the 
insert on gels. Employing a PCR methodology for the same purpose produced 
contradictory results; the first four constructs to be tested were correctly inserted 
according to PCR amplification, but the analysis of their sequences showed that all of 
the four inserts were in the wrong orientation. Finally, after exhaustive analysis, a 
positive clone was obtained with the insert correctly orientated according to a 
restriction analysis with EcoRV and Narl. This was confirmed by sequence analysis. 
Expression from this construct was induced with arabinose and could be tightly 
regulated according to the used inducer concentration. A diagram showing the 
localisation of the drrA gene PCR product inserted into the vector pBADTOPO 
thiofusion is shown below:
thioredoxin RBS
A
EK site-T
drrA PCR 
productI
A
T-V5 epitope 6 His Stop
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3.6 Transformation of £■. c<?//cells
The pET21a vector, carrying the drrA gene alone, or with drrB, was used to 
transform E. coli XL-10 for propagation of the plasmids. E. coli BL21 DE3 was 
transformed for protein expression. Similarly, E. coli DH5_ pro cells were used for 
the pET33b plasmid. Standard transform ation procedures were followed 
incorporating a 90 seconds heat shock at 42 °C that produced sufficient transformants 
for screening.
When transformation was carried out with the pBADTOPO thio-drrA  
construct, E. coli LMG194 or TOP-10 cells were employed. Heat shock at 42 °C for 
45 seconds, as suggested in the manual, produced sufficient transformants.
3. 7 Sequence analysis of the cloned drrAB  genes
The nucleotide sequences of the cloned PCR amplicons were consistent with 
those of the published drrA and drrB genes, except where restriction sites had been 
added to the primers, and where poly histidine tags were included in the construct. 
For example, a A/ioI site was introduced at the 3’ end of the drrA gene sequence for 
cloning of drrA alone into when the pET21 a vector, and no restriction site was 
included at the drrA 3’ terminus when cloning included drrB. The sequence data 
confirmed the success of the initial PCR reactions with genomic DNA and hence the 
transformed E. coli strains were laid down as glycerol stock cultures. An in silico 
analysis of the cloned sequences was also performed to establish that each encoded 
the expected DrrA and DrrB proteins.
3.7.1 Sequence analysis of the drrA-thio fusion
The drrA gene fused to thioredoxin bore some additional sequence from the 
pBADTOPO thiofusion vector comprising nucleotides for the Enterokinase (EK) site 
upstream from the 5Terminus of drrA, and the V5 epitope downstream from the 3’ 
terminus of drrA.
The whole coding sequence in the pBADTOPO thio-drrA construct was 1,446 
bp, encoding a protein of 481 amino acids. 990 bp were derived from drrA and of the
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remaining 456 bp, 18 coded for the histidine tag, 42 for the V5 epitope, and almost all 
the remainder, for the thioredoxin gene sequence.
3.8 Discussion
Vectors of pET series, and specially pET21a, were considered to be the best 
option for cloning and expressing the drrA gene. These vectors are popular because 
they offer several options for selection with antibiotics, tags for purification, such as 
the histidine repeat can be positioned at the N- or C-termini of the translation product 
and multiple cloning sites are available. In addition, they carry a strong promoter 
(T7), suitable for the transcription and expression of soluble proteins. Previous 
publications (Guilfoile and Hutchinson, 1991; and Kaur, 1997; Kaur and Russell, 
1998) reported that DrrA was a hydrophilic soluble protein, peripheral to the 
membrane. This suggested that vectors such as the pET series would be good 
vehicles to overexpress appropriate quantities of soluble DrrA for functional analysis. 
The pET21a vector seemed to be the most suitable of these pET vectors to achieve 
this aim.
In designing primers, care was taken to ensure the resulting DrrA protein 
would carry as few non-native residues as possible. By using N del and Xhol 
restriction sites, the gene could be cloned into pET in frame with tags and additional 
bases within the multiple-cloning site could be excluded. In addition, the presence of 
the histidine tag at the C-terminus of DrrA would avoid the co-purification by nickel- 
agarose affinity chromatography of products degraded from this terminus of the 
protein, ensuring the purification of a full length product.
The choice of the pBADTOPO thiofusion vector formed an alternative option 
for production of soluble DrrA protein. TOPO ligation is a very effective way for 
insertion of PCR products but it suffered the disadvantage that products could ligate 
into the vector in either orientation. As it was not easy to find appropriate single 
restriction sites, it proved difficult to identify clones with the intended orientation.
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A further option of the co-expression of drrA and drrB genes was established 
as previous work suggested that there was some degree of interdependence in the 
DrrAB system (Kaur, 1997; Kaur and Russell, 1998). These studies concluded that 
DrrB was not overexpressed at all in the absence of DrrA, and that active DrrA 
protein could only be obtained when co-expressed with DrrB.
This chapter reports the successful cloning of the S. peucetius drrA gene, and 
its sub-cloning into vectors for overexpression of the proteins. This was an important 
target in order to accomplish the project aims of purification of large quantities of 
these proteins in order to further study the biochemical, structural and physiological 
properties of ABC transporters in general and the function of the S. peucetius DrrA 
protein in particular.
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Chapter 4 
Heterologous expression of recombinant proteins
On the assumption that the cloned drrA gene would encode the nucleotide- 
binding domain (NBD) of the S. peucetius DrrAB pump, the next stage of the 
investigation involved its over-expression to obtain adequate quantities of protein for 
characterisation. After purification, it was planned that these studies would include 
the analysis of the ATPase activity of DrrA. This enzyme would utilise energy from 
ATP to drive the transport of the anthracycline compounds daunorubicin and 
doxorubicin out of the cell, avoiding their toxic effects.
Streptomyces is a soil microorganism, and its growth and handling are not as 
straightforward as for laboratory organisms. To overcome this handicap and avoid 
the requirement for special culturing facilities, it was decided that a biochemical study 
of DrrA would be founded upon its expression in a heterologous host. E. coli was 
selected since it has been used to overexpress successfully an enormous number of 
different proteins from biologically diverse species. Another very important reason 
for the use of E. coli is that genetic systems for the expression of heterologous 
proteins in this bacterium are well developed and characterised.
4.1 Heterologous over-expression of the S. peucetius DrrA protein
It was initially thought that drrA would be more easily cloned without drrB, 
and that the mainly hydrophilic properties of DrrA would favour the production of 
soluble protein for further characterisation.
4.1.1 Over-expression of the DrrA protein using the pET21a plasmid
The drrA gene was cloned into the pGEMT-Easy vector and sub-cloned into 
the pET21a vector. The start codon of drrA was thereby placed downstream of a 
bacteriophage T7 promoter, a lac operator sequence and an E. coli ribosome-binding 
site. These features should have ensured the repression of protein expression in the 
uninduced state, and high level transcription when the plasmid was transformed into a 
suitable host strain and induced with IPTG. The E. coli strain chosen for the purpose
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of expressing this gene was BL21 (DE3). This strain lacks two major cellular 
proteases, Lon and OmpT, which may interfere with the expression and purification 
of intact, full-length, recombinant protein; it also has a _DE3 lysogen, which is stably 
incorporated into the E. coli chromosome and encodes an IPTG inducible 
bacteriophage T7 RNA polymerase. It is the induction of this polymerase that allows 
transcription of the recombinant gene sequence. The vector also provided a six- 
histidine tag at the C-terminus of DrrA (see Ch. 3, sections 3.1 and 3.4.1).
4.1.1.1 Initial analysis of cell fractions
Cells of E. coli BL21 carrying pET21 a-<7rrri were grown at 37 ®C to 
exponential phase (ODeoonm = 0.6) in complex media (LB broth), and IPTG was added 
to 1 mM to induce expression. Growth continued for 3 hours and the cells were 
recovered by centrifugation. After disruption, a supernatant fraction and a pellet were 
obtained. The insoluble material in the disrupted cell pellet was prepared for analysis 
by incubation in 8 M urea Phosphate lysis buffer for 2 hours (see Ch. 2, section 2.9.2). 
The crude fractions were analysed for the presence of DrrA by addition of SDS- 
PAGE sample buffer and subsequent electrophoresis. A band on an SDS-PAGE gel 
with a molecular mass similar to that of the recombinant protein (37 kDa) was present 
in the insoluble fraction from the disrupted cells (designated the inclusion body 
fraction). The appearance of this band seemed to depend upon induction with IPTG 
(Fig. 4.1). The size of the recombinant protein and its expression in the presence of 
IPTG supported the notion that it was likely to be DrrA.
4.1.1.2 Optimisation of conditions for production of soluble protein
Attempts to shift the proportion of DrrA present in the insoluble fraction 
towards the cytosolic fraction, led us to test induction at lower temperatures, and 
induction with lower IPTG concentrations. Assays to obtain soluble DrrA protein 
using lower temperatures (30 and 25 °C) (Fig. 4.2) and lower IPTG concentrations 
(0.2 mM) did not increase the yield of soluble protein in early experiments using low 
volumes of media (1 L). Afterwards, induction at 18 °C provided some protein in the 
soluble fraction for purification by affinity chromatography (IMAC; see Ch. 2, section 
2.9), but the amounts were too low to proceed with characterisation assays (Fig. 4.3).
17
Initially the yield of soluble DrrA was no higher than 30 jug protein/L of culture. In 
further experiments, a concentration of 60±20 jug protein/L of culture was obtained by 
induction at 17 °C with 1 mM IPTG. The first two fractions eluted from five IMAC 
purifications (each purification corresponding to approximately 2 L of culture) were 
collected. About 1 mg of DrrA in approximately 9 ml of pooled elution buffer was 
collected and dialysed.
4.1.1.3 Over-expression of DrrA from the pET21a plasmid in strain BL21 AI
Expression of the pET21 a construct was tested in the E. coli strain BL21 AI to 
establish if it was possible to improve the yields of DrrA by using a different bacterial 
strain. In this system, IPTG and arabinose inducers provide stringent regulation over 
the expression of DrrA. In spite of expectations, the expression of DrrA at 37 ^C and 
17 °C was not improved relative to the BL21 (DE3) strain, although multiple 
combinations of inducers were used. Induction with 0.01 mM IPTG had the weakest 
effect on the expression of DrrA in this system (Fig. 4.4), while 0.1 mM was the best, 
rendering the highest yield of soluble protein.
4.1.1.4 Analysis of expression of DrrA from the pET21a vector by Western blot
Western blotting was used to demonstrate the presence and identity of DrrA 
protein expressed from different constructs, exploiting the presence of a Hisg epitope 
tag. Antibodies raised against DrrA were not available.
The recombinant 37 kDa protein was produced by induction with 0.1-1 mM 
IPTG (and with Arabinose and IPTG in the BE 21 AI strain). After transfer to PVDF, 
blots were probed with antibody against the histidine tag. At 37 °C, almost all the 
protein appeared in the insoluble cytoplasmic fraction, presumably in inclusion 
bodies. However, at 18 °C a small amount of DrrA could be detected in the soluble 
cytosolic fraction. A proportion of DrrA also appeared in the membrane fraction (Fig. 
4.5).
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Figure 4.1 Preliminary fractionation of £. coli BL21(DE3) grown at 37 ®C to 
determine sub-cellular localisation of DrrA
Bacteria carrying the pET21a expression construct were grown at 37 °C to exponential phase and 
induced with 1 mM IPTG for 3 hours. In a control experiment, cells were treated identically but for the 
omission o f  IPTG. Soluble cytosolic proteins were obtained by cell disruption and centrifugation. 
Proteins recovered from the disrupted pellet following addition o f  urea were termed the inclusion body 
fraction. Samples were analysed by SDS PAGE and GelCode blue staining.
M: Protein molecular weight markers 
Lane I; Crude soluble fraction - IPTG 
Lane 2; Crude soluble fraction + IPTG 
Lane 3: Inclusion body fraction - IPTG 
Lane 4: Inclusion body fraction + IPTG
Approximately 20 pg o f  protein was loaded per well. The 37 kDA protein presumed to be DrrA is 
indicated.
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Figure 4.2 Preliminary fractionation of E. coli BL21(DE3) grown at 25 ®C to 
determine the sub-cellular localisation of DrrA
Bacteria carrying the pET2la expression construct were grown at 37 °C to exponential phase, shifted to
25 °C and induced with 1 mM IPTG overnight. In a control experiment, cells were treated identically
but for the omission o f IPTG. Cell fractionation and analysis was carried out as described in Figure 4.1
M: Protein molecular weight markers
Lane 1; Crude soluble fraction - IPTG
Lane 2: Crude soluble fraction + IPTG
Lane 3: Inclusion body fraction - IPTG
Lane 4; Inclusion body fraction + IPTG
Approximately 30 pg o f  protein from the soluble fractions and 20 pg from the inclusion bodies 
fractions were loaded to the gel.
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Figure 4.3 Expression and purification of DrrA from E. coli BL21 (DE3) cultures 
induced at 18 "C
Bacteria carrying the pET21a expression construct were grown at 37 °C to exponential phase, shifted to 
18 °C and induced with 1 mM IPTG overnight. Proteins from the soluble cytoplasmic fraction were 
purified by IMAC. Samples were analysed by SDS PAGE and GelCode blue staining.
M: Protein molecular weight markers
IB; Inclusion body fraction
FT: Flow-through from the IMAC column
WB|: Wash fraction from the column (25 mM imidazole)
WB;: Wash fraction from the column (50 mM imidazole)
Lanes I and 2: Fractions eluted from the IMAC column with 300 mM imidazole
20 pg o f  protein from the inclusion body fraction was loaded to the gel. IMAC was carried out with
material prepared from about 2 L o f induced culture.
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Figure 4.4 Expression and purification of DrrA from E. coli BL21 AI cultures 
induced at 17 ”C
Bacteria carrying the pET21 a expression construct were grown at 37 °C to exponential phase, shifted to 
17 °C and induced with 0.002% arabinose and the IPTG concentrations indicated, overnight. Proteins 
from the soluble cytoplasmic fraction were purified by IMAC. Samples were analysed by SDS PAGE 
and Coomasie blue staining.
M: Protein molecular weight markers
1: Inclusion body fraction (induction with 0.01 mM IPTG)
2: Protein eluted from IMAC column after loading with soluble cytosolic fraction (induction with 0.01 
mM IPTG)
3: Inclusion body fraction (induction with 0.1 mM IPTG)
4-6: Fractions eluted from IMAC column after loading with soluble cytosolic fraction (induction with 
0.1 mM IPTG)
7: Inclusion body fraction (induction with 1 mM IPTG)
8-9: Fractions eluted from IMAC column after loading with soluble cytosolic fraction (induction with 1 
mM IPTG)
In each case, IMAC was carried out with material prepared from about 2 L o f induced culture.
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Figure 4.5 Expression, purification and blotting analysis of DrrA from E. coli 
BL21 (DE3) cultures induced at 18 **C
Bacteria carrying the pET21a expression construct were grown at 37 °C to exponential phase, shifted to 
18 °C and induced with 1 mM IPTG overnight. Proteins from the soluble cytoplasmic fraction were 
purified by IMAC and analysed by Samples were analysed by SDS PAGE and GelCode blue staining 
(left panel) and Western blotting with an antibody against the histidine purification tag (right panel).
1 ; Protein molecular weight markers 
2: Inclusion body fraction from induction at 18 °C 
3: Inclusion body fraction from induction at 30 °C
4-6; First 3 fractions eluted from IMAC column after loading with soluble cytosolic fraction (induction 
at 18 °C)
7: Membrane fi-action (induction at 18 °C)
IMAC was carried out with material prepared from about 1 L o f  induced culture.
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4.2 Heterologous over-expression of DrrA and DrrB using pET vectors
It has been reported that the expression of DrrA is dependent upon the 
presence of DrrB, indicating a tight interaction between both proteins (Kaur, 1997, 
2005; Kaur and Russell, 1998). Therefore, the expression of DrrA was investigated as 
a component of the whole DrrAB complex. Plasmids pET21a and 33b were chosen 
as vectors for the drrAB operon to test whether more soluble DrrA could be obtained 
when expression was translationally coupled to DrrB.
4.2.1 Heterologous over-expression of DrrA and DrrB proteins using the 
pET21a plasmid
When both drr genes were cloned into the pET21a vector for expression 
studies DrrA could not be detected on gels after induction with 1 mM IPTG. Yields 
could not be improved by induction at 16 °C. Sequencing confirmed that part of the 
DNA sequence encoding the histidine-tag was missing from the construct, but a new 
vector preparation in which this feature was corrected also failed to express DrrA.
4.2.2 Heterologous over-expression of DrrA and DrrB proteins using the 
pET33b plasmid
The same approach was attempted using the pET33b vector. The drrAB PCR 
product was cloned into the expression vector and transformed into E. coli 
BL21(DE3). Transformants were grown and induced with 1 mM IPTG at 37 ”C. No 
signs of DrrA expression could be detected when samples were analysed on gels. The 
temperature at induction was dropped to 17 °C and IPTG added to 1 or 0.1 mM, 
Soluble cytosolic proteins were purified by IMAC for gel analysis. This revealed 
several bands on the gel including one that matched the molecular weight expected 
for DrrA (-37 kDa). Two additional bands of similar concentration were present 
around 39 kDa (Fig. 4.6) but the yield and purity of the material was insufficient to 
allow further progress.
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Figure 4.6 Expression and purification of DrrA from drrAB construct induced at 
17 X
Bacteria carrying the pET33b expression construct were grown at 37 °C to exponential phase, shifted to 
17 °C and induced with 0.1 mM IPTG overnight. Proteins from the soluble cytoplasmic fraction were 
purified by IMAC and analysed by SDS-PAGE and Coomasie blue staining..
M: Protein molecular weight markers
Lanes 1-3: Fractions eluted from the IMAC column
Soluble protein from a 2 L culture was loaded to the column
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4.3 Heterologous over-expression of Thio-DrrA from the pBADTOPO 
thiofusion plasmid
Since only minimal quantities of soluble DrrA were obtained by expression of 
the pET constructs, a different approach was tested. The pBADTOPO thiofusion 
plasm id encodes for Thioredoxin, a protein of low molecular weight and high 
solubility, and the vector enables convenient fusion with the product of a cloned gene. 
It was considered that the properties of Thioredoxin might increase the proportion of 
DrrA protein in the soluble cytosolic fraction, although forming part o f a fusion 
protein. As this type of vector can be tightly regulated by an appropriate 
concentration of arabinose, a small-scale culture at 37 °C was used to determine the 
arabinose concentration that induced the highest expression of the Thio-DrrA fused 
protein. When the E. coli transformant were grown to an ODôoo of about 0.5, they 
were treated with different arabinose concentrations to induce expression of the DrrA 
protein (0.00002-0.2%; see section 2.7.2). Following a four-hour incubation period, 
the cells were recovered by centrifugation and samples from each culture were mixed 
and lysed with SDS NuPAGE buffer, and run on a gel. A Thioredoxin-DrrA fusion 
protein, of approximately 52 kDa molecular weight, was clearly expressed when 
cultures were induced with arabinose at concentrations between 0.002 and 0.2% (Fig. 
4.7).
Having chosen an arabinose concentration of 0.002% to induce the expression 
of the fused DrrA, experiments were carried out on a much larger scale (10 L). 
Although some protein appeared in the soluble cytosolic fraction when cultures were 
grown and induced at 37 °C (Fig. 4.8), most of the protein was present in the 
insoluble fraction (assumed to be inclusion bodies). Dropping the temperature of 
induction to 25 °C only produced a slight improvement in solubility (Fig. 4.9). Only 
when cultures were induced at 17 °C, did better yields of soluble Thio-DrrA emerge 
(Fig. 4.10). The presence of the histidine purification tag was confirmed by Western 
blotting using specific antibody (Fig. 4.11).
It was found that standardised experimental conditions of overnight culture at 
17 could produce Thio-DrrA at a concentration of 250 pg/mi in the eluate (12 ml). 
Using IMAC for purification, the first three fractions eluted from four purification
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runs (corresponding to 7 L of culture) yielded Thio-DrrA at 430 pg/L of culture. As 
DrrA comprises a 72.5% of the fused Thio-DrrA protein, it is possible to deduce that 
_  of this protein correspond to the DrrA fraction. This result shows that the inherent 
production of DrrA from the pBAD construct was about 3.6 fold higher than when the 
pET21a construct was used.
4.4 Comparative analysis of DrrA from expression vector systems
A comparative Western blot of DrrA proteins expressed from pET21 a and 
pBADTOPO thiofusion vectors after induction at 17 °C and 37 °C was performed. 
When E. coli cultures carrying these plasmids were induced at 37 °C, a very faint 
band of Thio-DrrA appeared on SDS-PAGE gels, whilst no DrrA could be detected 
from the pET21a expression system. The yield of DrrA from the pET21a construct 
when induced at 17 °C was scarcely more prominent than that obtained for Thio-DrrA 
produced at 37 “C, according to data from SDS-PAGE and Western blotting (Fig. 4.12 
and 4.13). Thus, it was concluded that the pET21a expression system worked best (if 
not ideally) when induced at 17°C and grown on overnight.
In contrast, the pBADTOPO ihio-drrA construct showed more promise as a 
vehicle for expression of recombinant DrrA. When induced with arabinose at 17 °C, 
this system yielded at least five times more Thio-DrrA than was obtained from other 
preparations as determined by SDS-PAGE (Fig. 4.12) and the determination of 
protein concentration. An additional band of similar size to DrrA appeared on the gel 
(Fig 4.12) and was reactive with anti-tag antibody in Western blots (Fig. 4.13). This 
was probably being a degradation product of the fused protein. Yields of soluble 
protein from the pET21a expression system were approximately 60 pg per litre of 
culture, whilst yields for Thio-DrrA were 375 pg/L (Table 4.1),
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Fig. 4.7 Expression of Thio-DrrA in E. coli LMG 194 after induction with 
different concentrations of arabinose
Cultures o f E. coli were grown at 37 °C to exponential phase, treated with varying concentrations o f  
arabinose, and incubated for an additional 4 hours. Total cellular protein was analysed by SDS-PAGE 
and GelCode blue staining.
M: Protein molecular weight markers
1 : Control taken at time o f induction, no arabinose added
2: Control at the end o f the induction period, no arabinose added
3: Culture induced with 0.000002% arabinose
4: Culture induced with 0.00002% arabinose
5: Culture induced with 0.0002% arabinose
6: Culture induced with 0.002% arabinose
7: Culture induced with 0.02% arabinose
8: Culture induced with 0.2% arabinose
A protein o f 52 kDa consistent with the size o f the Thioredoxin-DrrA fusion protein is indicated.
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Figure 4.8 Expression and purification of Thio-DrrA from E. coli LMG 194 
cultures induced at 37 C
Cultures o f  E. coli were grown at 37 °C to exponential phase, treated with 0.002% arabinose and 
incubated for an additional 4 hours. Cells were fractionated and recombinant protein purified from 
soluble cytoplasmic extracts by IMAC. Samples were analysed by SDS PAGE and Coomasie blue 
staining.
M: Protein molecular weight markers
IB: Inclusion body fraction
FT: Flow-through from the IMAC column
W Bl: Washings from the column (20 mM imidazole)
WB2: Washings from the column (50 mM imidazole)
1 and 2: Fractions eluted from the column (300 mM imidazole)
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Figure 4.9 Expression and purification of Thio-DrrA from E. coli LMG 194 
cultures induced at 25^C
Cultures o f E. coli were grown at 37 °C to exponential phase, shifted to 25 °C and treated with 0.002% 
arabinose overnight. Cells were fractionated and recombinant protein purified from soluble 
cytoplasmic extracts by IMAC. Samples were analysed by SDS PAGE and GelCode blue staining.
M; Protein molecular weight markers
Lane 1-2: First two fractions eluted from IMAC column (300 mM imidazole)
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Figure 4.10 Expression and purification of Thio-DrrA from E. coli LMG 194 
cultures induced at 17 "C
Cultures o f £. coli were grown at 37 ®C to exponential phase, shifted to 17 °C and treated with 0.002% 
arabinose overnight. Cells were fractionated and recombinant protein purified from soluble 
cytoplasmic extracts by IMAC. Samples were analysed by SDS PAGE and Coomasie blue staining.
M; Protein molecular weight markers
W,_2: Washings from the IMAC column (25 and 50 mM imidazole, respectively)
1-4: First four fractions eluted from the IMAC column (300 mM imidazole)
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Figure 4.11 Expression, purification and blotting analysis of Thio-DrrA from £. 
coli LMG 194 cultures induced at 17 ®C
Cultures o f E. coli were grown at 37 ®C to exponential phase, shifted to 17 °C and treated with 0.002% 
arabinose overnight. Cells were fractionated and recombinant protein purified from soluble 
cytoplasmic extracts by IMAC. Samples were analysed by SDS-PAGE and GelCode blue staining 
(upper panel) and Western blotting (lower panel) using antibodies against the histidine tag.
Lanes 1: First eluted fraction from IMAC column (300 mM imidazole)
Lane 2: DrrB prepared from a pET21 construct in a different experiment 
M (lane 3): Protein molecular weight markers
Lanes 4-9: Fractions 2-7 eluted from IMAC column (30 mM imidazole)
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Figure 4.12 Analysis of recombinant DrrA expressed as a single protein from 
pET21a and as a Thio-DrrA fusion protein
E. coli cultures were induced with 1 mM IPTG for expression o f  DrrA and with arabinose for 
expression o f  the Thio-DrrA fusion protein. Samples were analysed by SDS PAGE and GelCode blue 
staining.
M; Protein molecular weight markers
1: DrrA present in inclusion body fraction prepared from cultures induced at 37 °C
2: DrrA present in the soluble fraction prepared from cultures induced at 37 °C
3: DrrA present in the soluble fraction prepared from cultures induced at 17 °C
4: Thio-DrrA present in the soluble fraction prepared from cultures induced at 37 °C
5: Thio-DrrA present in the soluble fraction prepared from cultures induced at 17 °C
Sample loadings represent 0.1 % o f the disrupted cell pellet from 1 L o f culture. DrrA in the inclusion
body fraction (lane 1) was loaded as a reference marker for the migration o f DrrA
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Figure 4.13 Western blot analysis of DrrA expressed as a single protein from 
pET21a and as a Thio-DrrA fusion
Samples were prepared as in Figure 4.12
1 : DrrA present in inclusion body fraction prepared from cultures induced at 37 °C 
2; DrrA present in the soluble fraction prepared from cultures induced at 37 °C 
3; DrrA present in the soluble fraction prepared from cultures induced at 17 °C 
4: Thio-DrrA present in the soluble fraction prepared from cultures induced at 37 °C 
5; Thio-DrrA present in the soluble fraction prepared from cultures induced at 17 °C
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Table 4.1 Comparison of protein yields
Thio-DrrA DrrA
Volume of culture (L) 8 8
Volume eluted from IMAC 12 8
columns (ml)
Protein concentration (|ag/ml) 250 60
in the eluted material
Total protein obtained (mg) 3 0.48
Protein yield (pg/L) 375 60
Data was gathered from four independent purifications each using 2 L o f  culture, whose material was 
pooled for analysis. Protein yields represent the average from three determinations. In each case, E. 
coli strains were grown at 37 °C to exponential phase, shifted to 17 °C, treated with inducer (0.002% 
arabinose for Thio-DrrA, 1 mM IPTG for DrrA) and incubated overnight to induce expression. Proteins 
were isolated from soluble cytoplasmic fractions using IMAC.
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4.5 Discussion
Expression of transporter proteins has been a difficult task in the past. Membrane 
proteins need an appropriate environment for expression and purification besides 
intrinsic requirements for functionality. NBDs, on the other hand, have been 
classified as cytosolic domains, peripheral to the membrane, but they also are usually 
expressed with difficulty in hydrophilic environments. To overcome this drawback, 
researchers have usually had to search for particular approaches linked to the system 
under study. The following examples illustrate the different approaches investigators 
have used to overexpress transporters, particularly those of the ABC family;
a) Overexpression of eukaryotic genes using eukaryotic systems.
To overexpress eukaryote genes, eukaryotic vectors have been preferred to those 
of E. coli. Some examples include: mouse mdrl, where the biological activity of 
cDNAs were tested after cloning into the expression vector p91023b (Azzaria et aL, 
1989). This vector system had been used previously to express m drl (Gros et al., 
1986) and carries the adenovirus major late promoter and simian virus 40 enhancer to 
direct high levels of expression of cloned cDNAs. Wild-type human P-glycoprotein 
(ABCBl, MDRl gene product), has been expressed with a C-terminal histidine tag in 
S. cerevisiae plasma membranes using the yeast expression plasmid YEpMDRlHIS 
(A1 Shawi et al., 2003). Similarly, studies of human MRP 1 used baby hamster kidney 
(BHK-21) cells transfected with pNUT-MRP/His (Chang et al., 1997). The original 
vector (pNUT) also contains a mutant dihydrofolate reductase (DHFR) gene under the 
control of the SV40 early promoter, allowing for selection of transfectants with 
methotrexate
b) Overexpression of eukaiyotic genes using E. coli cells
Examples include that of the carboxyl-terminal NBD from Chinese hamster P-gp. 
This was cloned and overexpressed in the vectors pT7-7 and pET22b, and purified to 
allow structure-function studies of the NBDs. The overall yield of purified protein 
was of 25-50 pg/L of cell culture (Sharma and Rose, 1995). Mdll from S. cerevisiae 
has also been studied in this way to investigate its ATP hydrolysis cycle and 
properties of its NBD (Janas et al., 2003).
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c) Overexpression of prokaryotic genes using related prokaryotic systems
Overexpression of genes from E. coli or related bacteria has usually been
achieved with success. Examples include E. coli MsbA expressed in E. coli Novablue 
DE3 cells harboring a pET28b construct containing msbA (Reuter et aL, 2003); V. 
cholera MsbA, that was cloned into pET19b with a 23-residue fusion leader 
containing an N-terminal deca-histidine tag, and expressed in E. coli BL21(DE3) 
(Chang, 2003). In studies of the Mai transporter from E. coli, the components MalF, 
MalG, and MalK were overproduced simultaneously from two plasmids, pFG23, that 
carried malF and malG  under control of the trc promoter, and pMRll, that carried 
malK under the same promoter (Davidson and Nikaido, 1991). These plasmids were 
transformed into a strain HN597 carrying a deletion of the FoFi-ATPase. Mai 
proteins were recovered from membrane preparations and transport activity was 
reconstituted in proteoliposome vesicles. The maltose transport complex MalFGKi, 
modified with a polyhistidine tag at the N terminus of MalK, was also overexpressed 
in E. coli by Sharma and Davidson (Sharma and Davidson, 2000). The isolated MalK 
protein was purified from strain BL21(DE3) carrying the plasmid pMF8 with malK  
under control of a T7 promoter. Another example of a prokaryotic transporter gene 
expressed in a prokaryotic system is that of LmrA, which was overexpressed in L. 
lactis using nisin A-inducible vectors pNHLmrA, pNHLmrA-E314A, and pNHLmrA- 
E512Q (Balakiisluian et aL, 2004).
d) Overexpression of divergent prokaiyotic genes in E. coli
Recombinant proteins have been expressed in E. coli with varying degrees of 
suecess, depending in many cases of the approach of the research. MJ1267 from M. 
janaschii was cloned into pET28a and expressed in E. coli BL21(DE3) for further 
purification and crystallisation (Karpowich et aL, 2001). For another extremophile, 
glcV  from Sulfolobus solfataricus was inserted into the expression plasmid pETlSb 
and its product shown to undergo dimer formation in the presence of Mg-ATP 
(Verdon et aL, 2003). Of direct relevance to the present study, DrrA and DrrB from 
S. peucetius were subcloned and expressed either individually or together (Kaur and 
Russell, 1998). In a previous study (Kaur, 1997), the drr A and drrB genes were 
modified at to introduce restriction sites at their start codons. This aided subcloning 
to place expression under the control of the lac promoter in pSU2718, a vector
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previously used for expression of arsA. The drrA and drrB genes were also subcloned 
separately into pSU2718 at the Ndel-BBadlll sites after PCR amplification of the 
genes.
Despite the attraction of exceptionally high transcription and translation, the 
literature has plenty of examples where overexpression of recombinant proteins from 
the T7 promoter has given rise to the formation of inclusion bodies. Given that some 
transporters genes placed under the control of the T7 promoter have been 
overexpressed with success (e.g. the SMR of EmrE (Ma and Chang, 2003), the NBDs 
of HisP (Nikaido et aL, 1997) MalK (Schmees et aL, 1999) and others), cloning of 
drrA  under the control of this promoter in pET21a was an option worthy of 
exploration. It enabled very high levels of expression but almost all the recombinant 
protein was present in a fraction of insoluble protein, presumed to be inclusion bodies. 
No soluble DrrA was expressed at 37 °C whilst at 17 °C, some soluble protein was 
present and could be purified in low yield by IMAC. It is also worth noting that some 
DrrA appeared in the membrane fraction, but it was neither quantified nor was its 
ability to hydrolyse ATP assayed at this stage. One interpretation of these results is 
that the protein is less hydrophilic in character than indicated from SOSUI 
hydropathic analysis (not shown) and reported by other investigators (e.g. Guilfoile 
and Hutchinson, 1991; and Kaur, 1997). Utilisation of protein produced from pET21a 
would thus depend upon purification o f DrrA under denaturing conditions to 
solubilise the protein from inclusion bodies (Chapter 5). In this phase of the project, 
the other strategy explored was to seek greater yields of soluble protein by expression 
in different plasmid vectors.
We wished to assay co-expression of DrrA with DrrB as an option to improve the 
production of DrrA in the cytosol, but co-expression only seemed to be successful 
using the pET33b vector, and it did not show any improvement in DrrA yield over 
that from independent expression in pET21a. Moreover, IMAC isolated many other 
proteins from the soluble fraction, making this option even less satisfactory. The other 
strategy employed was to fuse DrrA to another protein of high solubility.
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Fusion to soluble proteins has allowed the overexpression of many proteins that 
previously formed inclusion bodies. NBDs such as mouse Pgp C-terminal NBD2 
(Baubichon-Cortay et aL, 1994) and M RPl (Cool et aL, 2002), both fused to 
Glutathione-N-transferase (GST), were recovered as soluble proteins. Similarly, 
NBDs such as those of Pgp (Sharma and Rose, 1995; Wang et aL, 1999; Berridge et 
aL, 2003), MRPl (Cool et a l, 2002), and OpuAC (Horn et al., 2005), have been fused 
to maltose-binding protein (MBP) and overexpressed as soluble proteins.
On the past decade, LaVallie et al. (1993) developed a promising E. coli 
expression system based on the use of E. coli thioredoxin as a gene fusion partner. 
Previously expressed as inclusion bodies, a variety of mammalian cytokines and 
growth factors could be expressed as soluble proteins to high levels when they were 
fused to Thioredoxin. Equally promising, fusion of Thioredoxin to the D-lactate 
dehydrogenase VanH, produced soluble, functional protein when other expression 
systems had completely failed. The intact fusion protein was used for kinetic studies 
and crystallization trials. Michaelis constants for NADPH, NADH, and pyruvate 
were derived for VanH and found to be comparable to those reported for the native 
dehydrogenase (Stoll et aL, 1998). The effect of Thioredoxin fusion on the 
production and folding of single chain Fv (scFv) antibodies in the cytoplasm of E. coli 
is another interesting example of protein fusion that resulted in high level expression 
and the retention of the correct folding pattern even in the absence of disulfide-bond 
isomerase Dsbc, an enzyme which has been shown to act as a chaperone for scFvs in 
the cytoplasm. When compared to MBP, Thioredoxin fusion was more effective in 
this regard. Another important feature of this Thio fusion was that antigen-binding 
assays showed that the scFv moiety maintained its affinity for the antigen, despite the 
presence of its fusion partner. It was concluded that Thio-scFv fusions could be used 
without removal of the Thioredoxin fusion partner and that the Thioredoxin acted 
largely as an intramolecular protein chaperone (Jurado et aL, 2006). An additional 
example where a Thioredoxin fusion has been important to overcome the formation of 
inclusion bodies is that of S. aureus gyrase A (Strahilevitz et aL, 2006). For this 
protein, the expression vector pBADTOPO thiofusion, was modified by the addition 
of DNA sequences encoding a hexahistidine tag upstream and a eleavage site for 
tobaceo etch virus protease downstream of the gene for Thioredoxin. A high level
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expression of soluble GyrA was achieved using this expression system in E. coli TOP 
10 strain and GyrA was purified to over 95% homogeneity.
In this project, improvement in expression of soluble DrrA was achieved 
tlu'ough fusion to Thioredoxin, What advantages prompted the use of Thioredoxin 
over other potential fusion partners? Thioredoxin is a low molecular weight protein 
(11.7 kDa) that is characterised by high solubility: It was hoped that this feature 
might help to maintain DrrA in solution under those conditions where the pET21a 
construct failed. If so, it was thought that the low size of Thioredoxin might not affect 
other properties of the fused protein under study. In addition, the pBADTOPO 
thioredoxin fusion vector provided tight regulation over expression through 
incorporation of the arabinose promoter. Although many studies have shown MBP to 
be effective in maintaining fusion partners in soluble form, its size (44 kDa) is 
significant and can be higher than the fused moiety. This can affect the intrinsic 
properties of the target protein, and makes necessary its elimination from the fusion 
complex. This can be done by cleave with proteases such as Factor Xa but this 
requires the introduction of a tluombin cleavage site to release MBP and assumes that 
the protease will not alter the protein of interest. At 29 kDa, Glutathione-5'- 
transferase suffers similar limitations.
Studies using the pBADTOPO thiofusion system confirmed that higher yields 
of DrrA protein could indeed be obtained by fusion to Thioredoxin, Although yields 
of the DrrA fusion protein at 37 °C remained very poor, reduction below 21 °C 
provided more protein that was soluble, and suggested that characterisation studies 
with recombinant DrrA would be possible.
140
Chapter 5
Purification of DrrA
The purification of proteins over-expressed from the different vectors was a 
necessary step before proceeding to studies aimed at their characterisation. The 
production of these proteins with a tag such as the histidine repeat enabled the use of 
irmnobilised metal affinity chromatography (IMAC) for purification. Whilst these 
tags were present in several of the vectors used for the study, in other instances they 
were added to the PCR products to appear at the N- or C- termini of the protein. This 
feature provides a useful means to rapid and efficient purification.
5.1 Purification of DrrA under denaturing conditions
A common obstacle to the expression of recombinant proteins in foreign host 
cells is the accumulation of insoluble, aggregated protein in morphological structures 
called inclusion or refractile bodies. Several reasons can explain the origin of these 
elements: the target proteins may require specialised post-translational modification 
for full biological activity utilising enzyme systems that are lacking in the host 
organism used for expression. The natural conformation of the recombinant protein 
may not be able to form in the particular conditions prevailing in the host cell cytosol 
(e.g. when extracellular secreted proteins are expressed as intracellular recombinant 
proteins). In the natural producing organism, a variety of additional protein factors 
may be involved in assisting the protein to fold, and their level and specificity may 
differ in the expression host thereby affecting the refolding and solubility of the 
recombinant protein. Another important reason that may be responsible for this 
phenomenon is that the recombinant proteins may be produced at a rate and to a level 
that exceeds the limits of physiological solubility (Thatcher et aL, 1996).
Although the formation of inclusion bodies may not be desirable, typically the 
target protein comprises 70-90% of the structure and this represents a great advantage 
in the purification process, as the enclosed protein is concentrated. Given this, 
solubilisation and refolding need not yield large amounts of functional, recombinant 
protein to make possible other studies. Recovery of functionally active protein
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commonly requires the solubilisation of inclusion bodies under strong denaturing 
conditions to effectively separate and unfold the aggregated protein, followed by 
refolding. This can be accomplished by dialysis or dilution of the denaturing agent.
5.1.1 Refolding of DrrA from inclusion bodies using an 8 M urea gradient
Solubilisation of inclusion bodies is usually carried out in 8 M urea or 6 M 
guanidine hydrochloride at alkaline pH and in the presence of a reducing agent. In the 
case of a-chymotrypsin, Hibbard and Tulinsky (Hibbard and Tulinsky, 1978) showed 
the effective penetration of the interior of the enzyme by urea, in contrast to guanidine 
hydrochloride which showed no significant changes in the protein interior. Urea 
bound within the interior of a protein is presumed to stabilise the partly folded protein 
chains (Guo and Clark, 2001). Thus, for the purpose of unfolding/refolding proteins in 
inclusion bodies, urea appears to be a suitable choice as it is expected to stabilize the 
unfolded intermediates and simultaneously help unfolding the insoluble protein 
bodies sufficiently to correct any misfolded structures. Moreover, urea is one of the 
denaturing agents most eommonly employed in protein refolding processes, due to the 
fact that it is cheap, easily available, and can be easy removed without irreparable 
modification of the protein under investigation.
Work to this point established that the over-expression of DrrA always 
rendered the protein insoluble, and redueing the temperature and inducer (IPTG) 
concentrations below 37 °C and 1 mM, respectively, failed to raise the proportion of 
soluble recombinant protein. Since inclusion bodies containing DrrA were readily 
available, it was decided to attempt purification from this starting material. 
Conventional methods for refolding insoluble recombinant proteins include slow 
dialysis or dilution into a large volume o f refolding buffer or chromatographic 
refolding using packed columns. Chromatographic methods can include solvent- 
exchange, size exclusion chromatography and immobilization of the denatured protein 
onto a column or gel matrix, with subsequent dilution of dénaturant to promote 
refolding.
Examining reports in the literature, the advantages of on-column chemical 
refolding included: lack of dependence upon protein concentration, high yields of
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soluble protein, simultaneous purification and refolding and amenability to high- 
throughput refolding. Furthermore, physical separation of the molecules, for example 
by immobilising them on an IMAC resin, is thought to reduce the possibility of 
unfavourable protein-protein interactions occurring during the refolding process that 
can lead to aggregation and eventual precipitation of the target protein. Therefore, 
refolding of DrrA from the inclusion bodies was attempted, using as starting material 
E. coli cells carrying the pET21a-c/rrX construct, grown at 37 °C and induced with 1 
mM IPTG. Refolding was attempted on-column using a decreasing urea gradient (8-0 
M).
The DrrA inclusion bodies were solubilised in Tris-PICl buffer with 8 M urea 
(see Methods sections 2.9.2 and 2.9.2.1), mixed withNi^’^ -NTA agarose resin to bind 
the histidine tag carried by the protein, and loaded into a glass chromatography 
column. The refolding process consisted of washing the protein-NiNTA resin 
complex in the column with decreasing concentrations of urea over an 8-0 M range. 
Finally, the protein was eluted from the column using a high concentration of 
imidazole (250-300 mM). The DrrA protein appeared in all eluted fractions and 
showed good purity on gel analysis (Fig. 5.1). After dialysis of the eluted purified 
material, DrrA fluorescence changes were initially monitored in the absence and 
presence of ATP-Mg^"^ as a means to evaluate the success of the refolding process. 
This analysis failed to show that the changes detected on the protein fluorescence 
were genuinely caused by the interaction between DrrA and the ATP-Mg^^ complex 
(see Chapter 7 section 7.1). Therefore, this methodology was replaced by an ATPase 
activity assay using the Molecular Probes EnzCheek phosphate assay.
As the EnzCheck phosphate assay (up to 150 pM of Pi detected) did not reveal 
any ATPase activity from the putatively refolded DrrA, further refolding experiments 
were devised to assess the ATPase activity of DrrA with a method that was more 
sensitive (1 to 30 _M; 50 to 1500 picomoles of Pi) and easier to set up, the Malachite 
green assay (Harder et aL, 1994).
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Figure 5.1 Purification of DrrA after urea gradient treatment on an IMAC 
column
Bacteria carrying pET21a-ûfr'r/< were grown at 37 °C to exponential phase and induced with ImM IPTG 
for 4 hours. 200 pg o f insoluble protein (“inclusion bodies”) was solubilised in 8 M urea and loaded to 
the IMAC column. After progressive reduction in the urea concentration and washing, protein was 
eluted with imidazole. Samples were analysed by SDS PAGE and Coomasie blue staining.
M: Protein molecular markers
WB (1-2); Wash fractions using 25 and 50 mM imidazole respectively 
1-6: Eluted fractions (300 mM)
A protein consistent with the predicted size o f DrrA is indicated
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Again, inclusion bodies from the disrupted cell pellet were solubilised in 8 M 
urea and the process of binding to NiNTA and reduction in the concentration of urea 
was repeated (section 2.9.2). The six fractions eluted from the IMAC column (0.5 ml 
each) contained DrrA protein, and fractions 3, 4 and 5, which had the highest protein 
concentrations, were pooled, dialysed and tested for ATP-ase activity using Malachite 
green. The kinetics of ATPase is typically followed for 15 minutes, but in this 
instance, the reaction was monitored for I hour to allow complete ATP hydrolysis. 
Again, the release of inorganic phosphate by the “refolded” DrrA could not be 
detected.
This experiment was repeated with 2-6 fold more starting material (up to 3 ml 
of disrupted cell pellet paste) solubilised in 8 M Urea, to increase the chances of 
detection o f even small amounts of “refolded” protein in the ATP-ase assay. 
Although it was possible to visualise intensely-staining bands corresponding to DrrA 
on polyacrylamide gels, there were no signs of ATP-ase activity using the Malachite 
green assay. These results confirmed that the solubilisation of DrrA from inclusion 
bodies using urea and on-column removal of the dénaturant did not yield 
appropriately folded DrrA protein.
5.1.2 Assay with a refolding kit
The Hampton Research Foldit Screen allows researchers to determine with a 
reasonable degree of confidence if a protein of interest can be folded from inclusion 
bodies. Sixteen different refolding formulations are arranged, and assayed to find the 
best conditions for proper refolding of proteins; these were assayed for the DrrA 
protein (Fig. 5.2 and 5.3) in another attempt to try to obtain active protein for 
characterisation. This system allows convenient variation of multiple variables 
(Tables 2,2 and 2.3 in Chapter 2) that include the type and concentration of buffer, 
salt, presence and absence of denaturing agent, type of cation chelator, polar and non­
polar additives, presence and type of detergent, reducing agents, ligand addition, and 
protein concentration. Reagents to enable protein refolding should favour the 
formation of the native fold and minimise the aggregation of folding intermediates. 
Reagents such as polar additives (arginine), osmolytes (polyethylene glycol), 
detergents (lauryl maltoside), and chaotropes (guanidine hydrochloride) can minimise
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aggregation and increase the yield of properly folded protein (Foldtit Screen Hampton 
Research manual).
Inclusion bodies were solubilised with 6 M guanidine hydrochloride then 
diluted into the test conditions in order to reduce the dénaturant concentration. 
Refolding was assayed with protein alone, and in the presence of doxorubicin (Fig.
5.2 and 5.3). A summary of the refolding parameters tested is presented in Table 5.1.
To measure the success of refolding, ATPase activity was assayed using the 
Molecular Probes EnzCheck phosphate method. Although DrrA protein samples did 
not show signs of precipitation in the dialysis tubes under several sets of conditions 
(Fig. 5.3), none showed any ATPase activity. Binding of the ATP analogue MANT- 
ATP in the presence and absence of doxorubicin was also tested, but there were no 
fluorescence changes that would suggest some interaction between the protein and the 
ligands.
As attempts to refold DrrA from inclusion bodies were unsuccessful, 
alternative procedures were considered to express the protein in an active form and in 
sufficient quantities to proceed with further characterisation.
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Table 5.1 Hampton Research Foldit Screen refolding parameters tested for 
DrrA
Protein concentration 0.1 mg/ml vs. 1.0 nig/ml
Presence of polar additive +/- 550 inM L-Arginine
Presence of detergent +/- 30 mM Lauryl Maltoside
pH pH 6.5 vs. pH 8,2
RedOx potential 100 mM DTT vs. 100 mM GSH
Presence of chaotropic salt +/- 550 mM Guanidine Hydrochloride
Ionic strength 264 mM NaCl +11 niM KCl vs. 
10.56 mM NaCl + 0.44 mM KCl
Presence of cations or chelator 2.2 mM CaCl + 2.2 mM MgCl vs. 
1.1 mM EDTA
Presence of osmolyte +/- 0.055% (w/v) PEG 3350
Presence of non-polar additive +/- 440 mM Sucrose
Presence of ligand +/- 30 pg/ml doxorubicin
The detailed formulation is presented in the Methods section 2,9.2 in Chapter 2
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Figure 5.2 DrrA after treatment with 16 Foldtlt Screen refolding formulations 
(FOLDLT SCREEN from Hampton Research)
Bacteria carrying pET21 a-f/rr/l were grown at 37 ®C to exponential phase and induced with 1 mM 
IPTG for 4 hours. Insoluble protein (“inclusion bodies”) was solubilised in 6 M Guanidine-HCI at 0.1 
mg/ml protein concentration according to the Foldtlt Screen refolding formulations from Tables 2.5 
and 2.6 presented in the Methods section 2.9.2.2 and Table 5.1. After incubation for 7 hours, samples 
were dialysed in 20 mM Tris buffer. Samples were analysed by SDS PAGE and Coomasie blue 
staining.
M: Protein molecular markers
1-16: DrrA from Foldtlt Screen refolding formulations 1-16 
A protein consistent with the predicted size o f DrrA is indicated
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Figure 5.3 DrrA after treatment with different Foldtlt Screen refolding 
formulations (FOLDLT SCREEN from Hampton Research) in presence and 
absence of doxorubicin
Bacteria carrying pET21a-rfrr/l were grown at 37 °C to exponential phase and induced with 1 mM 
IPTG for 4 hours. Insoluble protein (“inclusion bodies”) was solubilised in 6 M Guanidine-HCI at 0.1 
mg/ml protein concentration except in samples number 5, 13, 14 and 16, where 1 mg/ml o f protein was 
used. After incubation for 7 hours, samples were dialysed in 20 mM Tris buffer. Samples were 
analysed by SDS PAGE and GelCode blue staining.
M; Protein molecular markers
1, 3, 5, 7, 10, 12, 14, and 16: DrrA from the same numbered Foldtlt Screen refolding formulations in 
presence o f ligand doxorubicin
2, 3, and 14: DrrA from the same numbered Foldtlt Screen refolding formulations in absence o f ligand 
doxorubicin
A protein consistent with the predicted size o f DrrA is indicated
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5.2 Native purification of DrrA and Thio-DrrA
Initially phosphate buffer had been used to solubilise DrrA from extracts of E. 
coli cells, but Tris-HCl buffer pH 8.0 was preferred in the experiments that followed. 
By using Tris buffers, phosphate was excluded and the sample was better suited for 
assays of ATPase activity. A buffer containing 50 mM Tris-HCl, 150 mM NaCl, and 
10% glycerol, adjusted to pH 8.0, seemed to be adequate for primary DrrA or Thio- 
DrrA protein purification.
Soluble extracts were prepared by ultracentrifugation to remove inclusion 
bodies and membrane components. The soluble fraction was divided into batches 
(1/2-3 L culture), mixed with Ni^ "*" agarose resin, incubated for 1 h and loaded onto an 
Econo glass column. After washing, the protein was eluted with 300 mM imidazole, 
and purified DrrA or Thio-DrrA was obtained under these conditions.
The eluted fractions that had the highest concentrations of protein, as determined 
from gel analysis, were pooled. This represented the total yield of soluble DrrA or 
Thio-DrrA obtained from the original culture (usually 10 L). Generally, these were 
the first two fractions eluted off the column. Some other bands with different sizes 
also appeared on the gel. Dialysis was necessary to remove the high concentration of 
imidazole used for elution, as it interferes with protein determination by the BCA 
method. Usually, four hours of dialysis in a volume of 3 L, was enough for pooled 
sample of less than 10 ml volume. If necessary, fractions were concentrated using an 
Amicon Centricon AlO centrifugal concentrator, or Stirred Ultrafiltration Cell that 
seemed to reduce low molecular weight contaminants as well. In the last case 
Millipore filter membranes with a cut off separation range of 30 and 10 kDa were 
used for Thio-DrrA (approximate size of 52 kDa) and DrrA (approximate size of 39 
kDa), respectively.
By including imidazole at concentrations of up to 50 mM in the wash buffers, the 
purification protocol yielded preparations of DrrA and Thio-DrrA of sufficient purity, 
as judged from gels by direct visualisation. However, some additional bands were 
present and further trials were attempted to achieve 95% purity, and also increase 
protein yields by about 20%.
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5.3 Trials for improved purification of Thio-DrrA using IMAC
Some changes in the concentration and/or the composition of the purification 
buffer were tested. The Tris buffer composition was varied to try and reduce the 
presence of contaminant bands in the protein preparation, and if possible, to also 
improve the yield of the Thio-DrrA protein. The addition of a reducing agent (2- 
mercaptoethanol) and detergent (dodecyl maltoside) was tested along with increases 
in glycerol and salt concentrations in the buffer. None of these changes produced an 
improvement in the purification of Thio-DrrA without detriment to the protein yield 
(Fig. 5.4 and 5.5). A buffer containing 50 mM Tris-HCl, 150 mM NaCl, 10% 
glycerol and 10 mM imidazole, pH 8.0, was retained as the basic composition of 
purification buffers.
The other approach to increase purity was to employ a lower concentration of 
inducer for the Thio-DrrA expression. The arabinose concentration was reduced 10- 
fold, from 0.002 % to 0,0002 % (Fig. 5.6). The protein produced and purified under 
these new conditions showed fewer contaminating proteins in the higher molecular 
weight range, but it was also much less concentrated than protein induced with 
0.002% arabinose, reducing the protein yield. It is probable that the partial 
disappearance of upper bands on the gel was caused by the low protein coneentration 
that was found in that preparation, when compared to induction with 0.002% 
arabinose.
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Thio-DrrA
Figure 5.4 IMAC purification of Thio-DrrA under different Tris-HCl buffer 
conditions: presence of DDM and 2-Mercaptoethanol
Cultures o f  E. coli LMG 194 carrying pBADTOPO thio-drrA were grown at 37 °C to exponential 
phase, shifted to 17 °C and treated with 0.002% arabinose overnight. Cells were fractionated and 
recombinant protein purified from soluble cytoplasmic extracts by IMAC. Buffer composition was 50 
mM Tris-HCl pH 8.0, 150 mM NaCl and 10% glycerol. Additionally, elution buffer was 300 mM 
imidazole. Samples were analysed by SDS PAGE and Coomasie blue staining.
M: Protein molecular weight markers
1-3: First three fractions from sample solubilised in buffer containing 10 mM 2-Mercaptoethanol (ME) 
eluted from the IMAC column
4-6: First three fractions from sample solubilised in buffer containing 0.05% Dodecyl-maltoside 
(DDM) eluted from the IMAC column
7-9: First three fractions from samples solubilised in control 50 mM Tris-HCl buffer 150 mM NaCl and 
10% glycerol
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Figure 5.5 IMAC purification of Thio-DrrA under different Tris-HCl buffer 
conditions: 20% of glycerol and 400 mM NaCl
Cultures o f  E. coli LMG 194 carrying pBADTOPO thio-drrA were grown at 37 °C to exponential 
phase, shifted to 17 °C and treated with 0.002% arabinose overnight. Cells were fractionated and 
recombinant protein purified from soluble cytoplasmic extracts by IMAC. Buffer composition was 50 
mM Tris-HCl pH 8.0, ISO mM NaCl and 10% glycerol. Additionally, elution buffer was 300 mM 
imidazole. Samples were analysed by SDS PAGE and Coomasie blue staining.
M; Protein molecular weight markers
1-3: First three fractions from sample solubilised in buffer containing 20% glycerol eluted from the 
IMAC column
4-6: First three fractions from sample solubilised in buffer containing 400 mM NaCl eluted from the 
IMAC column
7-9: First three fractions from samples solubilised in control 50 mM Tris-HCl buffer 150 mM NaCl and 
10% glycerol
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Figure 5.6 Expression of Thio-DrrA after induction with 0.0002 and 0.002% 
arabinose
Cultures o f  E. coli LMG 194 carrying pBADTOPO thio-drrA were grown at 37 °C to exponential 
phase, shifted to 17 °C and treated with 0.002% or 0.0002% arabinose overnight. Cells were 
fractionated and recombinant protein purified from soluble cytoplasmic extracts by IMAC. Buffer 
composition was 50 mM Tris-HCl pH 8.0, 150 mM NaCl and 10% glycerol. Additionally, elution 
buffer was 300 mM imidazole. Samples were analysed by SDS PAGE and Coomasie blue staining.
M: Protein molecular weight markers
1-4: First four fractions containing Thio-DrrA from cultures induced with 0.0002% arabinose, eluted 
from the IMAC column
5-8: First four fractions containing Thio-DrrA from cultures induced with 0.002% arabinose, eluted 
from the IMAC column 
9: Control Thio-DrrA dialised
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5.4 Purification of DrrA from the membrane fraction
In a 10 L trial with pET21a-JrrZ[, the soluble and the membrane fractions were 
purified and checked for the presence of DrrA. Although in the past some DrrA could 
be detected by Western blot in the membrane fraction, its yield was low. When the 
induction temperature was reduced to 16 °C, an appreciable quantity of DrrA protein 
partitioned to the membrane fraction suggesting that under these conditions, higher 
amounts of DrrA might be obtained from membrane fractions. The level of over­
expression can be estimated when samples from soluble and membrane fractions from 
the same culture are compared (Fig. 5.7 and 5.8). A yield of 65 pg/L was found for 
DrrA from the membrane fraction, against 40 pg/L found for DrrA from the soluble 
fraction in the same experiment.
When DrrA isolated from membrane fractions failed to show any ATPase 
activity, it was thought that the high amount of detergent used in the solubilisation of 
the membrane and in the purification protocol might have affected the integrity of the 
protein. Reducing the concentration of the detergent DDM from 2 to 1 % for 
solubilisation, and to 0.05 % for purification, failed to recover active DrrA.
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Figure 5.7 Overexpression of soluble DrrA from 10 L of media in four batches of 
2.5 L
Bacteria carrying the pET21a expression construct were grown at 37 °C to exponential phase, shifted to 
17 °C and induced with 0.2 mM IPTG overnight. Cells were fractionated and recombinant protein 
purified from soluble cytoplasmic extracts by IMAC. Samples were analysed by SDS PAGE and 
Coomasie blue staining.
M: Protein molecular markers
1-4: Fractions o f  the first purification batch (corresponding to 2.5 L o f culture) eluted from the IMAC 
column
1 ’-4 ’: Fractions o f the second purification batch (corresponding to 2.5 L o f  culture) eluted from the 
IMAC column
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Figure 5.8 Overexpression of DrrA from 10 L of media and its purification from 
the membrane fraction
Bacteria carrying the pET21a expression construct were grown at 37 °C to exponential phase, shifted to 
17 ”C and induced with 0.2 mM IPTG overnight. Cells were fractionated and recombinant protein 
purified from membrane extract by IMAC. Solubilisation buffer for the DrrA membrane fraction was 
50 mM Tris-HCl pH 8.0, 150 mM NaCl, 10% glycerol and 10 mM Imidazole plus 2% DDM. Washing 
buffers were the same Tris buffer with 0.2% DDM. Elution buffer was 50 mM Tris-HCl pH 8.0, 150 
mM NaCl, 10% glycerol and 300 mM Imidazole plus 0.2% DDM. Samples were analysed by SDS 
PAGE and Coomasie blue staining.
M: Protein molecular markers
1-9: Fractions o f the membrane purification (corresponding to 10 L o f culture) eluted from the IMAC 
column
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5.5 Discussion
The use of a histidine tag in the different constructs allowed the purification of 
the different forms of DrrA in a few stages. Immobilised metal affinity 
chromatography (IMAC) was effective even when material from inclusion bodies was 
used. The insoluble cytoplasmic fraction formed the richest source of DrrA from all 
the vectors when cells were cultivated at 37 °C.
Solubilisation of inclusion bodies that contain recombinant proteins and 
refolding appeared an option worth investigating, although the efficiency of refolding 
was uncertain at best. Strong denaturing conditions such as the use of high 
concentrations of chaothropic agents like urea or guanidine hydrochloride in alkaline 
conditions are necessary to effectively separate and unfold the aggregated protein 
present in inclusion bodies. The use of 8 M urea for dénaturation and refolding of 
recombinant proteins has been reported by a number of authors. Zhang (Zhang et al., 
2005) reported studies in which pro-carboxypeptidase was successively refolded 
using urea gradient gel filtration. Further chromatography resulted in an enzyme 
preparation that was active and 90% pure. Zhang et al. (Zhang et al., 1998) worked 
with urea-denatured adenylate kinase and monitored the formation o f secondary 
structure, changes in surface hydrophobicity, and the recovery of catalytic activity 
during a refolding protocol. The outer membrane protein and ferric enterobactin 
receptor FepA from E. coli has also been successfully refolded from solubilised 
inclusion bodies using a combination of sulfobetaine 3-14 and sodium dodecylsulfate, 
prior to purification by using anion exchange and gel filtration chromatography 
(Buchanan, 1999). Finally, Liu et al. recently described the refolding of urea- 
denatured transglutaminase from S. fradiae expressed from a pET21a vector using an 
on-column refolding procedure (Liu et a l, 2006). Using a similar approach, the 
solubilisation of DrrA in 8 M urea, and its gradual refolding was investigated to try 
and make best use of the target protein from inclusion bodies. However, these 
attempts to refold DrrA as an active protein were not successful.
Denaturing conditions generated with guanidine hydrochloride have also been 
reported for the refolding of diverse recombinant proteins with varying degrees of 
success. Rehm et al. have described the purification of class II polyhydroxyalkanoate
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(PHA) synthase from P. aeruginosa (Rehm et al., 2001). The enzyme was 
overexpressed from the strong _10 promoter in E, coli BL21(DE3), leading to the 
formation of inactive inclusion bodies, comprising approximately 30% of total 
cellular protein. Inclusion bodies were dissolved and denatured with 6 M guanidine 
hydroehloride, and after the pro te in  was im m obilized on a NP"^ ~ 
nitrilotriacetate-agarose matrix, it was refolded by gradual removal of the denaturing 
reagent. Refolded PHA synthase showed a spécifié enzyme activity corresponding to 
27% of the maximum specific activity of the native enzyme; Lee et ah, 2002, 
expressed a single-chain antibody derived from a murine monoclonal specific for 
human apolipoprotein B 100 in E. coli from a T7 promoter. Refolding was achieved 
through slow dilution into refolding buffer, and the soluble scFv was purified by 
affinity chromatography to obtain an active fraction with antigen-binding activity 
comparable with that of native Fab.
When generic refolding procedures are being developed, several arrays are 
available that aid the identification of appropriate refolding conditions. Among them, 
the Foldtlt screen from Hampton Research has been developed from reports by 
Armstrong et a l, (1999), Chen and Gouaux, (1997), and Rudolph and Lilly, (1996). 
This resource allowed convenient testing of 16 different folding conditions, and 
additional trials were assayed to seek properly folded DrrA from inclusion bodies. In 
spite of the diverse the conditions tested, none enabled the recovery of active DrrA, 
leaving the perception that refolding conditions would prove elusive, limiting the 
value of this purification strategy.
The small quantities of DrrA that were expressed finally as soluble protein 
from the pET21a construct, were active in hydrolysing ATP (see next chapter). These 
results did not support Kaur’s thesis that the catalytic component DrrA takes on an 
active conformation able to bind and/or hydrolyse ATP only when it is in complex 
with DrrB. Kaur and Russell (1998) showed in UV cross-linking studies with [_- 
^^P]ATP that only the membrane-bound form of DrrA in cells containing both DrrA 
and DrrB was in a conformation competent to bind ATP (Kaur, 1997; Kaur and 
Russell, 1998). Nonetheless, it is worth noting that Kaur's work was done in cell 
exti’acts, whilst in the experiments reported here, DrrA came from IMAC purification. 
As there are several examples in the literature of the binding and/or hydrolysis of ATP
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by isolated NBDs (HisP, Nikaido and Ames (1999); MalK, Walter et ah, (1992); 
MJ0796, from M. jannaschii. Moody et al., 2002), the observation that purified DrrA 
shared these properties is not implausible.
The partitioning o f DrrA into the membrane fraction at low induction 
temperatures might be responsible in part for the reduced DrrA concentration in the 
soluble fraction. This effect suggests the existence of a greater degree of hydrophobic 
characteristics in the protein than was expected. However, DrrA obtained from this 
source did not show any ATPase activity, even when milder detergent conditions 
were employed in purification. This result is not in contradiction with Kaur's 
proposal with respect to the functional conformation of membrane-bound DrrA. 
However, isolated bound-niembrane MalK could be overexpressed without its 
cognate Mai transport membrane proteins and recovered from inclusion bodies 
displaying ATPase activity (Walter et al., 1992).
The Thio-DrrA fusion protein became the main source of DrrA protein for the 
project, as protein could be expressed and purified to an acceptable degree and with 
sufficient yield for further characterisation studies. The yield of protein obtained 
from the pBAD construct could be improved to a modest extent and it was employed 
for the different characterisation trials that are presented in the following chapter. 
Efforts to improve the degree of purification of DrrA and obtain more rigorously 
purified Thio-DrrA protein were not successful and essentially, any slight 
improvements in purity were at the expense of the protein yield.
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Chapter 6
Characterisation of DrrA proteins
The characterisation of DrrA was one of the main goals of this work. Given 
its classification as a member of the ABC family, it was intended to test if DrrA could 
drive the efflux of the anthracyclines compounds daunorubicin and doxorubicin, via 
the DrrAB system from S. peucetius. Having established conditions for the expression 
and purification of soluble Thio-DrrA, the fusion protein was chosen for the analysis 
of biochemical properties. The low levels of soluble DrrA expressed from the pET21a 
vector created an obstacle to routine analysis of this form of the protein.
The characterisation of other ABC transporter NBDs has given rise to a wealth 
of experimental data on their biochemical properties. The study of P-glycoprotein, 
and other medically important ABC transporters like MRP and CFTR, has enlianced 
the research on other ABC transporters to reveal the essential structural and 
biochemical features of the transport process. This is of particular interest with regard 
to the phenomenon of drug resistance, since an understanding of transport could 
provide better approaches to the design of drugs or treatments to combat it.
6.1 Characterisation of the ATPase activity of DrrA proteins.
All ABC transporter NBDs identified to date have the ability to bind and 
hydrolyse ATP and, using the energy released by the phosphate bond, to drive 
transport processes. The role of DrrA as an ATPase to direct the extrusion of the self- 
produced anti-tumour compounds daunorubicin and doxorubicin out of the cells of S. 
peucetius was indicated in the works of Guilfoile and Hutchinson (1991), as also its 
similarity to P-glycoprotein, involved in resistance to anti-cancer drugs. One aim was 
therefore to characterise the ATPase activity of DrrA employing the Thio-DrrA fusion 
protein as representative of NBD.
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6.1.1 ATPase activity
To assess the ATPase activity of Thio-DrrA the protocol of Harder and 
collaborators (1994), based on the malachite green assay, was employed with some 
minor modifications (Nash, 2003; Maehatma, 2000). The assays, performed in 96 
well microtitre plates, displayed linearity over a range of Pi concentrations between 50 
and 4000 pmoles. Standard phosphate curves were prepared in order to quantify the 
amount of Pi released for each batch of reagent. The reagent was stable when stored 
at 4 ‘’C; at room temperature, with ageing, some precipitation and colour differences 
were found. Data generated for a typical standard curve can be seen in Figure 6.1.
The ATPase activity is a process dependent on the presence of divalent 
cations, in particular magnesium although other divalent cations have been shown to 
stimulate this activity to varying degrees. Total volumes of 500 pi were used in the 
reaction, in which the test protein was pre-incubated in the presence of ATP for five 
minutes at 37 °C; additional components were added after this pre-incubation stage. 
The addition of Mg^ "^  was used to initiate the reaction and 45 pi of sample were 
removed from the mix at 5 minutes intervals over a fifteen-minute time course 
reaction, and transferred to the wells of a microtitre plate well containing 5 pi of 
EDTA. The role of EDTA is to sequester Mg^ "^  and in consequence, stop the reaction. 
Having collected the required samples, 100 pi of malachite detection reagent was 
added to each sample and the results were collected immediately by measuring the 
absorbance at 610 nm. Although different authors (e.g. Mahatma et ah, 2000) 
recommend waiting some time to allow colour development (15-30 minutes), the 
strong aeidic conditions of the reagent causes the ATP in the samples to be gradually 
hydrolysed in the absence of enzymatic activity. This can mean that samples taken at 
zero time or controls that lack magnesium can also show development of green 
colour.
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Phosphate calibration curve
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Figure 6.1 Standard cui've to determine inorganic phosphate concentration by 
the Malachite green assay.
The standard curve above shows the response o f the malachite green Pj assay over a range o f 50 to 
3500 picomoles o f P|.
Samples containing different amounts o f phosphate were prepared by dilution o f a 1 mM NazHPO^ 
stock into Tris assay buffer (50 mM Tris-HCl, 150 mM NaCl, pH 8.0). An aliquot o f  45 pi o f each 
standard was mixed with 5 pi o f 500 mM EDTA in separate wells o f a 96-well microtitre plate. The 
assay was perform ed by adding 100 pi o f M alachite green detection reagent to each well and 
measuring the absorbance o f samples at 610 nm in a plate reader.
The curve showed linearity up to 3.5 nanomoles o f Pj
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In initial experiments to measure ATPase activity, Thio-DrrA was used at a 
concentration of 50 pg/ml following assays set up with M  tuberculosis Trx-DrrA 
(Nash, 2003). This concentration corresponds to approximately 1 pM fusion protein. 
It was found that a 15-minute reaction only produced an incipient light green colour. 
The reaction time was extended to 60 minutes in order to allow enough time for 
enzymatic hydrolysis of ATP (monitored as green colour development). DrrA fused 
to Thioredoxin, at a protein concentration of 50pg/ml, showed a 15-minute lag in 
activity after initiation of the reaction by the addition of Mg^ "^  and incubation for 60 
minutes. This delay could not be completely reversed by doubling the Thio-DrrA 
concentration to 2 pM and therefore it was necessary to use a higher concentration of 
protein. This resulted in an Aeionm of 0.34 in a reaction time of 15 minutes, without 
the aforementioned delay. Thus, in the following experiments, reactions were run for 
15 minutes but with higher protein concentrations that in the first experiments.
A Thio-DrrA concentration of 120 pg/ml (-2.5 pM) was usually sufficient to 
follow the development of colour in the reaction with Malachite green over a 15 
minute reaction time. Routine experiments were carried out using final 
concentrations of 450 pM Mg^^ and 250 pM ATP. Figure 6.2 shows a standard 
ATPase activity assay for Thio-DrrA, stimulated by Mg^ "^ , and results gathered in the 
absence of Mg^" .^ As clearly seen in the Figure, ATPase activity could be 
demonstrated for Thio-DrrA by the release of Pj .
ATPase activity could also be detected for the DrrA protein, expressed from 
the pBT2\a-drrA construct. Here, 1 pM DrrA, corresponding to a concentration of 37 
pg/ml, was used, giving an Aeionm of 0.35 after 15 minutes of reaction.
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Thio-DrrA ATPase activity
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Figure 6.2 Standard ATPase aetivity assay for Thio-DrrA
Two identical reaction mixtures (see above) were incubated at 37 °C for five minutes prior to the 
addition o f 450 pM M gCli (diamonds), or H2O (squares). Forty-five pi samples were withdrawn from 
the reaction mixtures at five minute intervals, deposited in separate wells o f a m icrotitre plate, and 
mixed with 5 pi o f 500 pM  EDTA, to halt the reaction. Samples were analysed for P| content by 
reading their absorbance at 610 nm after the addition o f 100 pi o f the M alachite green detection 
reagent. Released P; values were obtained by comparison with a standard curve.
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6.1.2 Dependence on divalent cations: Mg^ ,^ Mn^\ Co^ ,^ and Ca^ ^
The ATPase activity of all known ABC transporter NBD’s has been shown to 
depend on the presence of divalent cations. These cations are potential stimulators of 
ATPase activity, Mg^ "^  being the most common stimulator of these systems. As 
expected, magnesium ions were neeessary for the ATPase activity of Thio-DrrA and 
DrrA (Figure 6.2). In order to determine if other divalent cations could substitute for 
Mg "^ ,^ ATPase assays were performed with different divalent cations. Manganese, 
cobalt, calcium and zinc, used as dichloride salts, were tested for their ability to 
modulate the ATPase activity of Thio-DrrA. Other authors (e.g. Nikaido et a l, 1997; 
Aparicio et al., 1996) have shown that some cations other than Mg^^ can be strong 
activators of the enzymatic hydrolysis of ATP, depending on the concentration of the 
divalent cation in the reaction mix. In ABC transporter NBD’s the Walker B 
sequence is characterised by a main set o f hydrophobic amino acids and by the 
presence of a highly conserved aspartate residue that is involved in the co-ordination 
of the divalent cation.
The stimulating effect o f different divalent cations was tested over a 
concentration range between 0.1 and 2 mM. All assays to determine the inorganic 
phosphate released from the reactions employed the Malachite green method, and 
were performed at 37 °C, for 15 minutes and with a Thio-DrrA concentration of 100 
pg/ml (~2 pM). The Thio-DrrA ATPase activity reached a maximum (specific 
activity of 44 nanomoles/min/mg of protein) with about 500 pM MgCB (Fig. 6.3). 
This maximal activity was maintained up to a concentration o f Mg^'^of 600 pM. 
These data indicated an E C 5 0  of about 500 pM. Mg^ "^  concentrations above 1 mM 
seemed to impair stimulation of the ATPase activity of the protein (data not shown).
Manganese ions also activated the ATP hydrolysis by Thio-DrrA but to about 
one third the level of that obtained for Mg^ "^  (Fig. 6.4). Cobalt ions appeared rather 
better (Fig. 6.5), stimulating the ATPase activity of Thio-DrrA to a maximum of 9 
nanomoles P/min/mg of protein, which was roughly a half that reached with M gCf. 
This was obtained with concentrations between 400-600 pM of CoCf.
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Figure 6.3 Effect of Mg^  ^ions on the ATPase activity of Thio-DrrA
ATPase activity was initiated by the addition o f at the concentrations indicated. The Malachite 
green P; release assay was used to calculate the rate o f ATP hydrolysis from 15-minute ATP hydrolysis 
kinetics at each concentration. D ata are presented as protein specific activity (nanomoles o f  Pi 
liberated/min/mg o f protein).
All assays were performed at 37 °C in a total volume o f 500 pi.
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Figure 6.4 Effect of ions on the ATPase activity of Thio-DrrA
ATPase activity was initiated by the addition ofM n"' at the concentrations indicated. The Malachite 
green P, release assay was used to calculate the rate o f ATP hydrolysis from 15-minute ATP hydrolysis 
kinetics at each Mn"+ concentration. Data are presented as protein specific activity (nanomoles o f  Pi 
liberated/min/mg o f protein).
All assays were performed at 37 °C in a total volume o f 500 p-1.
168
Ci 10 ACl
O)E
.5E
CLIEc
2.51.5 2.00.5 1.00.0
(mM)
Figure 6.5 Effect of ions on the ATPase activity of Thio-DrrA
ATPase activity was initiated by the addition o f  Co^  ^ at the concentrations indicated. The Malachite 
green P; release assay was used to calculate the rate o f ATP hydrolysis from 15-minute ATP hydrolysis 
kmetics at each Co^^concentration. Data are presented as protein specific activity (nanomoles o f P; 
liberated/min/mg o f protein).
All assays were performed at 37 °C in a total volume o f  500 (xl.
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Calcium ions were the least efficient modulators of the activity of Thio-DrrA, 
being ineffective between 0.1-1.0 mM (data not shown). Similarly, Zn^’*' failed to 
stimulate ATPase activity at any concentration (data not shown).
The behaviour of Thio-DrrA was not dissimilar to that of other NBDs, such as 
HisP (Nikaido et ah, 1997) and M  tuberculosis Trx-DrrA (Nash, 2003). For these 
proteins, optimal cation concentrations were found to be in a range of 1-2 mM.
6.1.3 Dependence on pH
Thio-DrrA was active between pH 7.0-9.0, with maximum activity at pH 8.0- 
8.5 (Fig. 6.6). At pH 9.0 only a slight decrease in the Thio-DrrA ATP hydrolysis was 
observed. Values below 7 were detrimental to the ATPase activity of this protein; 
when a pH of 6.5 was used, the enzymatic activity was completely abolished.
6.1.4 Dependence on protein concentration
The plot of ATPase activity against protein concentration was non-linear (Fig. 
6.7), suggesting that Thio-DrrA molecules do not hydrolyse ATP independently of 
one another. This result might suggest that ATP hydrolysis for this protein is a 
cooperative process, where more than one Thio-DrrA molecule is necessary for 
ATPase activity.
6.1.5 Dependence on temperature
Temperatures of 24, 37 and 44 °C were assayed to evaluate the ATPase activity 
kinetics of Thio-DrrA (Fig. 6.8 and Table 6.1). A temperature of 37 °C was well- 
suited to the assay, as the rate of ATP hydrolysis at 24 °C was 50% lower than at 37 
°C, and the velocity of the reaction at 44 °C was not significantly superior (Fig. 6.8). 
The temperature range at which inactivation o f Thio-DrrA took place was not 
investigated.
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Effect of pH on Thio-DrrA ATPase activity
c
'3 2 0  -sa
D)
5  10  -  c
1  5 -
6 6.5 7 7.5 8 98.5
pH
Figure 6.6 Effect of the pH on the ATPase activity of Thio-DrrA
The M alachite green P| release assay was used to calculate the rate o f ATP hydrolysis from 15-minute 
ATP hydrolysis kinetics in each pH experiment. D ata are presented as protein specific activity 
(nanomoles o f  Pi liberated/min/mg o f  protein).
Different buffers were required to achieve the pH values for the assay. MES was used for the range pH 
6.0 -  6.5, MOPS was used at neutral pH and Tris was used for pH 8 -  9. Other reaction conditions were 
as standardised
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Thio-DrrA ATPase activity dependent on protein 
concentration
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Figure 6.7 Effect of the protein concentration on the ATPase activity of Thio- 
DrrA
The M alachite green P, release assay was used to calculate the rate o f ATP hydrolysis from 15-minute 
ATP hydrolysis kinetics with each protein concentration. The rate o f ATP hydrolysis by Thio-DrrA 
was shown to vary linearly with increasing protein concentration (data not shown). From those data, 
the ATP hydrolysis rates (nanomoles o f  Pj liberated/min) obtained, were plotted against Thio-DrrA 
concentration.
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Thîo-DrrA ATPase kinetics at different 
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Figure 6.8 Effect of the temperature on the ATPase activity of Thio-DrrA
The M alachite green Pj release assay was used to calculate the rate o f  ATP hydrolysis in each 
experiment. The ATPase activity o f Thio-DrrA is displayed in 15-minute ATP hydrolysis kinetics, 
when the experiments were incubated at three different temperatures.
Table 6.1 Effect of the temperature on the Thio-DrrA ATPase activity
Temperature
24
37 °C 
44 °C
Specific activity 
(nanomoles Pi released /min/mg 
protein)
11.2
19.2
20.1
Specific activities were calculated on the basis o f  triplicated measurements o f the velocities calculated 
as in Fig. 6.8
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6.2 Substrate Specificity
6.2.1 Dependence of Thio-DrrA and DrrA activity on the concentration of ATP.
Determination of V,„ax and K,n
The determination of the steady-state kinetics parameters V,„ax and Km, gives 
useful information about the catalytic activity of the protein under study, allowing 
these parameters to be compared with similar proteins. K„, is the parameter that 
measures the affinity of the enzyme for its substrate, whilst Vmax measures the 
maximal velocity of the reaction at saturating substrate concentrations. ATPase 
activity data were obtained over a 200-fold range of ATP concentrations from 50 pM 
to 2 inM. The concentration of Thio-DrrA in these assays was chosen in order to 
obtain measurements of absorbance at 610 mn of approximately 0.34 at the end of the 
15-minute ATP hydrolysis reaction. This makes possible informative comparison 
between the different experiments. Thus, 3.7 pM protein was used for the 
determination of Vmax and K,». The rate of ATP hydrolysis varied in a hyperbolic 
maimer with increasing ATP concentrations, indicative of simple Michaelis-Menten 
type kinetics. Calculation of the affinity of Thio-DrrA for ATP gave a Km value of 
1.25 inM (Fig. 6.9), while for DrrA on its own, this value was in the order of 143 pM 
(Fig. 6.10), indicating different affinities for the substrate. Calculation of Vmax showed 
a substantial difference between the forms of DrrA, with values of 30 and 111 
nanomoles Pi/miiVmg protein for Thio-DrrA and DrrA, respectively. The low Vmax 
derived here for Thio-DrrA might be explained by the presence of additional amino 
acid sequences from Thioredoxin or a conformation that might diminish the original 
catalytic potential of DrrA, assuming that independently expressed DrrA retains its 
full ATPase activity.
A comparison of K,n and Vmax values for Thio-DrrA and DrrA with NBDs 
reported by other authors is shown in Table 6.2. The Km for the DrrA proteins does 
not suggest a high affinity for substrate, and although the Km for DrrA lies between 
values for MalK (S. typhimurium) and HisP {S. typhimurium), the Km for Thio-DrrA is 
10-fold higher and the highest in the Table. With reference to the Vmax parameter, 
DrrA showed again a value in the range reported for other systems, but Thio- 
DrrA displayed the lowest, suggesting an inappropriate state of that preparation.
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Figure 6.9 Effect of ATP concentration on the ATPase activity of Thio-DrrA
The Malachite green P| release assay was used to calculate the rate o f ATP hydrolysis from 15-minute 
ATP hydrolysis kinetics at each ATP concentration experiment. ATP assays were performed at 37 °C 
and initiated by the addition o f  45 pi ofMgCl^. The total volume for each assay was 500 pi with 45 pi 
o f sample analysed for P; content at 5-minute time intervals over a time course o f  15 minutes. A 
standard curve was used to convert absorbance values at 610 nm to nanomoles o f  P, Final values were 
expressed as specific activity in nanomoles ofP; released/minute/mg of protein.
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Figure 6.10 Effect of ATP concentration on the ATPase activity of DrrA
The M alachite green Pj release assay was used to calculate the rate o f ATP hydrolysis from 15-minute 
ATP hydrolysis kinetics at each ATP concentration experiment. ATP assays were perform ed at 37 “C 
and initiated by the addition o f 45 pi o fM gC l;. The total volum e for each assay was 500 pi with 45 pi 
o f  sam ple analysed for P; content at 5-minute tim e intervals over a tim e course o f  15 minutes. A 
standard curve was used to convert absorbance values at 610 nm to nanomoles o f  Pi. Final values were 
expressed as specific activity in nanom oles o f P| released/minute/m g o f protein.
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Table 6.2 Comparative analysis of K,n and Vmax values for different nucleotide- 
binding domains.
Protein
K„, (pM)
V
(nanomolesPi/min/mg
protein)
Reference
MalK (E. coll) 23.9 322 Morbach et 
a l,  1993
MalK {S. typhimurium) 80 700 Schneider et 
a l, 1995
HisP {S. typhimurium) 205 500 Nikaido et 
a l, 1997
PstB (M tuberculosis) 71.5 122 Sarin et a l ,  
2001
TrX“DrrA 84.8 52 Nash, 2003
Thio-DrrA 1250 30 This study
DrrA 143 111 This study
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As low specific activities were obtained for a number of different preparations 
of the protein, we thought this could be linked to the instability of the Thio-DrrA 
preparations.
6.2.2 Other Nucleotide Triphosphate as substrates for Thio-DrrA
Cytosine triphosphate (CTP), thymine triphosphate (TTP) and guanidine 
triphosphate (GTP) nucleotides were tested as alternative substrates for Thio-DrrA in 
a standard ATP reaction (Fig. 6.11). CTP did not act as substrate for Thio-DrrA at all 
and the TTP behaviour was not very different, although a minimal activity signal 
could be detected at the end of the reaction. GTP was the only NTP apart from ATP 
that acted as a substrate for this protein, suggesting that Thio-DrrA has a preference 
for pmine substrates.
6.2.3 Inhibitors of the ATPase aetivity of DrrA proteins
The effect of ADP on the ATPase activity of Thio-DrrA was tested. When 
used at the same concentration as ATP, it inhibited the Thio-DrrA ATPase activity by 
60% (Fig. 6.12). In the absence of ATP, no hydrolysis of ADP by Thio-DrrA could 
be detected.
Vanadate possessed the dual properties of a phosphate transition state ATPase 
analogue, and a photoactive chemical (Fetsch and Davidson, 2002). Therefore 
vanadate was tested as a potential inhibitor of the ATPase activity of DrrA and Thio- 
DrrA. Vanadate concentrations ranging from 10 pM to 4 mM were assayed. At a 
concentration of 500 pM, 50 % inhibition of the ATPase activity o f DrrA was 
detected; higher concentrations up to 4 mM did not enhance the level of inhibition 
(Fig. 6.13). The IC50 value of 0.5 mM was not dissimilar to the value reported by 
Nikaido and collaborators for the Histidine permease NBD, assayed in isolation from 
the other components of the histidine transporter. These authors reported a much 
more potent effect for vanadate when tested with the complete His transporter, 
reporting an IC50 of 6.5 pM (Nikaido et al., 1997). Similar results were reported for 
MalK, the ATPase subunit of the maltose transporter (Sclmeider, 2001).
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Thio-DrrA activity kinetics on diverse NTPs
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Figure 6.11 Nucleotide substrate specificity for Thio-DrrA
The M alachite green Pj release assay was used to calculate the rate o f nucleotide triphosphate (NTP) 
hydrolysis in each experiment. NTP assays were performed at 37 °C and initiated by the addition o f 45 
pi o f  MgClz. The N TPase activity o f  Thio-DrrA is displayed in 15-minute NTP hydrolysis kinetics, 
when the experiments were incubated with the different NTPs.
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Effect of ADP on the Thio-DrrA ATPase activity
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Figure 6.12 Effect of ADP on the ATPase aetivity of Thio-DrrA
The M alachite green Pj release assay was used to calculate the rate o f ATP hydrolysis in each 
experiment. ATP assays were performed at 37 °C and initiated by the addition o f 45 pi o f M gC^. The 
ATPase activity o f Thio-DrrA is displayed in 15-minute ATP hydrolysis kinetics. ADP was added at 
a concentration o f 250 pM.
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^Figure 6.13 Effect of Vanadate on the ATPase activity of DrrA
^ T h e  M alachite green Pj release assay was used to calculate the rate o f A T P hydrolysis from 15-minute 
^  A T P  hydrolysis kinetics at each vanadate concentration. A T P assays were perform ed at 37 °C in 
presence o f  different vanadate concentrations, and initiated by the addition o f 45 pi o f  MgCL- The 
total volume for each assay was 500 pi with 45 pi o f  sample analysed for Pj content at 5-minute time 
intervals over a time course o f 15 minutes. A  standard curve was used to convert absorbance values at 
610 nm to nanom oles o f Pj. Final values w ere expressed as specific activity in nanom oles o f Pj 
released/minute/mg protein.
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Thio-DrrA was used to test if increasing NaCl concentrations would inhibit 
ATPase activity, as reported for other NBDs (Nikaido et al., 1997). NaCl 
concentrations above 300 pM were found to inhibit the ATPase activity of Thio-DrrA 
substantially, as can be seen in Figures 6.14. For purification and assay of the protein, 
retaining a concentration of NaCl of 150 mM was thus validated.
6.2.4 Effect of the presence of DrrB on the ATPase aetivity of Thio-DrrA and 
DrrA
The presence of DrrB did not appear to influence the ATPase activity of Thio- 
DrrA, but the addition of the protein did appear to elevate background signals in the 
assay. A similar experiment was run using DrrA with a different preparation of DrrB 
that did not seem to generate background signal. According to these data (Fig. 6.15), 
DrrB did not elevate the ATPase activity in the reaction. It thus seemed unlikely that 
the proteins in their free state could interact in the same manner as is probably in the 
proposed complex DrrAiBi.
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Thio-DrrA ATPase kinetics under different NaCl
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Figure 6.14 ATPase activity of Thio-DrrA under different NaCl concentrations
The M alachite green Pi release assay was used to calculate the rate of ATP hydrolysis from 15-minute 
kinetics in presence o f  different NaCl concentrations. ATP assays were perform ed at 37 °C and 
initiated by the addition o f 45 pi o f M gCb. The total volume for each assay was 500 pi with 45 pi o f 
sample analysed for P| content at 5-minute time intervals over a time course o f 15 minutes. A standard 
curve was used to convert absorbance values at 610 nm to nanomoles o f Pj.
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Figure 6.15 Effect of DrrB on the ATPase activity of DrrA
The M alachite green Pj release assay was used to calculate the rate o f  ATP hydrolysis in each 
experiment. Assays were perform ed at 37 °C in the presence o f  DrrA (1 pM  ) in the absence or 
presence o f  DrrB (1 pM; the kindly gift o f  Dr. McKeegan, Wolfson Institute, University ofn Durham). 
Reactions were initiated by the addition of 45 pi o f MgClz. The total volume for each assay was 500 pi 
w ith 45 pi o f sample analysed for P, content at 5-minute tim e intervals over a tim e course o f 15 
minutes. A standard curve was used to convert absorbance values at 610 nm to nanomoles o f R. Final 
values were expressed in nanomoles o f P, released.
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6.2.5 Effect of Doxorubicin on the ATPase activity of Thio-DrrA and DrrA
When the compound doxorubicin was added to a reaction mix containing 
Thio-DrrA or DrrA, no change in ATPase activity could be detected. Doxorubicin 
concentrations from 1-20 pg/ml (1.5-35 pM) were assayed to evaluate the effect on 
the ATPase activity of DrrA (Fig. 6.16). A link with other elements involved in the 
DrrAB system has not been established when DrrA has been expressed without the 
remainder of the DrrAB system. Some expectations had been raised about the 
possibility that anthracyclines compounds could act as modulators of the ATPase 
activity of DrrA, as occurs in the ATPase subunit ArsA of the E. coli non ABC 
transporter ArsAB, with its substrates arsenate and antimonite (Rosen et al., 1999). 
Although that pump is not an ABC transporter, it shows some similarities in 
conformation and function with the ABC transporters.
The combined presence of the DrrB protein and doxorubicin was also assayed 
to monitor any change in the catalytic activity of DrrA. Once more, the DrrA activity 
was unaffected (Fig. 6.17).
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Figure 6.16 Effect of Doxorubicin on the ATPase activity of DrrA
The M alachite green Pi release assay was used to calculate the rate o f  ATP hydrolysis in each 
experim ent. ATP assays w ere perform ed at 37 °C in the presence o f  doxorubicin at several 
concentrations. Reactions were initiated by the addition o f 45 pi o f MgCla- The total volume for each 
assay was 500 pi with 45 pi o f sample analysed for Pj content at 5-minute time intervals over a time 
course o f 15 minutes. A standard curve was used to convert absorbance values at 610 nm to nanomoles 
o f Pj. Final values were expressed as nanomoles o f P; released.
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Effect of Doxorubicin on the ATPase activity of 
DrrA in presence and ab sen ce of DrrB
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Figure 6.17 Effect of Doxorubicin on the ATPase activity of DrrA in the 
presence of DrrB
The M alachite green Pj release assay was used to calculate the rate o f ATP hydrolysis in each 
experiment. ATP assays were performed at 37 °C with DrrA (1 pM) in the presence o f doxorubicin (2 
pM), and / or DrrB (1 pM ). Reactions were initiated by the addition o f 45 pi o f  M gCl2. The total 
volume for each assay was 500 pi with 45 pi o f  sample analysed for P; content at 5-minute time 
intervals over a time course of 15 minutes. A standard curve was used to convert absorbance values at 
610 nm to nanomoles o f Pj. Final values were expressed as nanomoles o f Pj released.
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6.3 Comparative analysis between the proteins DrrA and Thio-DrrA
Overexpression of DrrA at 16 °C from the pET21a vector and of Thio-DrrA 
from the pBADTOPO thiofusionvector, provided the best sources of DrrA proteins in 
terms of purity and quantity. The properties of the DrrA preparations are compared in 
Table 6.3. It is interesting to notice the higher stability of the DrrA protein when it is 
stored at -20 °C, as it maintains almost 100% of activity over a period of two weeks, 
whilst Thio-DrrA appeared to be more sensitive to loss of activity during storage.
Table 6.3 Comparative analysis between experimental DrrA proteins
Thio-DrrA DrrA
ATPase activity (K m ) K m = = 1 .2 5  mM K m = 1 4 3  p M
Velocity of the reaction 3 0  nanomoles P/m in/m g 1 1 1  nanomoles Pj/min/mg
(V max) protein protein
B iophysical properties Similar
such as induction by
d ivalen t cations, pH,
inliibitors
A ctivity stability after Loss of 5 0  % activity in 2 Loss of 5  % activity in 2
ageing weeks time at -20 °C weeks time at -20  °C
Post-purification stability Variable and low High
Protein yield 2 5 0  pg/L 4 0  pg/L
Thio-DrrA was overexpressed from the pBADTOPO thio-drrA  fusion vector, induced with 0.002 % 
arabinose, whilst DrrA was over-expressed from the pE T 21 a-t/zvyt vector and induced with 1.0 mM 
IPTG.
Data on protein yields were taken from single experiments.
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6.4 Discussion
A partial characterisation o f Thio-DrrA was made using established 
biochemical methods, complemented by the characterisation of DrrA. The main 
property assayed was the ATPase activity of the proteins. This was of primary 
importance as there are reports that DrrA expressed in the absence of DrrB does not 
possess ATPase activity (Kaur, 1997; Kaur and Russell, 1998).
Essentially, the characterisation of the Thio-DrrA fusion protein showed 
features shared with other NBD’s, such as HisP and MalK from S. typhimurium, 
MalK from E. coli and DrrA from M. tuberculosis (Liu et ah, 1997; Nikaido et al, 
1997; Morbach et ah, 1993; Nash, 2003). Although the S. peucetius drrAB operon 
has been characterised by others (Guilfoile and Hutchinson, 1991), and the ability of 
DrrA to bind ATP has been reported (Kaur, 1997; Kaur and Russell, 1998), the data 
presented here are the first to show the hydrolysis of ATP by DrrA.
Thio-DrrA and DrrA possessed detectable catalytic activity consistent with a 
role in energising transmembrane transport. The protein was shown to be a cation 
dependent ATPase able of binding and hydrolysing ATP in a similar manner to the 
NBDs of well-characterised prokaryotic ABC transporters.
The Vmax value obtained for the Thio-DrrA fusion was markedly lower than 
that for DrrA and other NBDs, suggesting that the fusion protein at the time of assay 
had a low ATPase activity. This might reflect the inappropriate folding or reduced 
integrity of the protein under the conditions of expression or purification that were 
employed rather than its intrinsic activity. This fact seems to be supported by the 
results with DrrA expressed in isolation; the average velocity for this species was 
comparable with other NBDs. Km for DrrA was also in the range of values reported 
for other NBDs, but for Thio-DrrA the same parameter, was 9-fold higher, indicating 
a reduced affinity for ATP. Although higher Km values for ABC transporters have 
been reported (3.0 mM for MRP; Chang et ah, 1997) it appears possible that the 
fusion affected the character and catalytic activity of DrrA. Characterisation of Thio- 
DrrA therefore allow qualitative assessment of the features of DrrA. Whilst data from 
analysis of DrrA might be considered more informative with regard to the kinetics of 
the DrrA system {Km and Vmax), very limited amounts of the protein were available for
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experimentation due to its insolubility. Also, early reports make mention that DrrA is 
only functionally active when forming part of the membrane fraction. Hence, the 
potential necessity of membrane interactions needs to be considered before definitive 
evaluation of the ATPase activity of DrrA can be made.
Inhibition of ATPase activity by high NaCl concentrations has been reported for 
some NBDs (Nikaido et al., 1997), however, it was surprising to find inhibition of 
Thio-DrrA at concentrations below those (300 mM) recommended for IMAC 
purification. This might explain the low activities detected when NaCl was used at 
400 mM for the extraction and purification of some preparations of the protein.
Although an interaction of DrrB and doxorubicin with DrrA might be expected, 
if  any interaction took place between these species it failed to enhance the ATPase 
activity of the reaction. It is clear that these experiments do not emulate the natural 
conditions of the assembled transporter In the cell. It has been reported that isolated 
NBDs do not show the same pattern of behaviour as the complete transporter in the 
presence of inhibitors like vanadate and V-ethylmaleimide. Vanadate strongly 
inhibits the ATPase activity in assembled ABC transporters (e.g. HisQMP2 ; Nikaido 
et a l,  1997) but scarcely affects their NBDs when tested in isolation. Several of these 
single NBDs have shown low sensitivity to these agents. It is not clear whether the 
inhibition of DrrA ATPase activity by vanadate is of biological significance. The 
pattern observed (Fig. 6.13) shows an inliibitory effect that appears real but it is only 
evident over vanadate concentrations (in excess of 0.1 mM) that are high by 
comparison to those that inhibit intact ABC transporter systems (e.g. HisQMPi is 
inhibited by vanadate with an I C 50 of 6.5 pM whereas the ATPAse activity of HisP is 
unaffected by concentrations of 0.5 mM; Nikaido et al., 1997).
In common with the finding that doxorubicin does not enhance the ATPase 
activity of DrrA or Thio-DrrA, the basal ATPase activity of P-glycoprotein MdiT is 
not enhanced by drugs when its NBDs or N- or C-terminal half-molecules have been 
separately expressed (Loo and Clarke, 1994; Buxbaum, 1999). It is now known that 
the drug-binding sites in P-glycoprotein are localised in the transmembrane domain 
(Ambudkar et a i,  1999). If we assume that the drug-binding sites in DrrAB are also
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located in its TMD in an equivalent manner to P-glycoprotein, this might explain why 
the addition of doxorubicin to DrrA did not enhance ATPase activity. However, 
studies on the mechanism of the E, coli ArsA ATPase have shown that ArsA 
possesses allosteric sites for As(III) and Sb(III), that are transport substrates for the 
ArsAB pump (Rosen et ah, 1999). Antimonite stimulated ATP hydrolysis by ArsA 
by 10- to 20-fold whilst with arsenite, the stimulation was lower. Similar allosteric 
sites might occur in ABC NBDs, and the existence of sites for ligands in DrrA was a 
possibility worth investigating.
It has been suggested that cooperativity between NBDs is a probable feature 
for all the NBDs in ABC transporters. A dimeric form of the NBD in the 
mitochondrial ABC transporter M dllp (Janas et a l,  2003) was suggested when its 
ATPase activity was dependent in a non-linear fashion on protein concentration and 
confirmed by the formation of intermediate dimeric transition states trapped by 
vanadate or beryllium fluoride. In addition, an active NBD dimer has been reported 
for the OpuA system of B. subtilis, evidenced by size exclusion chromatography 
(Plorn et a l,  2003). There was little evidence that the ATPase activity of Thio-DrrA 
departed from a linear relationship with protein concentration, but the result is far 
from conclusive. One feature of the Thio-DrrA protein was its high aggregation state, 
a property that impeded the successful use of size exclusion chromatography to assess 
whether a dimer was favoured as the active form for DrrA. Clearly, this might have 
bearing on the potential formation of dimers with ATPase activity different from that 
of monomeric forms. This issue could not be addressed with independently expressed 
DrrA, as insufficient soluble protein could be recovered for this type of assay.
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Chapter 7
Fluorescence spectroscopy of DrrA proteins
Spectroscopic methods can be used to monitor changes in the conformation of 
transporter proteins and time-resolve these changes. Fluorescence spectroscopy is 
preferred for monitoring ligand-membrane protein interactions whilst stopped-flow 
fluorescence (SFF) spectroscopy is favoured for determination of the mechanisms of 
ligand binding and translocation. The latter method is more sophisticated and uses 
rapid techniques to measure the rate constants governing the translocation of the 
substrate across the membrane (Walmsley, 2000).
7.1 Intrinsic tryptophan fluorescence of DrrA refolded from 
inclusion bodies in a urea gradient
Based on the fluorescence properties of the aromatic amino acids tryptophan 
and tyrosine, fluorescence spectroscopy has proved to be a powerful tool for 
investigating the properties o f ABC transporter complexes (e.g. P-glycoprotein; 
Sharom et al., 1998, 1999, and 2001). The technique relies upon the unique responses 
that small changes in the environment generate in the fluorescence properties of 
individual tryptophan residues within a protein. Therefore, conformational changes in 
a protein, induced by events such as ligand binding, can often be correlated with a 
change in the fluorescence of tryptophan residues.
Refolding of DrrA from inclusion bodies produced with the pET2la vector did 
not appear to generate protein with ATPase activity (see Chapter 5, section 5.1). 
Fluorescence spectroscopy techniques were used to seek evidence that the DrrA was 
able to interact with its substrate but unable to hydrolyse any bound ATP. 
Fluorescence changes in DrrA were monitored in the presence of the ligand 
doxorubicin and the nucleotide analogue MANT-ATP (Fig. 7.1). The peak in the 
spectrum in the absence of ligand was maximumal at 340 nm. This was consistent 
with a folded rather than a denatured structure as tryptophans in proteins that have 
been denatured by urea or guanidine hydrochloride exhibit a a^x of 350 nm 
(Reshetnyak and Burstein, 2001). The emission intensity fell by 29% in the presence 
of doxorubicin or MANT-ATP, and was reduced slightly more in the presence of
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both. When magnesium was added, emission intensity rose to match that of the 
doxorubicin-DrrA peak. The data thus suggested that MANT-ATP was binding the 
DrrA protein. The MANT-ATP, on the other hand, displayed a peak at 440 nm that 
remained the same even in the presence of the protein.
Although the protein displayed these spectroscopic properties, no ATPase 
activity was detectable for DrrA. Although this could be interpreted as evidence for 
the interaction of DitA with the ligands, the absence of ATPase activity did not justify 
further investigation.
7.2 Intrinsic tryptophan fluorescence of the fused protein Thio-DrrA
Protein fluorescence data, collected under steady-state conditions, can be used 
to calculate biochemical parameters such as the equilibrium dissociation constant 
and/or the stoichiometry of a particular protein-substrate interaction. These can also 
be time resolved to give mechanistic information. The detailed kinetic mechanism 
describing the activity of the E. coli ArsA ATPase was determined by Walmsley and 
collaborators using a combination o f these techniques (Walmsley et al., 2001). 
Conformational changes associated with ATP binding, metalloid binding, ATP 
hydrolysis and product release were all detected through changes in the tryptophan 
fluorescence of the protein.
In order to evaluate whether similar conformational changes might be detected 
during the binding of ATP to Thio-DrrA and its further hydrolysis, steady-state 
tryptophan emission spectra were collected for protein both in the presence and 
absence of nucleotide. A typical spectrum is shown in Figure 7.2. In absence of 
nucleotide, Thio-DrrA exhibited an emission maximum at a wavelength of 334 nm. 
The addition of 1 mM ATP to the protein resulted in a quench in the fluorescence (64 
% decrease), and the subsequent addition of 1 mM MgCb to the mix caused a further 
quench of 4%. Neither addition had any effect on the max value that remained 
constant at 334 nm.
The reduction in emission intensity after addition of ATP initially indicated 
that some of the four tryptophan residues present in Thio-DrrA was responsible for a
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nucleotide induced conformational change in the protein structure. Nevertheless, the 
adenine ring of ATP interferes with fluorescence measurements by absorbing 
photons, thereby reducing the intensity of both the excitation beam and of the 
observed emission spectrum. This phenomenon is known as “inner filter effect”, and 
has to be considered when measuring the steady-state fluorescence of ATP-binding 
proteins (Nash, 2003). The extent of the inner filter effect was evaluated for different 
concentrations of ATP (1.0-0.01 mM), and it was determined that the decrease in 
emission intensity for Thio-DrrA could be attributed to an inner filter phenomenon. 
The magnitude of the effect was substantial and it was judged that any further changes 
in tryptophan fluorescence of Thio-DrrA that might arise from specific interaction 
with ATP, were unlikely to be discernible by this technique. Further doubt was cast 
upon the value of this approach in control experiments with bovine albumin. BSA 
showed the same quench in protein fluorescence as DrrA protein when 1 mM ATP 
was added.
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Figure 7.1 Tryptophan fluorescence emission spectra of refolded DrrA in the 
presence of substrate and ligand
Protein was excited at 285 nm and emission scanned between 300 and 525 nm. Protein fluorescence 
peaks appeared at 340 nm. The composition o f  the test samples is indicated. The ATP analogue 
MANT-ATP has a fluorescence maximum peak at 440 nm (indicated). Fluorescence data are shown in
arbitrary units (A.U.).
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Figure 7.2 Tryptophan fluorescence emission spectra of Thio-DrrA
The fluorescence emission spectrum o f 2.5 pM Thio-DrrA was measured at room temperature in a 
buffer containing 50 mM Tris-HCl and 150 mM NaCl, pH 8.0. Tryptophan fluorescence was excited at 
a wavelength o f 285 nm and emission data gathered from samples (composition as indicated) between 
295 and 400 nm. Fluorescence data are shown in arbitrary units.
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7.3 Stopped-flow fluorescence studies of Thio-DrrA
Nucleotide interactions can produce transient changes in the fluorescence of 
proteins. Stopped-flow fluorescence spectroscopy allows the very rapid detection of 
changes in protein fluorescence in response to ligand binding. The method allows the 
rapid mixing of the protein with the ligand, and enables one to time-resolve changes 
in the fluorescence on a millisecond time scale (see Chapter 2, section 2.13.2).
Contrary to measurement of changes under steady-state conditions, the use of 
stopped-flow techniques negates inner filter effects because any reduction in signal 
due to the presence of ATP occurs prior to the onset of data collection. A second 
advantage of the technique is that even very small and rapid changes in fluorescence 
that may be missed under steady-state conditions can be detected and time-resolved to 
reveal mechanistic details of the interaction (Walmsley et aL, 2001). Stopped-flow 
experiments involve mixing two (or more) solutions together as rapidly as possible 
and getting them immediately to the optical observation point. The faster this 
happens, the earlier into the reaction one may observe (i.e. the smaller the dead time). 
Some stopped-flow instruments are capable of achieving dead times of less than 1.0 
millisecond.
7.3.1 Production of tryptophan mutants in Thio-DrrA for 
fluorescence experiments
Due to intrinsic fluorescence properties of the aromatic amino acids 
tryptophan and tyrosine, it is possible to measure changes in their signals when a 
ligand binds a protein with these residues adequately exposed. When this type of 
interaction was assessed for the nucleotide-binding domain of the pump DrrAB (Thio 
DrrA) in a stopped-flow device, no changes were detected in the presence of the 
natural substrate ATP, or its fluorescent-analogue MANT-ATP.
Site-directed mutagenesis is a valuable tool for studies of gene and protein 
structure and function that allows one to specifically change any given base in a 
cloned DNA sequence. In an attempt to obtain detectable signals, single mutations 
were constructed with the aim of introducing additional tryptophan residues in
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sections of the protein sequence that could be involved in the catalytic active site, or 
close to it. Tryptophan is more responsive to any change than tyrosine. Thio-DrrA 
contains four tryptophan residues, with two of them forming part of the Thioredoxin 
protein. The initial aim was to obtain a mutation in the protein ABC signature 
sequence to enhance its fluorescence signal without affecting its intrinsic ATPase 
activity. If this signal was not satisfactory, it was argued that different residues 
involved in the Walker A motif could be targeted later (Fig. 7.3).
Mutagenesis in Thio-DrrA
Fluorescence quenching following the addition of ATP had been previously 
reported for NBD’s (Schneider et al., 1994, working with MalK). The alleged ABC 
signature-sequence motif (also known as linker peptide) is one of the most highly 
conserved regions in ABC transporter NBD’s and it is generally represented by the 
consensus “LSGGQ”. It is located in the ABC transporter-specific a-helical sub- 
domain of the NBD. A number of crystallographic NBD dimers suggest this motif is 
part of a complex ATP binding site formed by juxtaposition of one NBD’s Walker A 
motif with the signature-sequence motif of a second molecule (Hopfner et al., 2000; 
Smith et al., 2002; Chen et al., 2003) . In S. peucetius DrrA the signature-sequence 
motif is represented by the sequence ‘YSGGM’, and it was selected as target for site- 
directed mutagenesis. Although not common, the same YSGGM signature sequence 
was reported for Streptococcus pyogenes OppD and OppF (Podbielski et al, 1996), 
and M. tuberculosis DrrA (Nash, 2003). Mutation of the m otifs  initial tyrosine 
residue (Y140) to a potentially fluorescent tryptophan residue (W) was devised. 
Being part of the most conserved sequence in these transporters, this region might 
well be intimately involved in both dimérisation of the NBD and the mechanism of 
ATP hydrolysis.
To produce this mutation in Thio-DrrA, primers were designed according to 
the protocols for the Promega Gene Editor system, and later, the QuickChange site 
directed mutagenesis system from Stratagene. In both cases, TAG codon was mutated 
to TGG, to replace tyrosine with tryptophan.
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(1) mntqptraie 1 1 TSGLVKVYNG TRAVDGLDLN VPAGLVYGIL
(40)
(41) T TGPNGAGKSTT IRMLATLLRP DGGTARVFGH DVTSEPDTVR (80)
(81) RRISVTGQYA SVDEGLTGTE1 NLVMMGRLQG YSWARARERA (120)
(121) AELIDGFGLG DARDRLLKTY SGGMRRRLDI AASIVVTPDL (160)
(161) LFLDEPTTGL DPRSRNQVWD IVRALVDAGT TVLLTTQYLD (200)
(201) EADQLADRIA VIDHGRVIAE GTTGELKSSL GSNVLRLRLH (240)
(241) DAQSRAEAER LLSAELGVTI HRDSPTALSD ARIDDPRQGM (280)
(281) RALAELSRTH LEVRSFSLGQ SSLDEVFLAL TGHPADDRST (320)
(321) EEAAEEEKVA KGELEGKPIP NPLLGLNSTR TGHHHHHHH
Figure 7.3 Positions of tryptophan mutations in the DrrA component of Thio-
DrrA
Residues selected for mutation by site directed mutagenesis are indicated in bold and shown by the 
arrow, corresponding to the mutations Y 37, A45 and T50 around the W alker A motif, and the mutation 
Y 140 that corresponds to the former ABC signature sequence mutation. In all these mutations, the 
original aminoacid was replaced by a tryptophan. Red text indicates the D rrA W alker A motif, blue 
shows W alker B and green highlights the ABC transporter signature-sequence.
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7.3.1.1 GeneEditor System (Promega):
To use the GeneEditor system, only a single primer was needed to produce the 
mutation and synthesise the mutated DNA. Its sequence was:
Primer SP DrrA
Sequence (5’ to 3’): CTC CTG AAG ACC TGG TCC GGT GGC
The original TAG codon was converted into TGG (fifth base triplet in the primer)
The first step in this protocol was to denature by alkali the plasmid DNA 
containing the gene of interest, and then use single stranded DNA as template for 
synthesis. This step was accomplished (Fig. 7.4), but no bacteria could be recovered 
that were transformed with the newly synthesised DNA plasmid. Numerous attempts 
to repeat the alkali dénaturation step did not show the expected pattern on gels with 
the single stranded DNA migrating ahead of the double stranded (Fig. 7.5). Although 
modifications were introduced such as the use of higher temperatures (70-80 °C) or 
longer incubation times (10-30 minutes) instead of room temperature and the five 
minutes suggested by the protocol, the electrophoresis pattern expected for denatured 
DNA could not be detected and transformation of competent cells with newly 
synthesised mutant DNA proved elusive.
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Figure 7.4 Alkali-mediated DNA dénaturation of pBADTOPO thio-drrA
NDP: Non-denatured plasmid DNA 
DP: Denatured pBAD thio-drrA plasmid
Double­
stranded
DNA
NDP
Figure 7.5 Unsuccessful attempts to generate alkali denatured DNA from 
pBADTOPO thio-drrA
NDP: Non-denatured plasmid DNA
1-3: Plasmid preparations treated with alkali
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7.3.1.2 QuickChange Site-Directed Mutagenesis (Stratagene)
Site-directed mutagenesis was also attempted with this methodology from 
Stratagene. In this protocol, it was necessary to construct a pair of complementary 
primers each carrying the mutation towards the middle of the primer, with five codons 
of native sequence at either side.
7.3.1.2.1 Mutagenesis in the Thio-DrrA ABC signature
The complementary primers bearing the mutant sequence are shown below:
Primer DrrA Y 140 forward
Sequence (5’ to 3’): CGG CTC CTG AAG ACC TGG: TCC GGT GGC ATG CGG 
Primer DrrA Y 140 reverse
Sequence (5’ to 3’): CCG CAT GCC ACC GGA CCA GGT CTT GAG GAG CCG
Twenty-five and 50 ng of double-stranded pBADTOPO thio-drrA DNA were 
used as template, and with both reaction mixtures, transformants were obtained that 
carried the mutation. Transformants were selected for resistance to ampicillin, the 
antibiotic marker present in the plasmid.
The mutant DNA carried the original pBADTOPO thio-drrA plasmid 
sequence with the original tyrosine codon (YSGGM) mutated to tryptophan 
(WSGGM). The mutation was confirmed by DNA sequencing. Plasmid DNA was 
purified and transformed into E. coli LMG194 for expression of the mutated Thio- 
DrrA. The ATPase activity of this modified protein was similar to that of wild-type 
Thio-DrrA (Table 7.1). The protein was used in stopped-flow spectroscopy 
experiments, but no improvement could be detected in fluorescence signals in the 
presence of ATPase reaction components.
7.3.1.2.2 Mutations inside and around the Thio-DrrA Walker A motif
In ABC transporters, two other regions have highly conserved motifs and are 
implicated in nucleotide binding and hydrolysis, the Walker A and Walker B motifs.
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The Walker A site is implicated in the binding of phosphate and consequently is 
known as the phosphate loop. If a tryptophan, generated by a single mutation in this 
region of the protein was fluorescence-responsive, an interaction with the substrate 
should change the fluorescence signal.
Single amino-acid mutations were designed for Thio-DrrA to either sides of 
the Walker A motif, and within the motif. In all mutants, a tryptophan residue 
replaced the original amino acid. In the first mutation, a tyrosine at position 37 was 
altered to tryptophan (Fig. 7.3). In the second, the alanine inside the Walker A motif 
was changed as illustrated below:
Native DrrA Walker A motif 4 1 - G P N G A G K S - 4 8I
Mutant (A45) 41- G P N G W G K  S -48
The highly conserved residues in the motif are in bold. A third mutation 
involving substitution of a threonine at position 50 was devised to the other flank of 
the Walker A motif (Fig. 7.3). All these plasmids were then purified from E. coli XLl 
Blue and transformed into E. coli LMG194 for expression of the Thio-DrrA mutants.
Although the Thio-DrrA mutants showed ATPase activity (Table 7.1), they 
did not give appropriate fluorescence signals in the stopped flow assays. Mutant 
Thio-DrrA Y37 showed 40% of the ATPase activity of wild-type Thio-DrrA, but its 
fluorescence was not responsive to the binding of ATP (Fig 7.6 A and B). For Thio- 
DrrA A45W, the protein lost almost all ATPase activity, indicating that the integrity 
of the Walker A motif is essential for activity (Fig. 7.6 C and D). For Thio-DrrA 
T50W, the protein retained full ATPase activity but did not give a fluorescence signal 
in stopped flow, although some signal amplification was suggested by the data (Fig. 
7.6 E and F).
Considering the SFF spectra obtained for the Thio-DrrA mutants, there are no 
net changes in fluorescence that appear to be linked to ATP binding or hydrolysis. 
Variation in the ATP concentration did not alter the strength of the fluorescent signal. 
The ATP analogue MANT-ATP possessed a fluorescence signal several times higher
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than that of ATP, but no improvement was noticed using this reagent, the main 
problem appearing to be a low signal-to-noise ratio. Additional mutations were 
generated to convert the tryptophan residues present in the Thioredoxin moiety into 
glycine to reduce the background signal. For example, a tiyptophan-free Thioredoxin 
moiety was exchanged into the Thio-DrrA T50 mutant. Assays with different ATP 
concentrations, ADP and MANT-ATP were performed in the stopped-flow 
instrument, but no improvement in the tryptophan fluorescence signal could be 
detected.
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Table 7.1 ATPase activity of mutant Thio-DrrA proteins constructed for 
stopped-flow assays
Tliio-DrrA Protein Specific activity (nmoles Pi/min/mg
protein)
Wild-type 40±2
Y140W 34±4
Y37W 15±3
A45W 3±0.5
T50W 374=3
The m alachite green Pj release assay was used to calculate the rate o f ATP hydrolysis, ATP assays 
were performed at 37 °C and initiated by the addition o f 45 pi o f  M gC f. The total volume for each 
assay was 500 pi with 45 pi o f  sample analysed for P; content at 5-minute time intervals over a time 
course o f 15 minutes. A standard curve was used to convert absorbance values at 610 nm to nanomoles 
o f  Pi. Final values were expressed as specific activity in nanom oles o f P| released/m inute/m g of 
protein.
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Figure 7.6 Stopped flow fluorescence spectra of Thio-DrrA mutant proteins in 
presence and absence of ATP and
Stopped-flow fluorescence traces generated by mixing 5 _M Thio-DrrA proteins with 1 mM ATP and 2 
mM MgCIz (final concentrations in the mixing chamber). ATP fluorescence was excited at 285 nm 
and emission data collected above 320 nm.
A and B represent Y37 T h io -D rrA ; C and D, A45 T h io -D rrA ; E and F, T50 T h io -D rrA , all in 
absence and presence o f ATP and Mg^^ respectively.
206
7.4 Summary
Analysis of the DrrA proteins was carried out by fluorescence spectroscopy to 
monitor changes in tryptophan fluorescence in presence of ligands. Intrinsic 
tryptophan fluorescence was assayed for DrrA purified from inclusion bodies, 
denatured and subsequently refolded using a urea gradient, to evaluate the success of 
the procedure. The data were consistent with the protein possessing a folded 
conformation but one that lacked ATPase activity.
Intrinsic tryptophan fluorescence was also assayed for Thio-DrrA proteins. 
With these proteins, a high inner filter effect was noted from ATP. This obscured any 
changes in tryptophan fluorescence that might be caused by ligand interaction with 
the protein.
Stopped flow-fluorescence was employed in an effort to detect and evaluate 
changes in Thio-DrrA fluorescence in response to ligand binding. Substantial and 
consistent changes in tryptophan fluorescence could not be detected. To overcome 
this, mutations were introduced at locations close to or within the motifs implicated in 
ATPase activity of the protein, such as the Walker A (Y37, A45, and T50) and the 
ABC signature (Y140) motifs. Although the mutants retained ATPase activity, no 
improvement in tryptophan fluorescence was obtained. Finally, a pair of tryptophan 
residues present in the Thioredoxin moiety was converted to glycine residues in an 
attempt to eliminate the background fluorescence of the fusion proteins. Analysis of 
the resulting Thio-DrrA constructs did not show any improvement.
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Chapter 8
Final Discussion
"'DrrA is a component o f  the DrrAB pump o f  S. peucetius and its role is to 
drive the efflux o f  the anthracycline compounds doxorubicin and daunorubicin out o f  
the cell. DrrA is a protein located peripheral to the membrane and has the 
characteristics o f a cytoplasmic protein'\
ABC transporters are formed by several functional units and organised into 
modules consisting of a minimum of four functional domains - two ATP- 
binding/hydrolysing domains and two membrane-spanning domains (Higgins et al., 
1986). In contrast, the model for the S. peucetius ABC transporter DrrAB proposes 
that it is composed of two functional domains: a nucleotide binding domain (NBD), 
and a transmembrane domain (TMD). It has been suggested that the NBD was 
duplicated and that this event also happened with the original TMD, resulting in a 
DrrAzBz stoichiometry for the complex (Kaur and Russell, 1998).
That was the state of knowledge about the experimental system chosen for this 
project at its start. If  the ATP binding domain could be functionally separated from 
the membrane domain of the transporter, it was argued that it might be possible to 
overproduce the domains separately for detailed structure-function studies. As the 
doxorubicin energy-dependent pump was thought to comprise distinct membrane and 
ATPase domains, this goal seemed achievable. The wider importance of the study 
remains that if the molecular mechanism for pumps linked with drug resistance can be 
better understood, this will provide a rational basis for combating the threat posed by 
microorganisms resistant to multiple antibiotics, and improving cancer chemotherapy.
Many other soluble proteins from bacteria have been successfully 
overexpressed as heterologous proteins in E. coli. There was no a priori reason to 
think that this would not be the case for DrrA and the expectation was that DrrA 
would be expressed in sufficient quantities to perform a complete study of its 
properties. However, this did not prove to be the case. Although substantial quantities
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of recombinant protein were overexpressed using a pET-based construct, the vast 
majority of the product was present as inactive, insoluble inclusion bodies. The lack 
of biological function associated with this form of the protein impeded further 
biochemical analysis of native DrrA. Diverse trials were conducted to refold the 
aggregates from inclusion body into an active conformation but this proved to be 
futile. It has been suggested that certain structural features of the NBD promote non- 
physiological interactions between individual molecules, resulting in aggregation and 
insolubility (Yuan et al., 2001), and it is now known that inclusion body formation is 
a rather common event when overexpressing NBDs of ABC transporters.
Since DrrA could not be expressed as a native protein and refolding proved 
unsuccessful, an alternative mode of expression was sought. By expressing DrrA as a 
translational fusion to E. coli Thioredoxin, a stable soluble Thio-DrrA was eventually 
produced in quantities just sufficient for analysis.
Similar approaches had been used extensively for the heterologous 
overexpression of both prokaryotic and eukaryotic ABC transporter NBDs. Even so, 
expression of a DrrA fusion protein from a pBADTOPO thio vector was not easy. 
Low concentrations of inducers did not really improve the yield of soluble protein at 
37 °C. A change of temperature to 25 °C at induction was not sufficient to provide 
soluble Thio-DrrA. This goal was only reached by dropping the temperature close to 
17 °C, when finally a small quantity of soluble, active DrrA and rather more Thio- 
DrrA were obtained. These results led to the characterisation of Thio-DrrA, a form of 
DrrA that showed signs of ATPase activity. The presence of additional sequence, not 
least the Thioredoxin moiety, could impact upon the behaviour of DrrA compared to 
its native form.
Given these problems, might the overexpression of DrrA have been easier in a 
host closer to S. peucetius? This strategy was seen as inconvenient from the beginning 
of the project. There was no previous experience in the team to support research 
along these lines, and the longer culture times for Streptomyces was seen as an 
obstacle. In contrast, E. coli was extensively used by others in the research team for 
the expression of heterologous proteins and its well characterised genetics,
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biochemistry and physiology and the extensive availability o f vectors for 
overexpression were seen as major advantages.
The characterisation of DrrA was mainly based on its ATPase activity and this 
was assessed by release of phosphate, as determined by a malachite green/ammonium 
molybdate assay. To evaluate this activity in the different trials assayed and to 
observe clearly their differences with control experiments, concentrations of Thio- 
DrrA were used that would generate Aôiomn values close to 0.34 at the end of the 
reaction. A protein concentration of 1 pM (about 52 pg/ml) was found to carry 
activity too low to meet this criterion for some preparations. This variation suggested 
that the protein was not being expressed with complete ATPase activity and that some 
variation in this property was evident, batch to batch. In consequence, protein 
concentrations between 1 and 3 pM were required to meet the assay criteria. This 
approach was adequate for qualitative comparisons. The ATPase activity of the Thio- 
DrrA fusion protein was shown to exhibit cation dependence, a feature consistent with 
its proposed role as the energy transducing sub-unit of an ABC transporter. The 
structural integrity of the Walker A nucleotide-binding motif, a feature shared by 
other ATPase families, was also important and a mutant protein in which this motif 
was disrupted displayed much reduced levels of ATP hydrolysis. Thio-DrrA was 
shown to exhibit a broad range of substrate preferences with regard to nucleotide 
triphosphates and divalent cations. This feature is not uncommon amongst isolated 
bacterial NBDs and may be seen as a further indication that the behaviour of Thio- 
DrrA is typical for an NBD. These data are the first to show that the S. peucetius 
DrrA protein is a functional ATPase.
However, the low specific activity of Thio-DrrA compared to other ATPases 
was notable and disappointing. Although the Vmax data showed variations between 
experiments, it was reasonable to assume that the Km of the DrrA proteins would be 
constant. However K,n values derived for Thio-DrrA were a ten times higher than the 
same parameter for the isolated DrrA protein, indicating that something was affecting 
the properties of the fused protein. Heterogeneous ATPase activities might be linked 
to the presence of mixtures of soluble but inactive DrrA fusions with active forms of 
the protein. This important phenomenon has been encountered by other investigators 
and purification strategies have been proposed based upon monodispersity (see
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Nomine et al., 2001). Expression of isolated DrrA from the pET vector system 
always produced protein with a high activity, although yields were consistently low 
and could not be improved.
A number of biochemical and structural data suggest that the ATPase active 
form of ABC transporter NBDs is a dimer, as shown for the Rad50 and MalK 
(Hopfner et a l, 2000; Chen et a l, 2003). A dimer formation for Thio-DrrA could not 
be further corroborated because of aggregation problems with Thio-DrrA, and 
insufficient quantities of DrrA protein for size exclusion cliromatography.
The ATPase activity of Thio-DrrA and DrrA did not appear to be modulated 
by the presence of the putative DrrAB substrates doxorubicin and daunorubicin. This 
argues against the presence of an antibiotic binding site or sites on DrrA. DrrA thus 
does not seem to be an allosteric protein like ArsA as has been suggested by Kaur 
(Kaur, 1997). Interaction between DrrA and DrrB could not be detected and overall 
these experiments failed to take forward an understanding of the manner in which 
DrrA interacts with the substrates and the membrane components of this pump. This 
phenomenon has been reported in other systems (Nash, 2003; Nikaido et a l, 1997; 
Morbach et al., 1993), where isolated components of ABC systems behave differently 
when assayed in dilute solution rather than as part of the entire transporter complex. 
It seems clear that isolated DrrA retains it ATPase activity but how ATP hydrolysis 
mechanism is coupled to multidrug extrusion remains unclear.
Since the ATP binding domain is strongly conserved among ABC transporters 
with various specificities, it seems unlikely that this domain is involved in initial 
substrate recognition. As a consequence, identification of an ABC-type nucleotide 
binding domain alone cannot be taken as evidence for a putative MDR transporter 
(Allikmets et a l ,  1993; Karow and Georgopolous, 1993). It should be stressed that 
alterations in the drug resistance profile have been observed as result of mutations in 
the nucleotide binding domain, which indicate an intimate relationship with the 
hydrophobic domain(s) (Beaudet and Gross, 1995). Both biochemical and structural 
data are beginning to suggest that the ABC transporter function is highly dependent 
upon interactions between the various domains of the complex. As such, a complete
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understanding of its fimction may require researchers to adopt a “system-approach” to 
its analysis, rather than more traditional tecluiiques.
To achieve a more detailed characterisation of the NBD of the S. peucetius 
DrrAB pump, in particular the mechanism by which DrrA interacts with its substrate, 
efforts should be directed to finding a better vehicle for overexpression and 
purification. Fusion with maltose binding protein and use of a Nus tag has been 
promoted for improving yields of soluble protein, but it is clear that no fusion system 
can guarantee overcoming aggregation problems. Vectors containing promoters 
weaker than T7, should be assayed but it should also be clarified if insertion of Dn’A 
into the bacterial membrane independently or as a component of the DrrAB system 
influences its activity.
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